<SEC-DOCUMENT>0001213900-23-054818.txt : 20230705
<SEC-HEADER>0001213900-23-054818.hdr.sgml : 20230705
<ACCEPTANCE-DATETIME>20230705164714
ACCESSION NUMBER:		0001213900-23-054818
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20230629
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230705
DATE AS OF CHANGE:		20230705

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			INTENSITY THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001567264
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				461488089
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41109
		FILM NUMBER:		231069981

	BUSINESS ADDRESS:	
		STREET 1:		61 WILTON ROAD, 3RD FLOOR
		CITY:			WESTPORT
		STATE:			CT
		ZIP:			06880
		BUSINESS PHONE:		203-221-7381

	MAIL ADDRESS:	
		STREET 1:		61 WILTON ROAD, 3RD FLOOR
		CITY:			WESTPORT
		STATE:			CT
		ZIP:			06880

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Intensity Therapeutics, Inc.
		DATE OF NAME CHANGE:	20130117
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea181296-8k_intensity.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:INTS="http://intensitytherapeutics.com/20230629">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_033_INTS_intensitytherapeutics.com_20230629 -->
<!-- Field: Set; Name: xdx; ID: xdx_04D_20230629_20230629 -->
<!-- Field: Set; Name: xdx; ID: xdx_05E_edei%2D%2DEntityCentralIndexKey_0001567264 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-06-29to2023-06-29" name="dei:EntityCentralIndexKey">0001567264</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-06-29to2023-06-29" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-06-29to2023-06-29" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="ints-20230629.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-06-29to2023-06-29">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001567264</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-06-29</xbrli:startDate>
        <xbrli:endDate>2023-06-29</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>WASHINGTON, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90C_edei--DocumentType_c20230629__20230629_z6pV49Newcu1"><ix:nonNumeric contextRef="From2023-06-29to2023-06-29" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>of the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Date of Report (Date of earliest event reported):
<span id="xdx_90E_edei--DocumentPeriodEndDate_c20230629__20230629_zMBRd4sSJHYf"><ix:nonNumeric contextRef="From2023-06-29to2023-06-29" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">June 29, 2023</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 12pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_908_edei--EntityRegistrantName_c20230629__20230629_zeRBKTrv6cue"><ix:nonNumeric contextRef="From2023-06-29to2023-06-29" name="dei:EntityRegistrantName">Intensity Therapeutics, Inc.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Exact name of Registrant as Specified in Its
Charter)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_903_edei--EntityIncorporationStateCountryCode_c20230629__20230629_zlj3yBUtrjsl"><ix:nonNumeric contextRef="From2023-06-29to2023-06-29" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90D_edei--EntityFileNumber_c20230629__20230629_zh8Q7FmYSkSa"><ix:nonNumeric contextRef="From2023-06-29to2023-06-29" name="dei:EntityFileNumber">001-41109</ix:nonNumeric></span></b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; width: 32%; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90B_edei--EntityTaxIdentificationNumber_c20230629__20230629_z4yiA77VNF4a"><ix:nonNumeric contextRef="From2023-06-29to2023-06-29" name="dei:EntityTaxIdentificationNumber">46-1488089</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(State or Other Jurisdiction<br />
of Incorporation)</b></p></td>
    <td>&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Commission File Number)</b></p></td>
    <td>&#160;</td>
    <td style="vertical-align: top">
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>(IRS Employer<br />
Identification No.)</b></p></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: top; width: 49%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_909_edei--EntityAddressAddressLine1_c20230629__20230629_zlwkAyZwPvPd"><ix:nonNumeric contextRef="From2023-06-29to2023-06-29" name="dei:EntityAddressAddressLine1">61
    Wilton Road</ix:nonNumeric></span>, <span id="xdx_901_edei--EntityAddressAddressLine2_c20230629__20230629_z0xdbOVGpmD8"><ix:nonNumeric contextRef="From2023-06-29to2023-06-29" name="dei:EntityAddressAddressLine2">3<sup>rd</sup> Floor</ix:nonNumeric></span><br />
    <span id="xdx_902_edei--EntityAddressCityOrTown_c20230629__20230629_z07DNo3rrva2"><ix:nonNumeric contextRef="From2023-06-29to2023-06-29" name="dei:EntityAddressCityOrTown">Westport</ix:nonNumeric></span></b><b>, <span id="xdx_907_edei--EntityAddressStateOrProvince_c20230629__20230629_zBzZrRjTsK5k"><ix:nonNumeric contextRef="From2023-06-29to2023-06-29" name="dei:EntityAddressStateOrProvince">CT</ix:nonNumeric></span></b></p></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: center; width: 49%"><span style="font-size: 10pt"><b><span id="xdx_90E_edei--EntityAddressPostalZipCode_c20230629__20230629_zAqEITVsLhL"><ix:nonNumeric contextRef="From2023-06-29to2023-06-29" name="dei:EntityAddressPostalZipCode">06880</ix:nonNumeric></span></b></span></td></tr>
  <tr>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>(Address of Principal Executive Offices)</b></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>(Zip Code)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_903_edei--CityAreaCode_c20230629__20230629_zeUkDlEVN3ri"><ix:nonNumeric contextRef="From2023-06-29to2023-06-29" name="dei:CityAreaCode">203</ix:nonNumeric></span>) <span id="xdx_90A_edei--LocalPhoneNumber_c20230629__20230629_zJ76DjhWsOpa"><ix:nonNumeric contextRef="From2023-06-29to2023-06-29" name="dei:LocalPhoneNumber">221-7381</ix:nonNumeric></span> (Registrant&#8217;s
Telephone Number, Including Area Code)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Not Applicable</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(Former Name or Former Address, if Changed Since
Last Report)</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2.
below):</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span id="xdx_905_edei--WrittenCommunications_c20230629__20230629_zr4BKpS1sWh7"><ix:nonNumeric contextRef="From2023-06-29to2023-06-29" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></td><td style="text-align: justify">Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span id="xdx_906_edei--SolicitingMaterial_c20230629__20230629_z0Kb2TQoqY78"><ix:nonNumeric contextRef="From2023-06-29to2023-06-29" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></td><td style="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span id="xdx_905_edei--PreCommencementTenderOffer_c20230629__20230629_zIi0dSuIOGE3"><ix:nonNumeric contextRef="From2023-06-29to2023-06-29" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75pt">&#160;</p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0in; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left"><span id="xdx_90E_edei--PreCommencementIssuerTenderOffer_c20230629__20230629_zjI5KD2X0rre"><ix:nonNumeric contextRef="From2023-06-29to2023-06-29" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></td><td style="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</td>
</tr></table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center"><span style="font-size: 10pt"><b>Title of Each Class:</b></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; vertical-align: bottom; width: 32%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Trading&#160;Symbol(s):</b></p></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 32%">
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Name of Exchange on Which
    Registered:</b></p></td></tr>
  <tr style="background-color: rgb(204,238,255)">
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_907_edei--Security12bTitle_c20230629__20230629_zwEqOoV8MtG3"><ix:nonNumeric contextRef="From2023-06-29to2023-06-29" name="dei:Security12bTitle">Common Stock, $0.0001 par value per share</ix:nonNumeric></span></b></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b><span id="xdx_90C_edei--TradingSymbol_c20230629__20230629_zkNm35q9GaHc"><ix:nonNumeric contextRef="From2023-06-29to2023-06-29" name="dei:TradingSymbol">INTS</ix:nonNumeric></span></b></span></td>
    <td>&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font-size: 10pt"><b>The <span id="xdx_901_edei--SecurityExchangeName_c20230629__20230629_zE7PkFvGMhoh"><ix:nonNumeric contextRef="From2023-06-29to2023-06-29" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span id="xdx_900_edei--EntityEmergingGrowthCompany_c20230629__20230629_zDshEwhQjUP9"><ix:nonNumeric contextRef="From2023-06-29to2023-06-29" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span id="xdx_900_edei--EntityExTransitionPeriod_c20230629__20230629_z727hCVpcHbd"><ix:nonNumeric contextRef="From2023-06-29to2023-06-29" format="ixt:booleantrue" name="dei:EntityExTransitionPeriod">&#9746;</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>


<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Item 1.01. Entry Into
a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On June 29, 2023, Intensity
Therapeutics, Inc. (the &#8220;<b><i>Company</i></b>&#8221;) entered into an Underwriting Agreement (the &#8220;<b><i>Underwriting Agreement</i></b>&#8221;)
with The Benchmark Company, LLC, as representative of the underwriters named on Schedule 1 thereto (the&#160;<b><i>&#8220;Representative</i></b>&#8221;)
relating to the Company&#8217;s firm commitment underwritten initial public offering (the &#8220;<b><i>Offering</i></b>&#8221;) of common
stock, par value $0.0001 per share (the &#8220;<b><i>Common Stock</i></b>&#8221;), which was registered under the Securities Act of 1933,
as amended (the &#8220;<b><i>Securities Act</i></b>&#8221;) by the Company&#8217;s registration statement on Form S-1, as amended (File
No. 333-260565) (the &#8220;<b><i>Registration Statement</i></b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Pursuant to the Underwriting
Agreement, the Company agreed to sell 3,900,000 shares of Common Stock (the &#8220;<b><i>Firm Shares</i></b>&#8221;) to the Representative
at a public offering price of $5.00 per share (the &#8220;<b><i>Offering Price</i></b>&#8221;) for total gross proceeds of $19,500,000.
The Company also granted the Representative a 45-day over-allotment option to purchase up to 585,000 additional shares of Common Stock
(the &#8220;<b><i>Option Shares</i></b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company intends to
use the proceeds primarily to (i) initiate and conduct studies related to its therapeutic treatments, (ii) conduct clinical trials and
operations, (iii) develop its product candidates, and (iv) fund its working capital and general corporate activities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Underwriting Agreement
includes customary representations, warranties and covenants by the Company. It also provides that the Company will indemnify the Representative
against certain liabilities, including liabilities under the Securities Act. In exchange for the Representative&#8217;s services, the
Company agreed to (i) sell the Common Stock to the Representative at a purchase price of $4.65 per share representing a 7.0% underwriting
discount, (ii) pay accountable expenses of the Representative up to $175,000, (iii) pay a non-accountable expense allowance to the Representative
equal to 1% of the gross proceeds received at the closing of the Offering, and (ii) issue the Representative (or its designees) a warrant
to purchase shares of Common Stock representing 7.0% of the number of Firm Shares and Option Shares sold in the Offering (the &#8220;<b><i>Representative&#8217;s
Warrant</i></b>&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Offering closed on
July 5, 2023, and the Company sold 3,900,000 shares of Common Stock to the Representative. After deducting the underwriting commissions,
discounts, and offering expenses payable by the Company, the Company received net proceeds of approximately $16.2 million.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In addition, pursuant
to the Underwriting Agreement, the Company issued the Representative&#8217;s Warrant to purchase up to an aggregate of 273,000 shares
of Common Stock. The Representative&#8217;s Warrant may be exercised commencing from the closing of the Offering on July 5, 2023, and
expiring five (5) years from the effective date of the Registration Statement on July 5, 2028, at an exercise price of $6.00 per share
(120% of the public offering price of the Common Stock).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The foregoing summaries
of the Underwriting Agreement and Representative&#8217;s Warrant are qualified in their entirety by reference to the full text of the
Underwriting Agreement and form of Representative&#8217;s Warrant attached as Exhibits 10.1 and 4.1, respectively, to this Current Report
on Form 8-K and is incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>Item 5.03. Amendments to Certificate of Incorporation or Bylaws.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Amended and Restated Certificate of Incorporation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the closing of the Offering, on June 30, 2023, the
Company filed its Sixth Amended and Restated Certificate of Incorporation (the &#8220;<b><i>Sixth Amended and Restated Charter</i></b>&#8221;).&#160;
The Company&#8217;s board of directors previously approved the Sixth Amended and Restated Charter to be effective prior to the completion
of the Offering. The terms of the Sixth Amended and Restated Charter are the same as the terms set forth in the form previously filed
as an exhibit to the Registration Statement and as described therein, which are incorporated herein by reference. The Sixth Amended and
Restated Charter is filed herewith as Exhibit 3.1 and incorporated herein by reference.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Amended and Restated Bylaws</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the closing of the Offering, <span style="background-color: white">effective
as of July 5, 2023, the Company adopted amended and restated bylaws (the &#8220;<b><i>Amended and Restated Bylaws</i></b>&#8221;). The
Company&#8217;s board of directors previously approved the Amended and Restated Bylaws to be effective upon the closing of the Offering.
</span>The terms of the Amended and Restated Bylaws are the same as the terms set forth in the form previously filed as an exhibit to
the Registration Statement and as described therein. <span style="background-color: white">The Amended and Restated Bylaws are attached
hereto as Exhibit 3.2 and are incorporated herein by reference.&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Item 7.01 Regulation
FD Disclosure.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><i><span style="text-decoration: underline">Press Release</span></i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On June 29, 2023, the
Company issued a press release regarding the pricing of the initial public offering. A copy of the press release is attached as Exhibit
99.1 hereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On July 5, 2023, the
Company issued a press release regarding the closing of the initial public offering. A copy of the press release is attached as Exhibit
99.2 hereto.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The information in this
Item 7.01, including Exhibit 99.1 and Exhibit 99.2 attached hereto, is being furnished and shall not be deemed &#8220;filed&#8221; for
the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;<b><i>Exchange Act</i></b>&#8221;), nor shall
it be deemed incorporated by reference in any of the Company&#8217;s filings under the Securities Act, or the Exchange Act, whether made
before or after the date hereof, except as shall be expressly set forth by specific reference to this Report in such filing.</p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Item 9.01. Financial
Statements and Exhibits.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">(d) Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 9%"><span style="font-size: 10pt"><b>Exhibit No.</b></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 90%"><span style="font-size: 10pt"><b>Description</b></span></td></tr>
  <tr>
    <td style="vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">3.1</span></td>
    <td>&#160;</td>
    <td><a href="ea181296ex3-1_intensity.htm"><span style="font-size: 10pt">Sixth Amended and Restated Certificate of Incorporation, dated June 30, 2023.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">3.2</span></td>
    <td>&#160;</td>
    <td><a href="ea181296ex3-2_intensity.htm"><span style="font-size: 10pt">Amended and Restated Bylaws, dated July 5, 2023.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">4.1</span></td>
    <td>&#160;</td>
    <td><a href="ea181296ex4-1_intensity.htm"><span style="font-size: 10pt">Representative&#8217;s Warrant.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td><span style="font-size: 10pt">10.1</span></td>
    <td>&#160;</td>
    <td><a href="ea181296ex10-1_intensity.htm"><span style="font-size: 10pt">Underwriting Agreement, dated June 29, 2023.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">99.1</span></td>
    <td>&#160;</td>
    <td><a href="ea181296ex99-1_intensity.htm"><span style="font-size: 10pt">Press Release issued June 29, 2023.</span></a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>99.2</td>
    <td>&#160;</td>
    <td><a href="ea181296ex99-2_intensity.htm">Press Release issued July 5, 2023.</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><span style="font-size: 10pt">104</span></td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Cover Page Interactive Data File (formatted in Inline XBRL).</span></td></tr>
  </table>

<p style="margin-top: 0; margin-bottom: 0">&#160;</p>

<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dated: July 5, 2023</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="3"><span style="font-size: 10pt"><b>Intensity Therapeutics, Inc.</b></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td><span style="font-size: 10pt">By:</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid"><span style="font-size: 10pt">/s/ Lewis H. Bender</span></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="width: 5%"><span style="font-size: 10pt">Name:&#160;</span></td>
    <td style="width: 31%"> <span style="font-size: 10pt">Lewis H. Bender</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-size: 10pt">Title: </span></td>
    <td><span style="font-size: 10pt">Chief Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<i>Signature Page to the Form 8-K</i>]</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">3</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5Fm1a/KFvWlTEKlJEfI12K8E2Wzbx70je0tgiLgvLMvPNCNETS1roChmOszyDPdZNpRxCjiUymjN6R7paJ+BvjhdtHSvj2vcHpuQZ9MywLycnL7TWu7ZYJBCOB2E8iGKQMolHMN2I4KunZEpdoHFaVaBMATumhjU6xa8uYa+eZKh+tVUHZKvJJCD7YSe/IQplBFu6qwfx1UKWpSLotROIJdOt+dbcrKMa5hXWvst26H+DDxQOSUE= -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>ea181296ex3-1_intensity.htm
<DESCRIPTION>SIXTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION, DATED JUNE 30, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin-top: 0; margin-bottom: 0; margin-left: 0"><B>Exhibit 3.1</B></P>

<P STYLE="margin-top: 0; margin-bottom: 0; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">SIXTH AMENDED AND RESTATED<BR>
CERTIFICATE OF INCORPORATION<BR>
OF<BR>
INTENSITY THERAPEUTICS, INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">(Pursuant to Sections 242 and 245 of the<BR>
General Corporation Law of the State of Delaware)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">Intensity Therapeutics, Inc.,
a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the
&ldquo;<B>General Corporation Law</B>&rdquo;),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><B>DOES HEREBY CERTIFY:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>1. </B></FONT>That
the name of this corporation is Intensity Therapeutics, Inc., and that this corporation was originally incorporated pursuant to the General
Corporation Law on November 30, 2012, upon the conversion of its predecessor, Intensity Therapeutics LLC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>2. </B></FONT>That
the Board of Directors duly adopted resolutions proposing to amend and restate the Certificate of Incorporation of this corporation, declaring
said amendment and restatement to be advisable and in the best interests of this corporation and its stockholders, and authorizing the
appropriate officers of this corporation to solicit the consent of the stockholders therefor, which resolution setting forth the proposed
amendment and restatement is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><B>RESOLVED</B>, that the Certificate
of Incorporation of this corporation be amended and restated in its entirety to read as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>First:
</B></FONT>The name of this corporation is Intensity Therapeutics, Inc. (the &ldquo;<B>Corporation</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Second:
</B></FONT>The address of the registered office of the Corporation in the State of Delaware is Corporation Service Company, 251 Little
Falls Drive, Wilmington, County of New Castle, Delaware 19808. The name of its registered agent at such address is Corporation Service
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Third:
</B></FONT>The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which corporations
may be organized under the General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Fourth:
</B></FONT>The total number of shares of all classes of stock which the Corporation shall have authority to issue is (i) 135,000,000 shares
of Common Stock, $0.0001 par value per share (&ldquo;<B>Common Stock</B>&rdquo;) and (ii) 15,000,000 shares of Preferred Stock, $0.0001
par value per share (&ldquo;<B>Preferred Stock</B>&rdquo;). Subject to the rights of the holders of any series of Preferred Stock, the
number of authorized shares of any of the Common Stock or Preferred Stock may be increased or decreased (but not below the number of shares
thereof then outstanding) by the affirmative vote of the holders of a majority in voting power of the capital stock of the Corporation
entitled to vote thereon irrespective of the provisions of Section 242(b)(2) of the General Corporation Law, and no vote of the holders
of any of the Common Stock or Preferred Stock voting separately as a class shall be required therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">The following is a statement
of the designations and the powers, privileges and rights, and the qualifications, limitations or restrictions thereof in respect of each
class of capital stock of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">A. COMMON
STOCK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">1. <U>General</U>.
The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the rights, powers and
preferences of the holders of the Preferred Stock set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">2. <U>Voting</U>.
Except as otherwise provided by law or by the resolution or resolutions providing for the issue of any series of Preferred Stock, the
holders of outstanding shares of Common Stock shall have the exclusive right to vote for the election and removal of directors and for
all other purposes. Notwithstanding any other provision of this Sixth Amended and Restated Certificate of Incorporation (as amended from
time to time, including the terms of any Preferred Stock Designation (as defined below), this &ldquo;<B>Certificate of Incorporation</B>&rdquo;)
to the contrary, the holders of Common Stock shall not be entitled to vote on any amendment to this Certificate of Incorporation (including
any Preferred Stock Designation) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders
of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote
thereon pursuant to this Certificate of Incorporation (including any Preferred Stock Designation) or the General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">3. <U>Dividends</U>.
Subject to the rights of the holders of Preferred Stock, holders of shares of Common Stock shall be entitled to receive such dividends
and distributions and other distributions in cash, stock or property of the Corporation when, as and if declared thereon by the Board
of Directors from time to time out of assets or funds of the Corporation legally available therefor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">4. <U>Rights
Upon Liquidation</U>. Subject to the rights of the holders of Preferred Stock, shares of Common Stock shall be entitled to receive the
assets and funds of the Corporation available for distribution in the event of any liquidation, dissolution or winding up of the affairs
of the Corporation, whether voluntary or involuntary. A liquidation, dissolution or winding up of the affairs of the Corporation, as such
terms are used in this Section A.4., shall not be deemed to be occasioned by or to include any consolidation or merger of the Corporation
with or into any other person or a sale, lease, exchange or conveyance of all or a part of its assets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">B. PREFERRED
STOCK</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">Shares of Preferred Stock may
be issued from time to time in one or more series. The Board is hereby authorized to provide by resolution or resolutions from time to
time for the issuance, out of the unissued shares of Preferred Stock, of one or more series of Preferred Stock, without stockholder approval,
by filing a certificate pursuant to the applicable law of the State of Delaware (the &ldquo;<B>Preferred Stock Designation</B>&rdquo;),
setting forth such resolution and, with respect to each such series, establishing the number of shares to be included in such series,
and fixing the voting powers, full or limited, or no voting power of the shares of such series, and the designation, preferences and relative,
participating, optional or other special rights, if any, of the shares of each such series and any qualifications, limitations or restrictions
thereof. The powers, designation, preferences and relative, participating, optional and other special rights of each series of Preferred
Stock, and the qualifications, limitations and restrictions thereof, if any, may differ from those of any and all other series at any
time outstanding. The authority of the Board with respect to each series of Preferred Stock shall include, but not be limited to, the
determination of the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">1. the
designation of the series, which may be by distinguishing number, letter or title;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">2. the
number of shares of the series, which number the Board may thereafter (except where otherwise provided in the Preferred Stock Designation)
increase or decrease (but not below the number of shares thereof then outstanding);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">3. the
amounts or rates at which dividends will be payable on, and the preferences, if any, of shares of the series in respect of dividends,
and whether such dividends, if any, shall be cumulative or noncumulative;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">4. the
dates on which dividends, if any, shall be payable;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">5. the
redemption rights and price or prices, if any, for shares of the series;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">6. the
terms and amount of any sinking fund, if any, provided for the purchase or redemption of shares of the series;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">7. the
amounts payable on, and the preferences, if any, of shares of the series in the event of any voluntary or involuntary liquidation, dissolution
or winding up of the affairs of the Corporation;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">8. whether
the shares of the series shall be convertible into or exchangeable for, shares of any other class or series, or any other security, of
the Corporation or any other corporation, and, if so, the specification of such other class or series or such other security, the conversion
or exchange price or prices or rate or rates, any adjustments thereof, the date or dates at which such shares shall be convertible or
exchangeable and all other terms and conditions upon which such conversion or exchange may be made;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">9. restrictions
on the issuance of shares of the same series or any other class or series;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">10. the
voting rights, if any, of the holders of shares of the series generally or upon specified events; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">11. any
other powers, preferences and relative, participating, optional or other special rights of each series of Preferred Stock, and any qualifications,
limitations or restrictions of such shares,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in">all as may be determined from
time to time by the Board and stated in the resolution or resolutions providing for the issuance of such Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0in">Without limiting the generality
of the foregoing, the resolutions providing for issuance of any series of Preferred Stock may provide that such series shall be superior
or rank equally or be junior to any other series of Preferred Stock to the extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 58.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 58.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Fifth:
</B></FONT>This Article FIFTH is inserted for the management of the business and for the conduct of the affairs of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">A. <FONT STYLE="text-transform: uppercase">General
Powers</FONT>. The business and affairs of the Corporation shall be managed by or under the direction of the Board, except as otherwise
provided by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">B. <FONT STYLE="text-transform: uppercase">Number
of Directors; Election of Directors</FONT>. Subject to the rights of holders of any series of Preferred Stock to elect directors, the
number of directors of the Corporation shall be fixed from time to time solely by resolution of the majority of the Whole Board. For purposes
of this Certificate of Incorporation, the term &ldquo;Whole Board&rdquo; will mean the total number of authorized directors, whether or
not there exist any vacancies in previously authorized directorships. No decrease in the number of directors constituting the Board shall
shorten the term of any incumbent director.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">C. <FONT STYLE="text-transform: uppercase">Classes
of Directors</FONT>. Subject to the rights of holders of any series of Preferred Stock to elect directors, the Board shall be and is divided
into three classes, designated Class I, Class II and Class III. Each class shall consist, as nearly as may be possible, of one third of
the total number of directors constituting the entire Board. The Board is authorized to assign members of the Board already in office
to Class I, Class II or Class III at the time such classification becomes effective.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">D. <FONT STYLE="text-transform: uppercase">Terms
of Office</FONT>. Subject to the rights of holders of any series of Preferred Stock to elect directors, each director shall serve for
a term ending on the date of the third annual meeting of stockholders following the annual meeting of stockholders at which such director
was elected; provided that each director initially assigned to Class I shall serve for a term expiring at the Corporation&rsquo;s first annual
meeting of stockholders held after the effectiveness of this Certificate of Incorporation; each director initially assigned to Class II
shall serve for a term expiring at the Corporation&rsquo;s second annual meeting of stockholders held after the effectiveness of this Certificate
of Incorporation; and each director initially assigned to Class III shall serve for a term expiring at the Corporation&rsquo;s third annual
meeting of stockholders held after the effectiveness of this Certificate of Incorporation; provided further, that the term of each director
shall continue until the election and qualification of his or her successor and be subject to his or her earlier death, disqualification,
resignation or removal.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">E. <FONT STYLE="text-transform: uppercase">Vacancies</FONT>.
Subject to the rights of holders of any series of Preferred Stock, any newly created directorship that results from an increase in the
number of directors or any vacancy on the Board that results from the death, disability, resignation, disqualification or removal of any
director or from any other cause shall be filled solely by the affirmative vote of a majority of the total number of directors then in
office, even if less than a quorum, or by a sole remaining director and shall not be filled by the stockholders. Any director elected
to fill a vacancy not resulting from an increase in the number of directors shall hold office for the remaining term of his or her predecessor.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">F. <FONT STYLE="text-transform: uppercase">Removal</FONT>.
Any director or the entire Board may be removed from office at any time, but only for cause and only by the affirmative vote of the holders
of at least 66 2/3% in voting power of the stock of the Corporation entitled to vote thereon.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">G. <FONT STYLE="text-transform: uppercase">Committees</FONT>.
Pursuant to the [Amended and Restated] Bylaws of the Corporation (the &ldquo;Bylaws&rdquo;), the Board may establish one or more committees
to which may be delegated any or all of the powers and duties of the Board to the full extent permitted by law.</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 0.5in">H. <FONT STYLE="text-transform: uppercase">Stockholder
Nominations and Introduction of Business</FONT>. Advance notice of stockholder nominations for election of directors and other business
to be brought by stockholders before a meeting of stockholders shall be given in the manner provided by the Bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Sixth:
</B></FONT>Elections of directors need not be by written ballot unless the Bylaws of the Corporation shall so provide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Seventh:
</B></FONT>In furtherance and not in limitation of the powers conferred upon it by law, the Board is expressly authorized and empowered
to adopt, amend and repeal the Bylaws by the affirmative vote of a majority of the Whole Board. Notwithstanding any other provision of
this Certificate of Incorporation or any provision of law that might otherwise permit a lesser vote or no vote, but in addition to any
affirmative vote of the holders of any series of Preferred Stock required by law, by this Certificate of Incorporation or by any Preferred
Stock Designation, the Bylaws may also be amended, altered or repealed and new Bylaws may be adopted by the affirmative vote of the holders
of at least 66 2/3% in voting power of the stock of the Corporation entitled to vote thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Eighth:
</B></FONT>Subject to the terms of any series of Preferred Stock, any action required or permitted to be taken by the stockholders of
the Corporation must be effected at an annual or special meeting of the stockholders called in accordance with the Bylaws and may not
be effected by written consent in lieu of a meeting. Meetings of stockholders may be held within or without the State of Delaware, as
the Bylaws of the Corporation may provide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Ninth:
</B></FONT>Special meetings of stockholders for any purpose or purposes may be called at any time by the majority of the Whole Board,
the Chairman of the Board or the Chief Executive Officer of the Corporation, and may not be called by another other person or persons.
Business transacted at any special meeting of stockholders shall be limited to matters relating to the purpose or purposes stated in the
notice of meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Tenth:
</B></FONT>The books of the Corporation may be kept outside the State of Delaware at such place or places as may be designated from time
to time by the Board of Directors or in the Bylaws of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Eleventh:
</B></FONT>To the fullest extent permitted by law, a director of the Corporation shall not be personally liable to the Corporation or
its stockholders for monetary damages for breach of fiduciary duty as a director. If the General Corporation Law or any other law of the
State of Delaware is amended after approval by the stockholders of this Article Ninth to authorize corporate action further eliminating
or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to
the fullest extent permitted by the General Corporation Law as so amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 0in">Any repeal or modification
of the foregoing provisions of this Article Ninth by the stockholders of the Corporation shall not adversely affect any right or protection
of a director of the Corporation existing at the time of, or increase the liability of any director of the Corporation with respect to
any acts or omissions of such director occurring prior to, such repeal or modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Twelfth:
</B></FONT>To the fullest extent permitted by applicable law, the Corporation is authorized to provide indemnification of (and advancement
of expenses to) directors, officers and agents of the Corporation (and any other persons to which General Corporation Law permits the
Corporation to provide indemnification) through Bylaw provisions, agreements with such agents or other persons, vote of stockholders or
disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by <U>Section 145</U> of the
General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 0in">Any amendment, repeal
or modification of the foregoing provisions of this Article Tenth shall not adversely affect any right or protection of any director,
officer or other agent of the Corporation existing at the time of such amendment, repeal or modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Thirteenth:
</B></FONT> Unless the Corporation consents in writing to the selection of an alternative forum, the Court of Chancery in the State of
Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i)&nbsp;any derivative action
or proceeding brought on behalf of the Corporation, (ii)&nbsp;any action asserting a claim of breach of fiduciary duty owed by any director,
officer or other employee of the Corporation to the Corporation or the Corporation&rsquo;s stockholders, (iii)&nbsp;any action asserting
a claim against the Corporation, its directors, officers or employees arising pursuant to any provision of the Delaware General Corporation
Law or the Corporation&rsquo;s certificate of incorporation or bylaws or (iv)&nbsp;any action asserting a claim against the Corporation,
its directors, officers or employees governed by the internal affairs doctrine, except for, as to each of (i) through (iv) above, any
claim as to which the Court of Chancery determines that there is an indispensable party not subject to the jurisdiction of the Court of
Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following
such determination), which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery, or for which
the Court of Chancery does not have subject matter jurisdiction. If any provision or provisions of this Article Eleventh shall be held
to be invalid, illegal or unenforceable as applied to any person or entity or circumstance for any reason whatsoever, then, to the fullest
extent permitted by law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions
of this Article Eleventh (including, without limitation, each portion of any sentence of this Article Eleventh containing any such provision
held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of such
provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase"><B></B></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; text-transform: uppercase"><B>Fourteenth:
</B></FONT>If any provision or provisions of this Certificate of Incorporation shall be held to be invalid, illegal or unenforceable as
applied to any circumstance for any reason whatsoever: (i) the validity, legality and enforceability of such provisions in any other circumstance
and of the remaining provisions of this Certificate of Incorporation (including, without limitation, each portion of any paragraph of
this Certificate of Incorporation containing any such provision held to be invalid, illegal or unenforceable that is not itself held to
be invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and (ii) to the fullest extent possible, the
provisions of this Certificate of Incorporation (including, without limitation, each such portion of any paragraph of this Certificate
of Incorporation containing any such provision held to be invalid, illegal or unenforceable) shall be construed so as to permit the Corporation
to protect its directors, officers, employees and agents from personal liability in respect of their good faith service or for the benefit
of the Corporation to the fullest extent permitted by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 49.5pt; text-align: justify; text-indent: 0in">The Corporation reserves
the right at any time from time to time to amend, alter, change or repeal any provision contained in this Certificate of Incorporation,
and any other provisions authorized by the General Corporation Law may be added or inserted, in the manner now or hereafter prescribed
by law; and all rights, preferences and privileges of whatsoever nature conferred upon stockholders, directors or any other persons whomsoever
by and pursuant to this Certificate of Incorporation in its present form or as hereafter amended are granted subject to the right reserved
in this Article ELEVENTH. Notwithstanding any other provision of this Certificate of Incorporation or any provision of law that might
otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any series of Preferred Stock required
by law, by this Certificate of Incorporation or by any Preferred Stock Designation, the affirmative vote of the holders of a majority
in voting power of the stock of the Corporation entitled to vote thereon shall be required to amend, alter, change or repeal any provision
of this Certificate of Incorporation, or to adopt any new provision of this Certificate of Incorporation; provided, however, that the
affirmative vote of the holders of at least 66 2/3% in voting power of the stock of the Corporation entitled to vote thereon shall be
required to amend, alter, change or repeal, or adopt any provision inconsistent with, any of Article FIFTH, Article SEVENTH, Article EIGHTH,
Article NINTH, Article ELEVENTH, Article TWELFTH, Article THIRTEENTH, and this sentence of this Certificate of Incorporation, or in each
case, the definition of any capitalized terms used therein or any successor provision (including, without limitation, any such article
or section as renumbered as a result of any amendment, alteration, change, repeal or adoption of any other provision of this Certificate
of Incorporation). Any amendment, repeal or modification of any of Article ELEVENTH, Article TWELFTH, and this sentence shall not adversely
affect any right or protection of any person existing thereunder with respect to any act or omission occurring prior to such repeal or
modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">* &nbsp;&nbsp;&nbsp;&nbsp;* &nbsp;&nbsp;&nbsp;*</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>3. </B></FONT>That
the foregoing amendment and restatement was approved by the holders of the requisite number of shares of this corporation in accordance
with Section 228 of the General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>4. </B></FONT>That
this Sixth Amended and Restated Certificate of Incorporation, which restates and integrates and further amends the provisions of this
Corporation&rsquo;s Certificate of Incorporation, has been duly adopted in accordance with Sections 242 and 245 of the General Corporation
Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">[Signature Page Follows]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in"><B>IN WITNESS WHEREOF</B>,
this Sixth Amended and Restated Certificate of Incorporation has been executed by a duly authorized officer of this corporation on June
30, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 60%">&nbsp;</TD>
  <TD STYLE="width: 4%">By: </TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%">/s/
Lewis H. Bender</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>Lewis H. Bender, President and Chief Executive Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 2.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 2.5in"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; margin-left: 0; text-indent: 2.5in">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>3
<FILENAME>ea181296ex3-2_intensity.htm
<DESCRIPTION>AMENDED AND RESTATED BYLAWS, DATED JULY 5, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 3.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amended and Restated Bylaws of </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Intensity Therapeutics, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(a Delaware corporation) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Table of Contents </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.25in; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Article I - Corporate Offices</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top; width: 10%"><FONT STYLE="font-size: 10pt">1.1</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 80%"><FONT STYLE="font-size: 10pt">Registered Office</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; width: 10%"><FONT STYLE="font-size: 10pt">1</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">1.2</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Other Offices</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Article II - Meetings of Stockholders</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">2.1</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Place of Meetings</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">2.2</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Annual Meeting</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">2.3</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Special Meeting</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">2.4</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Notice of Business to be Brought before a Meeting</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">2</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">2.5</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Notice of Nominations for Election to the Board</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">4</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">2.6</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Notice of Stockholders&rsquo; Meetings</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">7</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">2.7</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Quorum</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">7</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">2.8</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Adjourned Meeting; Notice</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center">8</TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">2.9</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Conduct of Business</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">8</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">2.10</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Voting</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">8</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">2.11</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Record Date for Stockholder Meetings and Other Purposes</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">9</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">2.12</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Proxies</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">9</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">2.13</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">List of Stockholders Entitled to Vote</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">9</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">2.14</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Inspectors of Election</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">10</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">2.15</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Delivery to the Corporation</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">10</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">2.16</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Stockholder Action by Written Consent Without a Meeting</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">10</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Article III - Directors</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">11</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Powers</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">11</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">3.2</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Number of Directors</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">11</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">3.3</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Election, Qualification and Term of Office of Directors</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">11</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">3.4</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Resignation and Vacancies</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">11</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">3.5</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Place of Meetings; Meetings by Telephone</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">11</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">3.6</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Regular Meetings</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">12</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">3.7</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Special Meetings; Notice</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">12</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">3.8</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Quorum</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">13</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">3.9</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Board Action without a Meeting</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">13</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">3.10</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Fees and Compensation of Directors</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">13</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">3.11</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Removal of Directors</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">13</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Article IV - Committees</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">13</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Committees of Directors</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">13</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Committee Minutes</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">14</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">4.3</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Meetings and Actions of Committees</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">14</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">4.4</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Subcommittees</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">14</FONT></TD>
    </TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Article V - Officers</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">15</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; width: 10%">&nbsp;</TD>
    <TD STYLE="width: 80%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 10%">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">5.1</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Officers</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">15</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">5.2</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Appointment of Officers</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">15</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">5.3</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Subordinate Officers</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">15</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">5.4</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Removal and Resignation of Officers</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">15</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">5.5</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Vacancies in Offices</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">15</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">5.6</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Representation of Shares of Other Corporations</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">15</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">5.7</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Authority and Duties of Officers</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">15</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">5.8</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Compensation</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">15</FONT></TD>
    </TR>

<TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Article VI - Records</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">16</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Article VII - General Matters</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">16</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">7.1</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Execution of Corporate Contracts and Instruments</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">16</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">7.2</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Stock Certificates</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">16</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">7.3</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Special Designation of Certificates</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">17</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">7.4</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Lost Certificates</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">17</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">7.5</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Shares Without Certificates</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">17</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">7.6</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Construction; Definitions</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">17</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">7.7</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Dividends</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">17</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">7.8</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Fiscal Year</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">17</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">7.9</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Seal</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">18</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">7.10</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Transfer of Stock</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">18</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">7.11</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Stock Transfer Agreements</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">18</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">7.12</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Registered Stockholders</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">18</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">7.13</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Waiver of Notice</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">18</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Article VIII - Notice</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">19</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">8.1</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Delivery of Notice; Notice by Electronic Transmission</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">19</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Article IX - Indemnification</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center">20</TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">9.1</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Indemnification of Directors and Officers</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">20</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">9.2</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Indemnification of Others</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">20</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">9.3</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Prepayment of Expenses</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">20</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">9.4</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Determination; Claim</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">20</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">9.5</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Non-Exclusivity of Rights</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">20</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">9.6</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Insurance</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">21</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">9.7</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Other Indemnification</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">21</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">9.8</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Continuation of Indemnification</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">21</FONT></TD>
    </TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-align: left; vertical-align: top"><FONT STYLE="font-size: 10pt">9.9</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom"><FONT STYLE="font-size: 10pt">Amendment or Repeal; Interpretation</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt">21</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Article X - Amendments</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">22</FONT></TD>
    </TR>
  <TR STYLE="background-color: White">
    <TD COLSPAN="2">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">Article XI - Definitions</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">22</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Amended and Restated Bylaws of </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Intensity Therapeutics, Inc. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE I - Corporate Offices </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">1.1 <U>Registered Office</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The address of the registered
office of Intensity Therapeutics, Inc. (the &ldquo;<U>Corporation</U>&rdquo;) in the State of Delaware, and the name of its registered
agent at such address, shall be as set forth in the Corporation&rsquo;s certificate of incorporation, as the same may be amended and/or
restated from time to time (the &ldquo;<U>Certificate of Incorporation</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">1.2 <U>Other Offices</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Corporation may have
additional offices at any place or places, within or outside the State of Delaware, as the Corporation&rsquo;s board of directors (the
&ldquo;<U>Board</U>&rdquo;) may from time to time establish or as the business of the Corporation may require.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE II - Meetings of Stockholders </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">2.1 <U>Place of Meetings</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Meetings of stockholders
shall be held at any place, within or outside the State of Delaware, designated by the Board. The Board may, in its sole discretion, determine
that a meeting of stockholders shall not be held at any place, but may instead be held solely by means of remote communication as authorized
by Section&nbsp;211(a) of the General Corporation Law of the State of Delaware (the &ldquo;<U>DGCL</U>&rdquo;). In the absence of any
such designation or determination, stockholders&rsquo; meetings shall be held at the Corporation&rsquo;s principal executive office.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">2.2 <U>Annual Meeting</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Board shall designate
the date and time of the annual meeting. At the annual meeting, directors shall be elected and other proper business properly brought
before the meeting in accordance with <U>Section&nbsp;2.4</U> may be transacted. The Board may postpone, reschedule or cancel any previously
scheduled annual meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">2.3 <U>Special Meeting</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Special meetings of the stockholders
may be called only by such persons and only in such manner as set forth in the Certificate of Incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No business may be transacted
at any special meeting of stockholders other than the business specified in the notice of such meeting. The Board may postpone, reschedule
or cancel any previously scheduled special meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">2.4 <U>Notice of Business
to be Brought before a Meeting</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(a) At an annual meeting
of the stockholders, only such business shall be conducted as shall have been properly brought before the meeting. To be properly brought
before an annual meeting, business must be (i)&nbsp;specified in a notice of meeting given by or at the direction of the Board, (ii)&nbsp;if
not specified in a notice of meeting, otherwise brought before the meeting by the Board or the Chairperson of the Board or (iii)&nbsp;otherwise
properly brought before the meeting by a stockholder present in person who (A)&nbsp;(1) was a record owner of shares of the Corporation
both at the time of giving the notice provided for in this <U>Section&nbsp;2.4</U> and at the time of the meeting, (2)&nbsp;is entitled
to vote at the meeting and (3)&nbsp;has complied with this <U>Section&nbsp;2.4</U> in all applicable respects or (B)&nbsp;properly made
such proposal in accordance with Rule 14a-8 under the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder
(as so amended and inclusive of such rules and regulations, the &ldquo;<U>Exchange Act</U>&rdquo;). The foregoing clause (iii)&nbsp;shall
be the exclusive means for a stockholder to propose business to be brought before an annual meeting of the stockholders. The only matters
that may be brought before a special meeting are the matters specified in the notice of meeting given by or at the direction of the person
calling the meeting pursuant to <U>Section&nbsp;2.3</U>, and stockholders shall not be permitted to propose business to be brought before
a special meeting of the stockholders. For purposes of this <U>Section&nbsp;2.4</U>, &ldquo;<U>present in person</U>&rdquo; shall mean
that the stockholder proposing that the business be brought before the annual meeting of the Corporation, or a qualified representative
of such proposing stockholder, appear at such annual meeting in person, or by remote communication, if applicable. A &ldquo;<U>qualified
representative</U>&rdquo; of such proposing stockholder shall be a duly authorized officer, manager or partner of such stockholder or
any other person authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act
for such stockholder as proxy at the meeting of stockholders and such person must produce such writing or electronic transmission, or
a reliable reproduction of the writing or electronic transmission, at the meeting of stockholders. Stockholders seeking to nominate persons
for election to the Board must comply with <U>Section&nbsp;2.5</U>, and this <U>Section&nbsp;2.4</U> shall not be applicable to nominations
except as expressly provided in <U>Section&nbsp;2.5</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(b) Without qualification,
for business to be properly brought before an annual meeting by a stockholder, the stockholder must (i)&nbsp;provide Timely Notice (as
defined below) thereof in writing and in proper form to the Secretary of the Corporation and (ii)&nbsp;provide any updates or supplements
to such notice at the times and in the forms required by this <U>Section&nbsp;2.4</U>. To be timely, a stockholder&rsquo;s notice must
be delivered to, or mailed and received at, the principal executive offices of the Corporation not less than ninety (90)&nbsp;days nor
more than one hundred twenty (120)&nbsp;days prior to the one-year anniversary of the preceding year&rsquo;s annual meeting; <I>provided,
however</I>, that if no annual meeting was held in the preceding year, to be timely, a stockholder&rsquo;s notice must be so delivered,
or mailed and received, not earlier than the close of business on the one hundred and twentieth (120<SUP>th</SUP>) day prior to such annual
meeting and not later than the close of business on the later of the ninetieth (90<SUP>th</SUP>) day prior to such annual meeting or,
if later, the tenth (10<SUP>th</SUP>) day following the day on which public disclosure of the date of such annual meeting was first made
by the Corporation; <I>provided, further</I>, that if the date of the annual meeting is more than thirty (30)&nbsp;days before or more
than sixty (60)&nbsp;days after such anniversary date, to be timely, a stockholder&rsquo;s notice must be so delivered, or mailed and
received, not later than the ninetieth (90<SUP>th</SUP>) day prior to such annual meeting or, if later, the tenth (10<SUP>th</SUP>) day
following the day on which public disclosure of the date of such annual meeting was first made by the Corporation (such notice within
such time periods, &ldquo;<U>Timely Notice</U>&rdquo;). In no event shall any adjournment or postponement of an annual meeting or the
announcement thereof commence a new time period for the giving of Timely Notice as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(c) To be in proper form
for purposes of this <U>Section&nbsp;2.4</U>, a stockholder&rsquo;s notice to the Secretary of the Corporation shall set forth:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in">(i) As to each
Proposing Person (as defined below), (A)&nbsp;the name and address of such Proposing Person (including, if applicable, the name and address
that appear on the Corporation&rsquo;s books and records); and (B)&nbsp;the class or series and number of shares of the Corporation that
are, directly or indirectly, owned of record or beneficially owned (within the meaning of Rule 13d-3 under the Exchange Act) by such Proposing
Person, except that such Proposing Person shall in all events be deemed to beneficially own any shares of any class or series of the Corporation
as to which such Proposing Person has a right to acquire beneficial ownership at any time in the future (the disclosures to be made pursuant
to the foregoing clauses (A)&nbsp;and (B) are referred to as &ldquo;<U>Stockholder Information</U>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in">(ii) As to each
Proposing Person, (A)&nbsp;the full notional amount of any securities that, directly or indirectly, underlie any &ldquo;derivative security&rdquo;
(as such term is defined in Rule 16a-1(c) under the Exchange Act) that constitutes a &ldquo;call equivalent position&rdquo; (as such term
is defined in Rule 16a-1(b) under the Exchange Act) (&ldquo;<U>Synthetic Equity Position</U>&rdquo;) and that is, directly or indirectly,
held or maintained by such Proposing Person with respect to any shares of any class or series of shares of the Corporation; <I>provided</I>
that, for the purposes of the definition of &ldquo;Synthetic Equity Position,&rdquo; the term &ldquo;derivative security&rdquo; shall
also include any security or instrument that would not otherwise constitute a &ldquo;derivative security&rdquo; as a result of any feature
that would make any conversion, exercise or similar right or privilege of such security or instrument becoming determinable only at some
future date or upon the happening of a future occurrence, in which case the determination of the amount of securities into which such
security or instrument would be convertible or exercisable shall be made assuming that such security or instrument is immediately convertible
or exercisable at the time of such determination; and, <I>provided, further</I>, that any Proposing Person satisfying the requirements
of Rule 13d-1(b)(1) under the Exchange Act (other than a Proposing Person that so satisfies Rule 13d-1(b)(1) under the Exchange Act solely
by reason of Rule 13d-1(b)(1)(ii)(E)) shall not be deemed to hold or maintain the notional amount of any securities that underlie a Synthetic
Equity Position held by such Proposing Person as a hedge with respect to a bona fide derivatives trade or position of such Proposing Person
arising in the ordinary course of such Proposing Person&rsquo;s business as a derivatives dealer, (B)&nbsp;any rights to dividends on
the shares of any class or series of shares of the Corporation owned beneficially by such Proposing Person that are separated or separable
from the underlying shares of the Corporation, (C)&nbsp;any material pending or threatened legal proceeding in which such Proposing Person
is a party or material participant involving the Corporation or any of its officers or directors, or any affiliate of the Corporation,
(D)&nbsp;any other material relationship between such Proposing Person, on the one hand, and the Corporation or any affiliate of the Corporation,
on the other hand, (E)&nbsp;any direct or indirect material interest in any material contract or agreement of such Proposing Person with
the Corporation or any affiliate of the Corporation (including, in any such case, any employment agreement, collective bargaining agreement
or consulting agreement), (F) a representation that such Proposing Person intends or is part of a group that intends to deliver a proxy
statement or form of proxy to holders of at least the percentage of the Corporation&rsquo;s outstanding capital stock required to approve
or adopt the proposal or otherwise solicit proxies from stockholders in support of such proposal and (G)&nbsp;any other information relating
to such Proposing Person that would be required to be disclosed in a proxy statement or other filing required to be made in connection
with solicitations of proxies or consents by such Proposing Person in support of the business proposed to be brought before the meeting
pursuant to Section&nbsp;14(a) of the Exchange Act (the disclosures to be made pursuant to the foregoing clauses (A)&nbsp;through (G)
are referred to as &ldquo;<U>Disclosable Interests</U>&rdquo;); <I>provided</I>, <I>however</I>, that Disclosable Interests shall not
include any such disclosures with respect to the ordinary course business activities of any broker, dealer, commercial bank, trust company
or other nominee who is a Proposing Person solely as a result of being the stockholder directed to prepare and submit the notice required
by these bylaws on behalf of a beneficial owner; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in">(iii) As to each
item of business that the stockholder proposes to bring before the annual meeting, (A)&nbsp;a brief description of the business desired
to be brought before the annual meeting, the reasons for conducting such business at the annual meeting and any material interest in such
business of each Proposing Person, (B)&nbsp;the text of the proposal or business (including the text of any resolutions proposed for consideration
and in the event that such business includes a proposal to amend the bylaws, the language of the proposed amendment), (C)&nbsp;a reasonably
detailed description of all agreements, arrangements and understandings (x)&nbsp;between or among any of the Proposing Persons or (y)&nbsp;between
or among any Proposing Person and any other person or entity (including their names) in connection with the proposal of such business
by such stockholder, and (D)&nbsp;any other information relating to such item of business that would be required to be disclosed in a
proxy statement or other filing required to be made in connection with solicitations of proxies in support of the business proposed to
be brought before the meeting pursuant to Section&nbsp;14(a) of the Exchange Act; <I>provided</I>, <I>however</I>, that the disclosures
required by this <U>Section&nbsp;2.4(c)(iii)</U> shall not include any disclosures with respect to any broker, dealer, commercial bank,
trust company or other nominee who is a Proposing Person solely as a result of being the stockholder directed to prepare and submit the
notice required by these bylaws on behalf of a beneficial owner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For purposes of this <U>Section&nbsp;2.4</U>,
the term &ldquo;<U>Proposing Person</U><I>&rdquo; </I>shall mean (i)&nbsp;the stockholder providing the notice of business proposed to
be brought before an annual meeting, (ii)&nbsp;the beneficial owner or beneficial owners, if different, on whose behalf the notice of
the business proposed to be brought before the annual meeting is made, and (iii)&nbsp;any participant (as defined in paragraphs (a)(ii)-(vi)
of Instruction 3 to Item 4 of Schedule 14A) with such stockholder in such solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(d) A Proposing Person shall
update and supplement its notice to the Corporation of its intent to propose business at an annual meeting, if necessary, so that the
information provided or required to be provided in such notice pursuant to this <U>Section&nbsp;2.4</U> shall be true and correct as of
the record date for stockholders entitled to vote at the meeting and as of the date that is ten (10)&nbsp;business days prior to the meeting
or any adjournment or postponement thereof, and such update and supplement shall be delivered to, or mailed and received by, the Secretary
of the Corporation at the principal executive offices of the Corporation not later than five (5)&nbsp;business days after the record date
for stockholders entitled to vote at the meeting (in the case of the update and supplement required to be made as of such record date),
and not later than eight (8)&nbsp;business days prior to the date for the meeting or, if practicable, any adjournment or postponement
thereof (and, if not practicable, on the first practicable date prior to the date to which the meeting has been adjourned or postponed)
(in the case of the update and supplement required to be made as of ten (10)&nbsp;business days prior to the meeting or any adjournment
or postponement thereof). For the avoidance of doubt, the obligation to update and supplement as set forth in this paragraph or any other
Section of these bylaws shall not limit the Corporation&rsquo;s rights with respect to any deficiencies in any notice provided by a stockholder,
extend any applicable deadlines hereunder or enable or be deemed to permit a stockholder who has previously submitted notice hereunder
to amend or update any proposal or to submit any new proposal, including by changing or adding matters, business or resolutions proposed
to be brought before a meeting of the stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(e) Notwithstanding anything
in these bylaws to the contrary, no business shall be conducted at an annual meeting that is not properly brought before the meeting in
accordance with this <U>Section&nbsp;2.4</U>. The presiding officer of the meeting shall, if the facts warrant, determine that the business
was not properly brought before the meeting in accordance with this <U>Section&nbsp;2.4</U>, and if he or she should so determine, he
or she shall so declare to the meeting and any such business not properly brought before the meeting shall not be transacted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(f) This <U>Section&nbsp;2.4</U>
is expressly intended to apply to any business proposed to be brought before an annual meeting of stockholders other than any proposal
made in accordance with Rule 14a-8 under the Exchange Act and included in the Corporation&rsquo;s proxy statement. In addition to the
requirements of this <U>Section&nbsp;2.4</U> with respect to any business proposed to be brought before an annual meeting, each Proposing
Person shall comply with all applicable requirements of the Exchange Act with respect to any such business. Nothing in this <U>Section&nbsp;2.4</U>
shall be deemed to affect the rights of stockholders to request inclusion of proposals in the Corporation&rsquo;s proxy statement pursuant
to Rule 14a-8 under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(g) For purposes of these
bylaws, &ldquo;<U>public disclosure</U>&rdquo; shall mean disclosure in a press release reported by a national news service or in a document
publicly filed by the Corporation with the Securities and Exchange Commission pursuant to Sections 13, 14 or 15(d) of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">2.5 <U>Notice of Nominations
for Election to the Board</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(a) Nominations of any person
for election to the Board at an annual meeting or at a special meeting (but only if the election of directors is a matter specified in
the notice of meeting given by or at the direction of the person calling such special meeting) may be made at such meeting only (i)&nbsp;by
or at the direction of the Board, including by any committee or persons authorized to do so by the Board or these bylaws, or (ii)&nbsp;by
a stockholder present in person (A)&nbsp;who was a record owner of shares of the Corporation both at the time of giving the notice provided
for in this <U>Section&nbsp;2.5</U> and at the time of the meeting, (B)&nbsp;is entitled to vote at the meeting, and (C)&nbsp;has complied
with this <U>Section&nbsp;2.5</U> as to such notice and nomination. For purposes of this <U>Section&nbsp;2.5</U>, &ldquo;<U>present in
person</U>&rdquo; shall mean that the stockholder proposing that the business be brought before the meeting of the Corporation, or a qualified
representative of such stockholder, appear at such meeting in person, or by remote communication, if applicable. A &ldquo;<U>qualified
representative</U>&rdquo; of such proposing stockholder shall be a duly authorized officer, manager or partner of such stockholder or
any other person authorized by a writing executed by such stockholder or an electronic transmission delivered by such stockholder to act
for such stockholder as proxy at the meeting of stockholders and such person must produce such writing or electronic transmission, or
a reliable reproduction of the writing or electronic transmission, at the meeting of stockholders. The foregoing clause (iii)&nbsp;shall
be the exclusive means for a stockholder to make any nomination of a person or persons for election to the Board at an annual meeting
or special meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(b) (i) For a stockholder
to make any nomination of a person or persons for election to the Board at an annual meeting, the stockholder must (1)&nbsp;provide Timely
Notice (as defined in <U>Section&nbsp;2.4</U>) thereof in writing and in proper form to the Secretary of the Corporation, (2)&nbsp;provide
the information, agreements and questionnaires with respect to such stockholder and its candidate for nomination as required to be set
forth by this <U>Section&nbsp;2.5</U> and (3)&nbsp;provide any updates or supplements to such notice at the times and in the forms required
by this <U>Section&nbsp;2.5</U><I>. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in">(ii) If the election
of directors is a matter specified in the notice of meeting given by or at the direction of the person calling a special meeting, then
for a stockholder to make any nomination of a person or persons for election to the Board at a special meeting, the stockholder must (i)&nbsp;provide
Timely Notice thereof in writing and in proper form to the Secretary of the Corporation at the principal executive offices of the Corporation,
(ii)&nbsp;provide the information with respect to such stockholder and its candidate for nomination as required by this <U>Section&nbsp;2.5</U>
and (iii)&nbsp;provide any updates or supplements to such notice at the times and in the forms required by this <U>Section&nbsp;2.5</U>.
To be timely, a stockholder&rsquo;s notice for nominations to be made at a special meeting must be delivered to, or mailed and received
at, the principal executive offices of the Corporation not earlier than the one hundred twentieth (120<SUP>th</SUP>) day prior to such
special meeting and not later than the ninetieth (90<SUP>th</SUP>) day prior to such special meeting or, if later, the tenth (10<SUP>th</SUP>)
day following the day on which public disclosure (as defined in <U>Section&nbsp;2.4</U>) of the date of such special meeting was first
made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in">(iii) In no event
shall any adjournment or postponement of an annual meeting or special meeting or the announcement thereof commence a new time period for
the giving of a stockholder&rsquo;s notice as described above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in">(iv) In no event
may a Nominating Person provide Timely Notice with respect to a greater number of director candidates than are subject to election by
stockholders at the applicable meeting. If the Corporation shall, subsequent to such notice, increase the number of directors subject
to election at the meeting, such notice as to any additional nominees shall be due on the later of (i)&nbsp;the conclusion of the time
period for Timely Notice, (ii)&nbsp;the date set forth in <U>Section&nbsp;2.5(b)(ii)</U> or (iii)&nbsp;the tenth day following the date
of public disclosure (as defined in <U>Section&nbsp;2.4</U>) of such increase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(c) To be in proper form
for purposes of this <U>Section&nbsp;2.5</U>, a stockholder&rsquo;s notice to the Secretary of the Corporation shall set forth:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in">(i) As to each
Nominating Person (as defined below), the Stockholder Information (as defined in <U>Section&nbsp;2.4(c)(i)</U>, except that for purposes
of this <U>Section&nbsp;2.5</U>, the term &ldquo;<U>Nominating Person</U>&rdquo; shall be substituted for the term &ldquo;<U>Proposing
Person</U>&rdquo; in all places it appears in <U>Section&nbsp;2.4(c)(i)</U>);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in">(ii) As to each
Nominating Person, any Disclosable Interests (as defined in <U>Section&nbsp;2.4(c)(ii)</U>, except that for purposes of this <U>Section&nbsp;2.5</U>,
the term &ldquo;<U>Nominating Person</U>&rdquo; shall be substituted for the term &ldquo;<U>Proposing Person</U>&rdquo; in all places
it appears in <U>Section&nbsp;2.4(c)(ii)</U> and the disclosure with respect to the business to be brought before the meeting in <U>Section&nbsp;2.4(c)(ii)</U>
shall be made with respect to the election of directors at the meeting); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.45pt; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.25in; text-align: justify; text-indent: 0.5in">(iii) As to each
candidate whom a Nominating Person proposes to nominate for election as a director, (A)&nbsp;all information with respect to such candidate
for nomination that would be required to be set forth in a stockholder&rsquo;s notice pursuant to this <U>Section&nbsp;2.5</U> if such
candidate for nomination were a Nominating Person, (B)&nbsp;all information relating to such candidate for nomination that is required
to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for election of
directors in a contested election pursuant to Section&nbsp;14(a) under the Exchange Act (including such candidate&rsquo;s written consent
to being named in the proxy statement as a nominee and to serving as a director if elected), (C)&nbsp;a description of any direct or indirect
material interest in any material contract or agreement between or among any Nominating Person, on the one hand, and each candidate for
nomination or his or her respective associates or any other participants in such solicitation, on the other hand, including, without limitation,
all information that would be required to be disclosed pursuant to Item 404 under Regulation S-K if such Nominating Person were the &ldquo;registrant&rdquo;
for purposes of such rule and the candidate for nomination were a director or executive officer of such registrant and (D)&nbsp;a completed
and signed questionnaire, representation and agreement as provided in <U>Section&nbsp;2.5(f)</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For purposes of this <U>Section&nbsp;2.5</U>,
the term &ldquo;<U>Nominating Person</U>&rdquo; shall mean (i)&nbsp;the stockholder providing the notice of the nomination proposed to
be made at the meeting, (ii)&nbsp;the beneficial owner or beneficial owners, if different, on whose behalf the notice of the nomination
proposed to be made at the meeting is made, and (iii)&nbsp;any other participant in such solicitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(d) A stockholder providing
notice of any nomination proposed to be made at a meeting shall further update and supplement such notice, if necessary, so that the information
provided or required to be provided in such notice pursuant to this <U>Section&nbsp;2.5</U> shall be true and correct as of the record
date for stockholders entitled to vote at the meeting and as of the date that is ten (10)&nbsp;business days prior to the meeting or any
adjournment or postponement thereof, and such update and supplement shall be delivered to, or mailed and received by, the Secretary of
the Corporation at the principal executive offices of the Corporation not later than five (5)&nbsp;business days after the record date
for stockholders entitled to vote at the meeting (in the case of the update and supplement required to be made as of such record date),
and not later than eight (8)&nbsp;business days prior to the date for the meeting or, if practicable, any adjournment or postponement
thereof (and, if not practicable, on the first practicable date prior to the date to which the meeting has been adjourned or postponed)
(in the case of the update and supplement required to be made as of ten (10)&nbsp;business days prior to the meeting or any adjournment
or postponement thereof). For the avoidance of doubt, the obligation to update and supplement as set forth in this paragraph or any other
Section of these bylaws shall not limit the Corporation&rsquo;s rights with respect to any deficiencies in any notice provided by a stockholder,
extend any applicable deadlines hereunder or enable or be deemed to permit a stockholder who has previously submitted notice hereunder
to amend or update any nomination or to submit any new nomination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(e) In addition to the requirements
of this <U>Section&nbsp;2.5</U> with respect to any nomination proposed to be made at a meeting, each Nominating Person shall comply with
all applicable requirements of the Exchange Act with respect to any such nominations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(f) To be eligible to be
a candidate for election as a director of the Corporation at an annual or special meeting, a candidate must be nominated in the manner
prescribed in <U>Section&nbsp;2.5</U> and the candidate for nomination, whether nominated by the Board or by a stockholder of record,
must have previously delivered (in accordance with the time period prescribed for delivery in a notice to such candidate given by or on
behalf of the Board), to the Secretary of the Corporation at the principal executive offices of the Corporation, (i)&nbsp;a completed
written questionnaire (in a form provided by the Corporation) with respect to the background, qualifications, stock ownership and independence
of such proposed nominee and (ii)&nbsp;a written representation and agreement (in form provided by the Corporation) that such candidate
for nomination (A)&nbsp;is not and, if elected as a director during his or her term of office, will not become a party to (1)&nbsp;any
agreement, arrangement or understanding with, and has not given and will not give any commitment or assurance to, any person or entity
as to how such proposed nominee, if elected as a director of the Corporation, will act or vote on any issue or question (a &ldquo;<U>Voting
Commitment</U>&rdquo;) or (2)&nbsp;any Voting Commitment that could limit or interfere with such proposed nominee&rsquo;s ability to comply,
if elected as a director of the Corporation, with such proposed nominee&rsquo;s fiduciary duties under applicable law, (B)&nbsp;is not,
and will not become a party to, any agreement, arrangement or understanding with any person or entity other than the Corporation with
respect to any direct or indirect compensation or reimbursement for service as a director that has not been disclosed to the Corporation
and (C)&nbsp;if elected as a director of the Corporation, will comply with all applicable corporate governance, conflict of interest,
confidentiality, stock ownership and trading and other policies and guidelines of the Corporation applicable to directors and in effect
during such person&rsquo;s term in office as a director (and, if requested by any candidate for nomination, the Secretary of the Corporation
shall provide to such candidate for nomination all such policies and guidelines then in effect).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(g) The Board may also require
any proposed candidate for nomination as a Director to furnish such other information as may reasonably be requested by the Board in writing
prior to the meeting of stockholders at which such candidate&rsquo;s nomination is to be acted upon in order for the Board to determine
the eligibility of such candidate for nomination to be an independent director of the Corporation in accordance with the Corporation&rsquo;s
corporate governance guidelines.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(h) A candidate for nomination
as a director shall further update and supplement the materials delivered pursuant to this <U>Section&nbsp;2.5</U>, if necessary, so that
the information provided or required to be provided pursuant to this <U>Section&nbsp;2.5</U> shall be true and correct as of the record
date for stockholders entitled to vote at the meeting and as of the date that is ten (10)&nbsp;business days prior to the meeting or any
adjournment or postponement thereof, and such update and supplement shall be delivered to, or mailed and received by, the Secretary of
the Corporation at the principal executive offices of the Corporation (or any other office specified by the Corporation in any public
announcement) not later than five (5)&nbsp;business days after the record date for stockholders entitled to vote at the meeting (in the
case of the update and supplement required to be made as of such record date), and not later than eight (8)&nbsp;business days prior to
the date for the meeting or, if practicable, any adjournment or postponement thereof (and, if not practicable, on the first practicable
date prior to the date to which the meeting has been adjourned or postponed) (in the case of the update and supplement required to be
made as of ten (10)&nbsp;business days prior to the meeting or any adjournment or postponement thereof). For the avoidance of doubt, the
obligation to update and supplement as set forth in this paragraph or any other Section of these bylaws shall not limit the Corporation&rsquo;s
rights with respect to any deficiencies in any materials delivered pursuant to this Section&nbsp;2.5 by a candidate for director, extend
any applicable deadlines hereunder or enable or be deemed to permit a stockholder who has previously submitted notice hereunder to amend
or update any proposal or to submit any new proposal, including by changing or adding nominees, matters, business or resolutions proposed
to amend or update any nomination or to submit any new nomination.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(i) No candidate shall be
eligible for nomination as a director of the Corporation unless such candidate for nomination and the Nominating Person seeking to place
such candidate&rsquo;s name in nomination has complied with this <U>Section&nbsp;2.5</U>. The presiding officer at the meeting shall,
if the facts warrant, determine that a nomination was not properly made in accordance with <U>Section&nbsp;2.5</U>, and if he or she should
so determine, he or she shall so declare such determination to the meeting, the defective nomination shall be disregarded and any ballots
cast for the candidate in question (but in the case of any form of ballot listing other qualified nominees, only the votes cast for the
nominee in question) shall be void and of no force or effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">(j) Notwithstanding anything
in these bylaws to the contrary, no candidate for nomination shall be eligible to be seated as a director of the Corporation unless nominated
and elected in accordance with <U>Section&nbsp;2.5.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">2.6 <U>Notice of Stockholders&rsquo;
Meetings</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless otherwise provided
by law, the Certificate of Incorporation or these bylaws, the notice of any meeting of stockholders shall be sent or otherwise given in
accordance with <U>Section&nbsp;8.1</U> not less than ten (10)&nbsp;nor more than sixty (60)&nbsp;days before the date of the meeting
to each stockholder entitled to vote at such meeting. The notice shall specify the place, if any, date and time of the meeting, the means
of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such meeting,
and, in the case of a special meeting, the purpose or purposes for which the meeting is called.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">2.7 <U>Quorum</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless otherwise provided
by law, the Certificate of Incorporation or these bylaws, the holders of a majority in voting power of the stock issued and outstanding
and entitled to vote, present in person, or by remote communication, if applicable, or represented by proxy, shall constitute a quorum
for the transaction of business at all meetings of the stockholders. A quorum, once established at a meeting, shall not be broken by the
withdrawal of enough votes to leave less than a quorum. If, however, a quorum is not present or represented at any meeting of the stockholders,
then either (i)&nbsp;the person presiding over the meeting or (ii)&nbsp;a majority in voting power of the stockholders entitled to vote
at the meeting, present in person, or by remote communication, if applicable, or represented by proxy, shall have power to recess the
meeting or adjourn the meeting from time to time in the manner provided in <U>Section&nbsp;2.8</U> until a quorum is present or represented.
At any recessed or adjourned meeting at which a quorum is present or represented, any business may be transacted that might have been
transacted at the meeting as originally noticed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">2.8 <U>Adjourned Meeting;
Notice</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">When a meeting is adjourned
to another time or place, unless these bylaws otherwise require, notice need not be given of the adjourned meeting if the time, place,
if any, thereof, and the means of remote communications, if any, by which stockholders and proxy holders may be deemed to be present in
person and vote at such adjourned meeting are announced at the meeting at which the adjournment is taken. At any adjourned meeting, the
Corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than thirty
(30)&nbsp;days, a notice of the adjourned meeting shall be given to each stockholder of record entitled to vote at the meeting. If after
the adjournment a new record date for determination of stockholders entitled to vote is fixed for the adjourned meeting, the Board shall
fix as the record date for determining stockholders entitled to notice of such adjourned meeting the same or an earlier date as that fixed
for determination of stockholders entitled to vote at the adjourned meeting, and shall give notice of the adjourned meeting to each stockholder
of record entitled to vote at such meeting as of the record date so fixed for notice of such adjourned meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">2.9 <U>Conduct of Business</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The date and time of the
opening and the closing of the polls for each matter upon which the stockholders will vote at a meeting shall be announced at the meeting
by the person presiding over the meeting. The Board may adopt by resolution such rules and regulations for the conduct of the meeting
of stockholders as it shall deem appropriate. At every meeting of the stockholders, the Chairperson of the Board, or in his or her absence
or inability to act, the Chief Executive Officer, or in his or her absence or inability to act, the officer or director whom the Board
shall appoint, shall act as chairperson of, and preside at the meeting. Except to the extent inconsistent with such rules and regulations
as adopted by the Board, the person presiding over any meeting of stockholders shall have the right and authority to convene and (for
any or no reason) to recess and/or adjourn the meeting, to prescribe such rules, regulations and procedures (which need not be in writing)
and to do all such acts as, in the judgment of such presiding person, are appropriate for the proper conduct of the meeting. Such rules,
regulations or procedures, whether adopted by the Board or prescribed by the person presiding over the meeting, may include, without limitation,
the following: (i)&nbsp;the establishment of an agenda or order of business for the meeting; (ii)&nbsp;rules and procedures for maintaining
order at the meeting and the safety of those present (including, without limitation, rules and procedures for removal of disruptive persons
from the meeting); (iii) limitations on attendance at or participation in the meeting to stockholders entitled to vote at the meeting,
their duly authorized and constituted proxies or such other persons as the person presiding over the meeting shall determine; (iv)&nbsp;restrictions
on entry to the meeting after the time fixed for the commencement thereof; and (v)&nbsp;limitations on the time allotted to questions
or comments by participants. The presiding person at any meeting of stockholders, in addition to making any other determinations that
may be appropriate to the conduct of the meeting (including, without limitation, determinations with respect to the administration and/or
interpretation of any of the rules, regulations or procedures of the meeting, whether adopted by the Board or prescribed by the person
presiding over the meeting), shall, if the facts warrant, determine and declare to the meeting that a matter of business was not properly
brought before the meeting and if such presiding person should so determine, such presiding person shall so declare to the meeting and
any such matter or business not properly brought before the meeting shall not be transacted or considered. Unless and to the extent determined
by the Board or the person presiding over the meeting, meetings of stockholders shall not be required to be held in accordance with the
rules of parliamentary procedure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">2.10 <U>Voting</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Except as may be otherwise
provided in the Certificate of Incorporation, these bylaws or the DGCL, each stockholder shall be entitled to one (1)&nbsp;vote for each
share of capital stock held by such stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Except as otherwise provided
by the Certificate of Incorporation, at all duly called or convened meetings of stockholders at which a quorum is present, for the election
of directors, a plurality of the votes cast shall be sufficient to elect a director. Except as otherwise provided by the Certificate of
Incorporation, these bylaws, the rules or regulations of any stock exchange applicable to the Corporation, or applicable law or pursuant
to any regulation applicable to the Corporation or its securities, each other matter presented to the stockholders at a duly called or
convened meeting at which a quorum is present shall be decided by the affirmative vote of the holders of a majority in voting power of
the votes cast (excluding abstentions and broker non-votes) on such matter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">2.11 <U>Record Date for Stockholder
Meetings and Other Purposes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In order that the Corporation
may determine the stockholders entitled to notice of or to vote at any meeting of stockholders or any adjournment thereof, the Board may
fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board,
and which record date shall, unless otherwise required by law, not be more than sixty (60)&nbsp;days nor less than ten (10)&nbsp;days
before the date of such meeting. If the Board so fixes a date, such date shall also be the record date for determining the stockholders
entitled to vote at such meeting unless the Board determines, at the time it fixes such record date, that a later date on or before the
date of the meeting shall be the date for making such determination. If no record date is fixed by the Board, the record date for determining
stockholders entitled to notice of or to vote at a meeting of stockholders shall be the close of business on the next day preceding the
day on which notice is first given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting
is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of stockholders shall apply to any adjournment
of the meeting; <I>provided, however</I>, that the Board may fix a new record date for determination of stockholders entitled to vote
at the adjourned meeting; and in such case shall also fix as the record date for stockholders entitled to notice of such adjourned meeting
the same or an earlier date as that fixed for determination of stockholders entitled to vote in accordance herewith at the adjourned meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In order that the Corporation
may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment or any rights or the stockholders
entitled to exercise any rights in respect of any change, conversion or exchange of capital stock, or for the purposes of any other lawful
action, the Board may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date
is adopted, and which record date shall be not more than sixty (60)&nbsp;days prior to such action. If no record date is fixed, the record
date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board adopts the resolution
relating thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">2.12 <U>Proxies</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Each stockholder entitled
to vote at a meeting of stockholders may authorize another person or persons to act for such stockholder by proxy authorized by an instrument
in writing or by a transmission permitted by law filed in accordance with the procedure established for the meeting, but no such proxy
shall be voted or acted upon after three (3)&nbsp;years from its date, unless the proxy provides for a longer period. The revocability
of a proxy that states on its face that it is irrevocable shall be governed by the provisions of Section&nbsp;212 of the DGCL. A proxy
may be in the form of an electronic transmission which sets forth or is submitted with information from which it can be determined that
the transmission was authorized by the stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">2.13 <U>List of Stockholders
Entitled to Vote</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Corporation shall prepare,
at least ten (10)&nbsp;days before every meeting of stockholders, a complete list of the stockholders entitled to vote at the meeting
(<I>provided, however</I>, that if the record date for determining the stockholders entitled to vote is less than ten (10)&nbsp;days before
the date of the meeting, the list shall reflect the stockholders entitled to vote as of the tenth (10<SUP>th</SUP>) day before the meeting
date), arranged in alphabetical order, and showing the address of each stockholder and the number of shares registered in the name of
each stockholder. The Corporation shall not be required to include electronic mail addresses or other electronic contact information on
such list. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting for a period of at least
ten (10)&nbsp;days prior to the meeting: (i)&nbsp;on a reasonably accessible electronic network, <I>provided</I> that the information
required to gain access to such list is provided with the notice of the meeting, or (ii)&nbsp;during ordinary business hours, at the Corporation&rsquo;s
principal executive office. In the event that the Corporation determines to make the list available on an electronic network, the Corporation
may take reasonable steps to ensure that such information is available only to stockholders of the Corporation. If the meeting is to be
held at a place, then the list shall be produced and kept at the time and place of the meeting during the whole time thereof, and may
be inspected by any stockholder who is present. If the meeting is to be held solely by means of remote communication, then the list shall
also be open to the examination of any stockholder during the whole time of the meeting on a reasonably accessible electronic network,
and the information required to access such list shall be provided with the notice of the meeting. Such list shall presumptively determine
the identity of the stockholders entitled to vote at the meeting and the number of shares held by each of them. Except as otherwise provided
by law, the stock ledger shall be the only evidence as to who are the stockholders entitled to examine the list of stockholders required
by this <U>Section&nbsp;2.13</U> or to vote in person or by proxy at any meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">2.14 <U>Inspectors of Election</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Before any meeting of stockholders,
the Corporation shall appoint an inspector or inspectors of election to act at the meeting or its adjournment and make a written report
thereof. The Corporation may designate one or more persons as alternate inspectors to replace any inspector who fails to act. If any person
appointed as inspector or any alternate fails to appear or fails or refuses to act, then the person presiding over the meeting shall appoint
a person to fill that vacancy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Such inspectors shall:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 79.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in">(i) determine the number
of shares outstanding and the voting power of each, the number of shares represented at the meeting and the validity of any proxies and
ballots;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 79.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in">(ii) count all votes or
ballots;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 79.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in">(iii) count and tabulate
all votes;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in">(iv) determine and retain
for a reasonable period a record of the disposition of any challenges made to any determination by the inspector(s); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 79.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in">(v) certify its or their
determination of the number of shares represented at the meeting and its or their count of all votes and ballots.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Each inspector, before entering
upon the discharge of the duties of inspector, shall take and sign an oath faithfully to execute the duties of inspection with strict
impartiality and according to the best of such inspector&rsquo;s</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ability. Any report or certificate made by the
inspectors of election is <I>prima facie</I> evidence of the facts stated therein. The inspectors of election may appoint such persons
to assist them in performing their duties as they determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">2.15 <U>Delivery to the Corporation.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Whenever this <U>ARTICLE
II</U>&nbsp;requires one or more persons (including a record or beneficial owner of stock) to deliver a document or information to the
Corporation or any officer, employee or agent thereof (including any notice, request, questionnaire, revocation, representation or other
document or agreement), such document or information shall be in writing exclusively (and not in an electronic transmission) and shall
be delivered exclusively by hand (including, without limitation, overnight courier service) or by certified or registered mail, return
receipt requested, and the Corporation shall not be required to accept delivery of any document not in such written form or so delivered.
For the avoidance of doubt, the Corporation expressly opts out of Section&nbsp;116 of the DGCL with respect to the delivery of information
and documents to the Corporation required by this <U>ARTICLE II</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">2.16 <U>Stockholder Action
by Written Consent Without a Meeting</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any action required or permitted
to be taken by the stockholders of the Corporation must be effected at an annual or special meeting of stockholders of the Corporation,
and may not be taken by written consent in lieu of a meeting. Notwithstanding the foregoing, any action required or permitted to be taken
by the holders of any series of preferred stock of the Corporation, voting separately as a series or separately as a class with one or
more other such series, may be taken without a meeting, without prior notice and without a vote, to the extent expressly so provided by
the applicable certificate of designation relating to such series of preferred stock of the Corporation, if a consent or consents in writing,
setting forth the action so taken, shall be signed by the holders of outstanding shares of the relevant series of preferred stock of the
Corporation having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at
which all shares entitled to vote thereon were present and voted and shall be delivered to the Corporation in accordance with the applicable
provisions of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE III - Directors </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.1 <U>Powers</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Except as otherwise provided
by the Certificate of Incorporation or the DGCL, the business and affairs of the Corporation shall be managed by or under the direction
of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.2 <U>Number of Directors</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the Certificate
of Incorporation, the total number of directors constituting the Board shall be determined from time to time by resolution of the Board.
No reduction of the authorized number of directors shall have the effect of removing any director before that director&rsquo;s term of
office expires.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.3 <U>Election, Qualification
and Term of Office of Directors</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Except as provided in <U>Section&nbsp;3.4</U>,
and subject to the Certificate of Incorporation, each director, including a director elected to fill a vacancy or newly created directorship,
shall hold office until the expiration of the term of the class, if any, for which elected and until such director&rsquo;s successor is
elected and qualified or until such director&rsquo;s earlier death, resignation, disqualification or removal. Directors need not be stockholders.
The Certificate of Incorporation or these bylaws may prescribe qualifications for directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.4 <U>Resignation and Vacancies</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any director may resign at
any time upon notice given in writing or by electronic transmission to the Corporation. The resignation shall take effect at the time
specified therein or upon the happening of an event specified therein, and if no time or event is specified, at the time of its receipt.
When one or more directors so resigns and the resignation is effective at a future date or upon the happening of an event to occur on
a future date, a majority of the directors then in office, including those who have so resigned, shall have power to fill such vacancy
or vacancies, the vote thereon to take effect when such resignation or resignations shall become effective, and each director so chosen
shall hold office as provided in <U>Section&nbsp;3.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless otherwise provided
in the Certificate of Incorporation or these bylaws, vacancies resulting from the death, resignation, disqualification or removal of any
director, and newly created directorships resulting from any increase in the authorized number of directors shall be filled only by a
majority of the directors then in office, although less than a quorum, or by a sole remaining director. Any director elected in accordance
with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or
occurred and until such director&rsquo;s successor shall have been elected and qualified.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.5 <U>Place of Meetings;
Meetings by Telephone</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Board may hold meetings,
both regular and special, either within or outside the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless otherwise restricted
by the Certificate of Incorporation or these bylaws, members of the Board, or any committee designated by the Board, may participate in
a meeting of the Board, or any committee, by means of conference telephone or other communications equipment by means of which all persons
participating in the meeting can hear each other, and such participation in a meeting pursuant to this bylaw shall constitute presence
in person at the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.6 <U>Regular Meetings</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Regular meetings of the Board
may be held within or outside the State of Delaware and at such time and at such place as which has been designated by the Board and publicized
among all directors, either orally or in writing, by telephone, including a voice-messaging system or other system designed to record
and communicate messages, facsimile, telegraph or telex, or by electronic mail or other means of electronic transmission. No further notice
shall be required for regular meetings of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.7 <U>Special Meetings;
Notice</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Special meetings of the Board
for any purpose or purposes may be called at any time by the Chairperson of the Board, the Chief Executive Officer or the Secretary of
the Corporation or a majority of the total number of directors constituting the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Notice of the time and place
of special meetings shall be:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 79.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in">(i) delivered personally
by hand, by courier or by telephone;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 79.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in">(ii) sent by United States
first-class mail, postage prepaid;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in">(iii) sent by facsimile
or electronic mail; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 79.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in">(iv) sent by other means
of electronic transmission,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">directed to each director at that director&rsquo;s
address, telephone number, facsimile number or electronic mail address, or other address for electronic transmission, as the case may
be, as shown on the Corporation&rsquo;s records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the notice is (i)&nbsp;delivered
personally by hand, by courier or by telephone, (ii)&nbsp;sent by facsimile or electronic mail, or (iii)&nbsp;sent by other means of electronic
transmission, it shall be delivered or sent at least twenty-four (24)&nbsp;hours before the time of the holding of the meeting. If the
notice is sent by U.S. mail, it shall be deposited in the U.S. mail at least four (4)&nbsp;days before the time of the holding of the
meeting. The notice need not specify the place of the meeting (if the meeting is to be held at the Corporation&rsquo;s principal executive
office) nor the purpose of the meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.8 <U>Quorum</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">At all meetings of the Board,
unless otherwise provided by the Certificate of Incorporation, a majority of the total number of directors shall constitute a quorum for
the transaction of business. The vote of a majority of the directors present at any meeting at which a quorum is present shall be the
act of the Board, except as may be otherwise specifically provided by statute, the Certificate of Incorporation or these bylaws. If a
quorum is not present at any meeting of the Board, then the directors present thereat may adjourn the meeting from time to time, without
notice other than announcement at the meeting, until a quorum is present.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.9 <U>Board Action without
a Meeting</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless otherwise restricted
by the Certificate of Incorporation or these bylaws, any action required or permitted to be taken at any meeting of the Board, or of any
committee thereof, may be taken without a meeting if all members of the Board or committee, as the case may be, consent thereto in writing
or by electronic transmission. After an action is taken, the consent or consents relating thereto shall be filed with the minutes of the
proceedings of the Board, or the committee thereof, in the same paper or electronic form as the minutes are maintained. Such action by
written consent or consent by electronic transmission shall have the same force and effect as a unanimous vote of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.10 <U>Fees and Compensation
of Directors</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless otherwise restricted
by the Certificate of Incorporation or these bylaws, the Board shall have the authority to fix the compensation, including fees and reimbursement
of expenses, of directors for services to the Corporation in any capacity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">3.11 <U>Removal of Directors</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the special rights
of the holders of one or more outstanding series of preferred stock of the Corporation to elect directors, the Board or any individual
director may be removed from office at any time, but only for cause and only by the affirmative vote of the holders of at least two-thirds
(66 and 2/3%) of the voting power of all the then outstanding shares of voting stock of the Corporation entitled to vote at an election
of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE IV - Committees </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">4.1 <U>Committees of Directors</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Board may designate one
(1)&nbsp;or more committees, each committee to consist of one (1)&nbsp;or more of the directors of the Corporation. The Board may designate
one (1)&nbsp;or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting
of the committee. In the absence or disqualification of a member of a committee, the member or members thereof present at any meeting
and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another member of
the Board to act at the meeting in the place of any such absent or disqualified member. Any such committee, to the extent provided in
the resolution of the Board or in these bylaws, shall have and may exercise all the powers and authority of the Board in the management
of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers that may require
it; but no such committee shall have the power or authority to (i)&nbsp;approve or adopt, or recommend to the stockholders, any action
or matter expressly required by the DGCL to be submitted to stockholders for approval, or (ii)&nbsp;adopt, amend or repeal any bylaw of
the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">4.2 <U>Committee Minutes</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Each committee shall keep
regular minutes of its meetings and report the same to the Board when required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">4.3 <U>Meetings and Actions
of Committees</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Meetings and actions of committees
shall be governed by, and held and taken in accordance with, the provisions of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 79.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in">(i) <U>Section&nbsp;3.5</U>
(<I>Place of Meetings</I>; <I>Meetings by Telephone</I>);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 79.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in">(ii) <U>Section&nbsp;3.6</U>
(<I>Regular Meetings</I>);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 79.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in">(iii) <U>Section&nbsp;3.7</U>
(<I>Special Meetings</I>; <I>Notice</I>);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 79.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in">(iv) <U>Section&nbsp;3.9</U>
(<I>Board Action Without a Meeting</I>); and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 79.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in">(v) <U>Section 7.13</U>
(<I>Waiver of Notice</I>),</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">with such changes in the context of those bylaws
as are necessary to substitute the committee and its members for the Board and its members; <I>provided, however</I>, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 79.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in">(i) the time of regular
meetings of committees may be determined either by resolution of the Board or by resolution of the committee;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 79.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in">(ii) special meetings of
committees may also be called by resolution of the Board or the chairperson of the applicable committee; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 79.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.75in">(iii) the Board may adopt
rules for the governance of any committee to override the provisions that would otherwise apply to the committee pursuant to this <U>Section&nbsp;4.3</U>,
<I>provided</I> that such rules do not violate the provisions of the Certificate of Incorporation or applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">4.4 <U>Subcommittees.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless otherwise provided
in the Certificate of Incorporation, these bylaws or the resolutions of the Board designating the committee, a committee may create one
(1)&nbsp;or more subcommittees, each subcommittee to consist of one (1)&nbsp;or more members of the committee, and delegate to a subcommittee
any or all of the powers and authority of the committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE V - Officers </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">5.1 <U>Officers</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The officers of the Corporation
shall include a Chief Executive Officer and a Secretary. The Corporation may also have, at the discretion of the Board, a Chairperson
of the Board, a Vice Chairperson of the Board, a President, a Chief Financial Officer, a Treasurer, one (1)&nbsp;or more Vice Presidents,
one (1)&nbsp;or more Assistant Vice Presidents, one (1)&nbsp;or more Assistant Treasurers, one (1)&nbsp;or more Assistant Secretaries,
and any such other officers as may be appointed in accordance with the provisions of these bylaws. Any number of offices may be held by
the same person. No officer need be a stockholder or director of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">5.2 <U>Appointment of Officers</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Board shall appoint the
officers of the Corporation, except such officers as may be appointed in accordance with the provisions of <U>Section&nbsp;5.3</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">5.3 <U>Subordinate Officers</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Board may appoint, or
empower the Chief Executive Officer to appoint, such other officers and agents as the business of the Corporation may require. Each of
such officers and agents shall hold office for such period, have such authority, and perform such duties as are provided in these bylaws
or as the Board may from time to time determine.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">5.4 <U>Removal and Resignation
of Officers</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Subject to the rights, if
any, of an officer under any contract of employment any officer may be removed, either with or without cause, by the Board or, except
in the case of an officer chosen by the Board, by any officer upon whom such power of removal may be conferred by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any officer may resign at
any time by giving written notice to the Corporation. Any resignation shall take effect at the date of the receipt of that notice or at
any later time specified in that notice. Unless otherwise specified in the notice of resignation, the acceptance of the resignation shall
not be necessary to make it effective. Any resignation is without prejudice to the rights, if any, of the Corporation under any contract
to which the officer is a party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">5.5 <U>Vacancies in Offices</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any vacancy occurring in
any office of the Corporation shall be filled by the Board or as provided in <U>Section&nbsp;5.2</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">5.6 <U>Representation of
Shares of Other Corporations</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Chairperson of the Board
or the Chief Executive Officer of this Corporation, or any other person authorized by the Board or the Chief Executive Officer, is authorized
to vote, represent and exercise on behalf of this Corporation all rights incident to any and all shares or voting securities of any other
corporation or other person standing in the name of this Corporation. The authority granted herein may be exercised either by such person
directly or by any other person authorized to do so by proxy or power of attorney duly executed by such person having the authority.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">5.7 <U>Authority and Duties
of Officers</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">All officers of the Corporation
shall respectively have such authority and perform such duties in the management of the business of the Corporation as may be provided
herein or designated from time to time by the Board and, to the extent not so provided, as generally pertain to their respective offices,
subject to the control of the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">5.8 <U>Compensation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The compensation of the officers
of the Corporation for their services as such shall be fixed from time to time by or at the direction of the Board. An officer of the
Corporation shall not be prevented from receiving compensation by reason of the fact that he or she is also a director of the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE VI - Records </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">A stock ledger consisting
of one or more records in which the names of all of the Corporation&rsquo;s stockholders of record, the address and number of shares registered
in the name of each such stockholder, and all issuances and transfers of stock of the corporation are recorded in accordance with Section&nbsp;224
of the DGCL shall be administered by or on behalf of the Corporation. Any records administered by or on behalf of the Corporation in the
regular course of its business, including its stock ledger, books of account, and minute books, may be kept on, or by means of, or be
in the form of, any information storage device, or method, or one or more electronic networks or databases (including one or more distributed
electronic networks or databases), <I>provided</I> that the records so kept can be converted into clearly legible paper form within a
reasonable time and, with respect to the stock ledger, that the records so kept (i)&nbsp;can be used to prepare the list of stockholders
specified in Sections 219 and 220 of the DGCL, (ii)&nbsp;record the information specified in Sections 156, 159, 217(a) and 218 of the
DGCL, and (iii)&nbsp;record transfers of stock as governed by Article 8 of the Uniform Commercial Code as adopted in the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE VII - General Matters </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">7.1 <U>Execution of Corporate
Contracts and Instruments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Board, except as otherwise
provided in these bylaws, may authorize any officer or officers, or agent or agents, to enter into any contract or execute any instrument
in the name of and on behalf of the Corporation; such authority may be general or confined to specific instances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">7.2 <U>Stock Certificates</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The shares of the Corporation
shall be represented by certificates or shall be uncertificated. Certificates for the shares of stock, if any, shall be in such form as
is consistent with the Certificate of Incorporation and applicable law. Every holder of stock represented by a certificate shall be entitled
to have a certificate signed by, or in the name of the Corporation by, any two officers authorized to sign stock certificates representing
the number of shares registered in certificate form. The Chairperson or Vice Chairperson of the Board, the Chief Executive Officer, the
President, if any, any Vice President, the Treasurer, any Assistant Treasurer, the Secretary or any Assistant Secretary of the Corporation
shall be specifically authorized to sign stock certificates. Any or all of the signatures on the certificate may be a facsimile. In case
any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate has ceased to
be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect
as if he or she were such officer, transfer agent or registrar at the date of issue.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Corporation may issue
the whole or any part of its shares as partly paid and subject to call for the remainder of the consideration to be paid therefor. Upon
the face or back of each stock certificate issued to represent any such partly paid shares, or upon the books and records of the Corporation
in the case of uncertificated partly paid shares, the total amount of the consideration to be paid therefor and the amount paid thereon
shall be stated. Upon the declaration of any dividend on fully paid shares, the Corporation shall declare a dividend upon partly paid
shares of the same class, but only upon the basis of the percentage of the consideration actually paid thereon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">7.3 <U>Special Designation
of Certificates.</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the Corporation is authorized
to issue more than one class of stock or more than one series of any class, then the powers, the designations, the preferences and the
relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations
or restrictions of such preferences and/or rights shall be set forth in full or summarized on the face or on the back of the certificate
that the Corporation shall issue to represent such class or series of stock (or, in the case of uncertificated shares, set forth in a
notice provided pursuant to Section&nbsp;151 of the DGCL); <I>provided, however</I>, that except as otherwise provided in Section&nbsp;202
of the DGCL, in lieu of the foregoing requirements, there may be set forth on the face of back of the certificate that the Corporation
shall issue to represent such class or series of stock (or, in the case of any uncertificated shares, included in the aforementioned notice)
a statement that the Corporation will furnish without charge to each stockholder who so requests the powers, the designations, the preferences
and the relative, participating, optional or other special rights of each class of stock or series thereof and the qualifications, limitations
or restrictions of such preferences and/or rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">7.4 <U>Lost Certificates</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Except as provided in this
<U>Section&nbsp;7.4</U>, no new certificates for shares shall be issued to replace a previously issued certificate unless the latter is
surrendered to the Corporation and cancelled at the same time. The Corporation may issue a new certificate of stock or uncertificated
shares in the place of any certificate theretofore issued by it, alleged to have been lost, stolen or destroyed, and the Corporation may
require the owner of the lost, stolen or destroyed certificate, or such owner&rsquo;s legal representative, to give the Corporation a
bond sufficient to indemnify it against any claim that may be made against it on account of the alleged loss, theft or destruction of
any such certificate or the issuance of such new certificate or uncertificated shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">7.5 <U>Shares Without Certificates</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Corporation may adopt
a system of issuance, recordation and transfer of its shares of stock by electronic or other means not involving the issuance of certificates,
provided the use of such system by the Corporation is permitted in accordance with applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">7.6 <U>Construction; Definitions</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless the context requires
otherwise, the general provisions, rules of construction and definitions in the DGCL shall govern the construction of these bylaws. Without
limiting the generality of this provision, the singular number includes the plural and the plural number includes the singular.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">7.7 <U>Dividends</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Board, subject to any
restrictions contained in either (i)&nbsp;the DGCL or (ii)&nbsp;the Certificate of Incorporation, may declare and pay dividends upon the
shares of its capital stock. Dividends may be paid in cash, in property or in shares of the Corporation&rsquo;s capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Board may set apart out
of any of the funds of the Corporation available for dividends a reserve or reserves for any proper purpose and may abolish any such reserve.
Such purposes shall include but not be limited to equalizing dividends, repairing or maintaining any property of the Corporation, and
meeting contingencies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">7.8 <U>Fiscal Year</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The fiscal year of the Corporation
shall be fixed by resolution of the Board and may be changed by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">7.9 <U>Seal</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Corporation may adopt
a corporate seal, which shall be adopted and which may be altered by the Board. The Corporation may use the corporate seal by causing
it or a facsimile thereof to be impressed or affixed or in any other manner reproduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">7.10 <U>Transfer of Stock</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Shares of the stock of the
Corporation shall be transferable in the manner prescribed by law and in these bylaws. Shares of stock of the Corporation shall be transferred
on the books of the Corporation only by the holder of record thereof or by such holder&rsquo;s attorney duly authorized in writing, upon
surrender to the Corporation of the certificate or certificates representing such shares endorsed by the appropriate person or persons
(or by delivery of duly executed instructions with respect to uncertificated shares), with such evidence of the authenticity of such endorsement
or execution, transfer, authorization and other matters as the Corporation may reasonably require, and accompanied by all necessary stock
transfer stamps. No transfer of stock shall be valid as against the Corporation for any purpose until it shall have been entered in the
stock records of the Corporation by an entry showing the names of the persons from and to whom it was transferred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">7.11 <U>Stock Transfer Agreements</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Corporation shall have
power to enter into and perform any agreement with any number of stockholders of any one or more classes or series of stock of the Corporation
to restrict the transfer of shares of stock of the Corporation of any one or more classes owned by such stockholders in any manner not
prohibited by the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">7.12 <U>Registered Stockholders</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Corporation:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 79.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 79.55pt">(i) shall be entitled to
recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends and to vote as such owner;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 79.55pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 79.55pt">(ii) shall not be bound
to recognize any equitable or other claim to or interest in such share or shares on the part of another person, whether or not it shall
have express or other notice thereof, except as otherwise provided by the laws of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">7.13 <U>Waiver of Notice</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Whenever notice is required
to be given under any provision of the DGCL, the Certificate of Incorporation or these bylaws, a written waiver, signed by the person
entitled to notice, or a waiver by electronic transmission by the person entitled to notice, whether before or after the time of the event
for which notice is to be given, shall be deemed equivalent to notice. Attendance of a person at a meeting shall constitute a waiver of
notice of such meeting, except when the person attends a meeting for the express purpose of objecting at the beginning of the meeting,
to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor
the purpose of, any regular or special meeting of the stockholders need be specified in any written waiver of notice or any waiver by
electronic transmission unless so required by the Certificate of Incorporation or these bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>ARTICLE VIII - Notice </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">8.1 <U>Delivery of Notice;
Notice by Electronic Transmission</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Without limiting the manner
by which notice otherwise may be given effectively to stockholders, any notice to stockholders given by the Corporation under any provisions
of the DGCL, the Certificate of Incorporation, or these bylaws may be given in writing directed to the stockholder&rsquo;s mailing address
(or by electronic transmission directed to the stockholder&rsquo;s electronic mail address, as applicable) as it appears on the records
of the Corporation and shall be given (1)&nbsp;if mailed, when the notice is deposited in the U.S. mail, postage prepaid, (2)&nbsp;if
delivered by courier service, the earlier of when the notice is received or left at such stockholder&rsquo;s address or (3)&nbsp;if given
by electronic mail, when directed to such stockholder&rsquo;s electronic mail address unless the stockholder has notified the Corporation
in writing or by electronic transmission of an objection to receiving notice by electronic mail. A notice by electronic mail must include
a prominent legend that the communication is an important notice regarding the Corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Without limiting the manner
by which notice otherwise may be given effectively to stockholders, any notice to stockholders given by the Corporation under any provision
of the DGCL, the Certificate of Incorporation or these bylaws shall be effective if given by a form of electronic transmission consented
to by the stockholder to whom the notice is given. Any such consent shall be revocable by the stockholder by written notice or electronic
transmission to the Corporation. Notwithstanding the provisions of this paragraph, the Corporation may give a notice by electronic mail
in accordance with the first paragraph of this section without obtaining the consent required by this paragraph.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any notice given pursuant
to the preceding paragraph shall be deemed given:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(i)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">if by facsimile telecommunication, when directed to a number at which the stockholder has consented to receive notice; </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">if by a posting on an electronic network together with separate notice to the stockholder of such specific posting, upon the later of (A)&nbsp;such posting and (B)&nbsp;the giving of such separate notice; and </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR>
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(iii)</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">if by any other form of electronic transmission, when directed to the stockholder. </FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Notwithstanding the foregoing,
a notice may not be given by an electronic transmission from and after the time that (1)&nbsp;the Corporation is unable to deliver by
such electronic transmission two (2)&nbsp;consecutive notices given by the Corporation and (2)&nbsp;such inability becomes known to the
Secretary or an Assistant Secretary of the Corporation or to the transfer agent, or other person responsible for the giving of notice;
<I>provided, however</I>, that the inadvertent failure to discover such inability shall not invalidate any meeting or other action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">An affidavit of the Secretary
or an Assistant Secretary of the Corporation or of the transfer agent or other agent of the Corporation that the notice has been given
shall, in the absence of fraud, be prima facie evidence of the facts stated therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ARTICLE IX - Indemnification </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 55.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">9.1 <U>Indemnification of
Directors and Officers</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Corporation shall indemnify
and hold harmless, to the fullest extent permitted by the DGCL as it presently exists or may hereafter be amended, any person who was
or is made or is threatened to be made a party or is otherwise involved in any action, suit or proceeding, whether civil, criminal, administrative
or investigative (a &ldquo;<U>Proceeding</U>&rdquo;) by reason of the fact that he or she, or a person for whom he or she is the legal
representative, is or was a director or officer of the Corporation or, while serving as a director or officer of the Corporation, is or
was serving at the request of the Corporation as a director, officer, employee or agent of another corporation or of a partnership, joint
venture, trust, enterprise or non-profit entity (a &ldquo;<U>covered person</U>&rdquo;), including, without limitation, service with respect
to employee benefit plans, against all liability and loss suffered and expenses (including, without limitation, attorneys&rsquo; fees,
judgments, fines, ERISA excise taxes or penalties, and amounts paid in settlement) reasonably incurred by such person in connection with
any such Proceeding. Notwithstanding the preceding sentence, except as otherwise provided in <U>Section&nbsp;9.4</U>, the Corporation
shall be required to indemnify a person in connection with a Proceeding initiated by such person only if the Proceeding was authorized
in the specific case by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 55.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">9.2 <U>Indemnification of
Others</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Corporation shall also
have the power to indemnify and hold harmless, to the fullest extent permitted by applicable law as it presently exists or may hereafter
be amended, any employee or agent of the Corporation who was or is made or is threatened to be made a party or is otherwise involved in
any Proceeding by reason of the fact that he or she, or a person for whom he or she is the legal representative, is or was an employee
or agent of the Corporation or is or was serving at the request of the Corporation as a director, officer, employee or agent of another
corporation or of a partnership, joint venture, trust, enterprise or non-profit entity, including service with respect to employee benefit
plans, against all liability and loss suffered and expenses reasonably incurred by such person in connection with any such Proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 55.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">9.3 <U>Prepayment of Expenses</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Corporation shall to
the fullest extent not prohibited by applicable law pay the expenses (including, without limitation, attorneys&rsquo; fees) incurred by
or on behalf of any covered person, and may also pay the expenses incurred by or on behalf of any employee or agent of the Corporation,
in defending any Proceeding in advance of its final disposition; <I>provided, however</I>, that such payment of expenses in advance of
the final disposition of the Proceeding shall be made only upon receipt of an undertaking by the person to repay all amounts advanced
if it should be ultimately determined that the person is not entitled to be indemnified under this <U>ARTICLE IX</U>&nbsp;or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 55.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">9.4 <U>Determination; Claim</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If a claim for indemnification
(following the final disposition of such Proceeding) under this <U>ARTICLE IX</U>&nbsp;is not paid in full within sixty (60)&nbsp;days,
or a claim for advancement of expenses under this <U>ARTICLE IX</U>&nbsp;is not paid in full within thirty (30)&nbsp;days, after a written
claim therefor has been received by the Corporation the claimant may thereafter (but not before) file suit to recover the unpaid amount
of such claim and, if successful in whole or in part, shall be entitled to be paid the expense of prosecuting such claim to the fullest
extent permitted by law. In any such action the Corporation shall have the burden of proving that the claimant was not entitled to the
requested indemnification or payment of expenses under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 55.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">9.5 <U>Non-Exclusivity of
Rights</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The rights conferred on any
person by this <U>ARTICLE IX</U>&nbsp;shall not be exclusive of any other rights which such person may have or hereafter acquire under
any statute, provision of the Certificate of Incorporation, these bylaws, agreement, vote of stockholders or disinterested directors or
otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 55.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 55.1pt"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 55.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">9.6 <U>Insurance</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Corporation may purchase
and maintain insurance on behalf of any person who is or was a director, officer, employee or agent of the Corporation, or is or was serving
at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust
enterprise or non-profit entity against any liability asserted against him or her and incurred by him or her in any such capacity, or
arising out of his or her status as such, whether or not the Corporation would have the power to indemnify him or her against such liability
under the provisions of the DGCL.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 55.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">9.7 <U>Other Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Corporation&rsquo;s obligation,
if any, to indemnify or advance expenses to any person who was or is serving at its request as a director, officer, employee or agent
of another corporation, partnership, joint venture, trust, enterprise or non-profit entity shall be reduced by any amount such person
actually collects as indemnification or advancement of expenses from such other corporation, partnership, joint venture, trust, enterprise
or non-profit enterprise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 55.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">9.8 <U>Continuation of Indemnification</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The rights to indemnification
and to prepayment of expenses provided by, or granted pursuant to, this <U>ARTICLE IX</U>&nbsp;shall continue notwithstanding that the
person has ceased to be a director or officer of the Corporation and shall inure to the benefit of the estate, heirs, executors, administrators,
legatees and distributees of such person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 55.1pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">9.9 <U>Amendment or Repeal;
Interpretation</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The provisions of this <U>ARTICLE
IX</U> shall constitute a contract between the Corporation, on the one hand, and, on the other hand, each individual who serves or has
served as a director or officer of the Corporation (whether before or after the adoption of these bylaws), in consideration of such person&rsquo;s
performance of such services, and pursuant to this <U>ARTICLE IX</U>&nbsp;the Corporation intends to be legally bound to each such current
or former director or officer of the Corporation. With respect to current and former directors and officers of the Corporation, the rights
conferred under this <U>ARTICLE IX</U>&nbsp;are present contractual rights and such rights are fully vested, and shall be deemed to have
vested fully, immediately upon adoption of theses bylaws. With respect to any directors or officers of the Corporation who commence service
following adoption of these bylaws, the rights conferred under this provision shall be present contractual rights and such rights shall
fully vest, and be deemed to have vested fully, immediately upon such director or officer commencing service as a director or officer
of the Corporation. Any repeal or modification of the foregoing provisions of this <U>ARTICLE IX</U>&nbsp;shall not adversely affect any
right or protection (i)&nbsp;hereunder of any person in respect of any act, omission or claim occurring or arising prior to the time of
such repeal or modification or (ii)&nbsp;under any agreement providing for indemnification or advancement of expenses to an officer or
director of the Corporation in effect prior to the time of such repeal or modification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any reference to an officer
of the Corporation in this <U>ARTICLE IX</U>&nbsp;shall be deemed to refer exclusively to the Chief Executive Officer and the Secretary
of the Corporation, or other officer of the Corporation appointed by (x)&nbsp;the Board pursuant to <U>ARTICLE V</U>&nbsp;or (y)&nbsp;an
officer to whom the Board has delegated the power to appoint officers pursuant to <U>ARTICLE V</U>, and any reference to an officer of
any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall be deemed to refer exclusively
to an officer appointed by the board of directors (or equivalent governing body) of such other entity pursuant to the certificate of incorporation
and bylaws (or equivalent organizational documents) of such other corporation, partnership, joint venture, trust, employee benefit plan
or other enterprise. The fact that any person who is or was an employee of the Corporation or an employee of any other corporation, partnership,
joint venture, trust, employee benefit plan or other enterprise has been given or has used the title of &ldquo;Vice President&rdquo; or
any other title that could be construed to suggest or imply that such person is or may be an officer of the Corporation or of such other
corporation, partnership, joint venture, trust, employee benefit plan or other enterprise shall not result in such person being constituted
as, or being deemed to be, an officer of the Corporation or of such other corporation, partnership, joint venture, trust, employee benefit
plan or other enterprise for purposes of this <U>ARTICLE IX</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Article X - Amendments </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Board is expressly empowered
to adopt, amend or repeal the bylaws of the Corporation. The stockholders also shall have power to adopt, amend or repeal the bylaws of
the Corporation; <I>provided, however</I>, that such action by stockholders shall require, in addition to any other vote required by the
Certificate of Incorporation or applicable law, the affirmative vote of the holders of at least two-thirds of the voting power of all
the then-outstanding shares of voting stock of the Corporation with the power to vote generally in an election of directors, voting together
as a single class.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Article XI - Definitions </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As used in these bylaws,
unless the context otherwise requires, the following terms shall have the following meanings:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">An &ldquo;<U>electronic transmission</U>&rdquo;
means any form of communication, not directly involving the physical transmission of paper, including the use of, or participation in,
one or more electronic networks or databases (including one or more distributed electronic networks or databases), that creates a record
that may be retained, retrieved and reviewed by a recipient thereof, and that may be directly reproduced in paper form by such a recipient
through an automated process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">An &ldquo;<U>electronic mail</U>&rdquo;
means an electronic transmission directed to a unique electronic mail address (which electronic mail shall be deemed to include any files
attached thereto and any information hyperlinked to a website if such electronic mail includes the contact information of an officer or
agent of the Corporation who is available to assist with accessing such files and information).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">An &ldquo;<U>electronic mail
address</U>&rdquo; means a destination, commonly expressed as a string of characters, consisting of a unique user name or mailbox (commonly
referred to as the &ldquo;local part&rdquo; of the address) and a reference to an internet domain (commonly referred to as the &ldquo;domain
part&rdquo; of the address), whether or not displayed, to which electronic mail can be sent or delivered.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The term &ldquo;<U>person</U>&rdquo;
means any individual, general partnership, limited partnership, limited liability company, corporation, trust, business trust, joint stock
company, joint venture, unincorporated association, cooperative or association or any other legal entity or organization of whatever nature,
and shall include any successor (by merger or otherwise) of such entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>CERTIFICATION OF ADOPTION OF AMENDED AND RESTATED
BYLAWS</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned hereby certifies that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">I am the President and Chief Executive Officer of Intensity Therapeutics, Inc., a Delaware corporation
(the &ldquo;<U>Corporation</U>&rdquo;); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">The foregoing Amended and Restated Bylaws is a true and correct copy of the Amended and Restated Bylaws
of the Corporation, as duly adopted and approved by the Board of Directors of the Corporation, effective as of July 5, 2023.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF, I have hereunder subscribed
my name this 5<SUP>th</SUP> day of July, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%"><FONT STYLE="font-size: 10pt"><U STYLE="text-decoration: none">/s/ Lewis H. Bender</U></FONT></TD>
    </TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Lewis H. Bender, President and Chief Executive Officer</FONT></TD>
    </TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>Certification of Adoption of Amended and Restated
Bylaws</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">23</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>4
<FILENAME>ea181296ex4-1_intensity.htm
<DESCRIPTION>REPRESENTATIVE'S WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 4.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form of Underwriter Warrant</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="text-transform: uppercase"><B>Intensity
Therapeutics, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 70%; font-size: 10pt">Warrant Shares: _______</TD>
    <TD STYLE="width: 30%; font-size: 10pt">Initial Exercise Date: January 5, 2023</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">Issue Date: July 5, 2023</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">THIS UNDERWRITER COMMON STOCK
PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, _____________ or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
January 5, 2023&nbsp;(the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on July 5, 2028&nbsp;(the
&ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Intensity Therapeutics, Inc., a Delaware
corporation (the &ldquo;<U>Company</U>&rdquo;), up to ______ shares (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;)
of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in
Section 2(b). This Warrant is issued pursuant to the Underwriting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 1</U>.&nbsp;<U>Definitions</U>.
In addition to the terms defined elsewhere in this Warrant, the following terms have the meanings indicated in this Section 1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person, as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York
City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the
Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed
or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)
in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith
by the Holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the fees and expenses
of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Business
Day</U>&rdquo; means any day other than Saturday, Sunday or other day on which commercial banks in The City of New York are authorized
or required by law to remain closed;&nbsp;<U>provided</U>,&nbsp;<U>however</U>, for clarification, commercial banks shall not be deemed
to be authorized or required by law to remain closed due to &ldquo;stay at home&rdquo;, &ldquo;shelter-in-place&rdquo;, &ldquo;non-essential
employee&rdquo; or any other similar orders or restrictions or the closure of any physical branch locations at the direction of any governmental
authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York
generally are open for use by customers on such day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Commission</U>&rdquo;
means the United States Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock</U>&rdquo; means the common stock of the Company, par value $0.0001 per share, and any other class of securities into which such
securities may hereafter be reclassified or changed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire
at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is
at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Registration
Statement</U>&rdquo; means the Company&rsquo;s registration statement on Form S-1 (File No. 333-260565).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Subsidiary</U>&rdquo;
means any subsidiary of the Company and shall, where applicable, also include any direct or indirect subsidiary of the Company formed
or acquired after the date hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Day</U>&rdquo; means a day on which the Common Stock is traded on a Trading Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Trading
Market</U>&rdquo; means any of the following markets or exchanges on which the Common Stock is listed or quoted for trading on the date
in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock
Exchange (or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Transfer
Agent</U>&rdquo; means Continental Stock Transfer &amp; Trust Company, the current transfer agent of the Company, with a mailing address
of 1 State Street, 30th Floor, New York, NY 10004-1561, and any successor transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Underwriting
Agreement</U>&rdquo; means the underwriting agreement, dated as of June 29, 2023 between the Company, The Benchmark Company, LLC, as representative
of the underwriters named therein, as amended, modified or supplemented from time to time in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date)
on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30
a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average
price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not
then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on the Pink Open Market (or a
similar organization or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock
so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected
in good faith by the holders of a majority in interest of the Warrants then outstanding and reasonably acceptable to the Company, the
fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&ldquo;<U>Warrants</U>&rdquo;
means this Warrant and other Common Stock purchase warrants issued by the Company pursuant to the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 2</U>.&nbsp;<U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;<U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy
or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank unless the
cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original Notice
of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise
be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant to
the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in
which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which
the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable
hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain records showing
the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise
within one (1) Business Day of receipt of such notice.&nbsp;<B>The Holder and any assignee, by acceptance of this Warrant, acknowledge
and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the
number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;<U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be $6.00, subject to adjustment hereunder (the &ldquo;<U>Exercise
Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;<U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for the issuance of the Warrant Shares to the Holder, then this Warrant may also be exercised, in whole or in
part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.55in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.34in; text-align: right">(A)</TD>
    <TD STYLE="width: 0.1in; text-align: center">=</TD>
    <TD STYLE="text-align: justify">as applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b)(68) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock on the principal Trading Market as reported by Bloomberg L.P. as of the time of the Holder&rsquo;s execution of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section 2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">(B)</TD>
    <TD STYLE="text-align: center">=</TD>
    <TD STYLE="text-align: justify">the Exercise Price of this Warrant, as adjusted hereunder; and</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: right">(X)</TD>
    <TD STYLE="text-align: center">=</TD>
    <TD STYLE="text-align: justify">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">If Warrant Shares
are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act,
the Warrant Shares shall take on the registered characteristics of the Warrants being exercised. The Company agrees not to take any position
contrary to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">Notwithstanding
anything herein to the contrary, if on the Termination Date there is no effective registration statement registering, or the prospectus
contained therein is not available for the issuance of the Warrant Shares to the Holder, then, this Warrant shall be automatically exercised
via cashless exercise pursuant to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 103.5pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;<U>Mechanics
of Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.&nbsp;<U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the Transfer
Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The Depository Trust Company
through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a participant in such system
and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant
Shares by Holder or (B) this Warrant is being exercised via cashless exercise, and otherwise by physical delivery of a certificate, registered
in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder
is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by the date that is the earliest
of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise, (ii) one (1) Trading Day after delivery of the
aggregate Exercise Price to the Company and (iii) the number of Trading Days comprising the Standard Settlement Period after the delivery
to the Company of the Notice of Exercise (such date, the &ldquo;<U>Warrant Share Delivery Date</U>&rdquo;). Upon delivery of the Notice
of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect
to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate
Exercise Price (other than in the case of a cashless exercise) is received within the earlier of (i) two (2) Trading Days and (ii) the
number of Trading Days comprising the Standard Settlement Period following delivery of the Notice of Exercise. If the Company fails for
any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company
shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise
(based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading
Day on the fifth Trading Day after such liquidated damages begin to accrue) for each Trading Day after such Warrant Share Delivery Date
until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant
in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement Period</U>&rdquo;
means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary Trading Market with respect
to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -9pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.&nbsp;<U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iii.&nbsp;<U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">iv.&nbsp;<U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date, and if after such date the Holder is required by its
broker to purchase (in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common
Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise
(a &ldquo;<U>Buy-In</U>&rdquo;), then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained
by multiplying (1) the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise
at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the
Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in
which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common
Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with
an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the
Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable
to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit
a Holder&rsquo;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree
of specific performance and/or injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock
upon exercise of the Warrant as required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">v.&nbsp;<U>No Fractional
Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Warrant. As
to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election,
either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or
round up to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vi.&nbsp;<U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder;&nbsp;<U>provided</U>,&nbsp;<U>however</U>,
that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent
fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">vii.&nbsp;<U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&nbsp;<U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise
any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance after exercise
as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any other Persons acting
as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons, &ldquo;<U>Attribution Parties</U>&rdquo;)),
would beneficially own in excess of the Beneficial Ownership Limitation (as defined below). For purposes of the foregoing sentence, the
number of shares of Common Stock beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number
of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude
the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant
beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii) exercise or conversion of the unexercised or
nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject
to a limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its
Affiliates or Attribution Parties. Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership
shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being
acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d)
of the Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent
that the limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other
securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable
shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the Holder&rsquo;s determination
of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution
Parties) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company
shall have no obligation to verify or confirm the accuracy of such determination. In addition, a determination as to any group status
as contemplated above shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated
thereunder. For purposes of this Section 2(e), in determining the number of outstanding shares of Common Stock, a Holder may rely on the
number of outstanding shares of Common Stock as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with
the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company
or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the
Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.
In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of
securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such
number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership Limitation</U>&rdquo; shall be 4.99% of
the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable
upon exercise of this Warrant. The Holder, upon notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions
of this Section 2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common
Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the
Holder and the provisions of this Section 2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will not be
effective until the 61<SUP>st</SUP>&nbsp;day after such notice is delivered to the Company. The provisions of this paragraph shall be
construed and implemented in a manner otherwise than in strict conformity with the terms of this Section 2(e) to correct this paragraph
(or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to
make changes or supplements necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph
shall apply to a successor holder of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 3</U>.&nbsp;<U>Certain
Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;<U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective
date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;<U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any
class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms
applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number
of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are
to be determined for the grant, issue or sale of such Purchase Rights (provided, however, that, to the extent that the Holder&rsquo;s
right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as
a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;<U>Pro Rata
Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution
of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise, other
than cash (including, without limitation, any distribution of stock or other securities, property or options by way of a dividend, spin
off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &ldquo;<U>Distribution</U>&rdquo;),
at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution
to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable
upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial
Ownership Limitation) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the
date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,&nbsp;<U>however</U>,
that, to the extent that the Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial
Ownership Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership
of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance
for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership
Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;<U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related transactions
effects any merger or consolidation of the Company with or into another Person, (ii) the Company or any Subsidiary, directly or indirectly,
effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one
or a series of related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company
or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other
securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the Company, directly
or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock
or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash
or property, or (v) the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement
or other business combination (including, without limitation, a reorganization, recapitalization, spin-off, merger or scheme of arrangement)
with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common
Stock (not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated
with the other Persons making or party to, such stock or share purchase agreement or other business combination) (each a &ldquo;<U>Fundamental
Transaction</U>&rdquo;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant
Share that would have been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option
of the Holder (without regard to any limitation in Section 2(e) on the exercise of this Warrant), the number of shares of Common Stock
of the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the
&ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of shares
of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation
in Section 2(e) on the exercise of this Warrant). For purposes of any such exercise, the determination of the Exercise Price shall be
appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of
one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration
in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common
Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be
given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.
The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor
Entity</U>&rdquo;) to assume in writing all of the obligations of the Company under this Warrant in accordance with the provisions of
this Section 3(e) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder
(without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange
for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this
Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent
to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise
of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such
shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction
and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of
protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably
satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall
succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring
to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may exercise every right and power of the Company and shall
assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the
Company herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&nbsp;<U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)&nbsp;<U>Notice
to Holder</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">i.&nbsp;<U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">ii.&nbsp;<U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the Common
Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the Company shall
authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock
of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of
all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other securities,
cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs
of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at its last facsimile
number or email address as it shall appear upon the Warrant Register of the Company, at least 20 calendar days prior to the applicable
record or effective date hereinafter specified, a notice stating (x) the date on which a record is to be taken for the purpose of such
dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as of which the holders of the Common
Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y) the date on
which such reclassification, consolidation, merger, sale, transfer or share exchange is expected to become effective or close, and the
date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock
for securities, cash or other property deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange;
provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the
corporate action required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains,
material, non-public information regarding the Company or any of the Subsidiaries, the Company shall simultaneously file such notice with
the Commission pursuant to a Current Report on Form 8-K. The Holder shall remain entitled to exercise this Warrant during the period commencing
on the date of such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)&nbsp;<U>Voluntary
Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of
this Warrant, subject to the prior written consent of the Holder, reduce the then current Exercise Price to any amount and for any period
of time deemed appropriate by the board of directors of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 4</U>.&nbsp;<U>Transfer
of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;<U>Transferability</U>.
Pursuant to FINRA Rule 5110(e), neither this Warrant nor any Warrant Shares issued upon exercise of this Warrant shall be sold, transferred,
assigned, pledged or hypothecated, or be the subject of any hedging, short sale, derivative, put or call transaction that would result
in the effective economic disposition of the securities by any person for a period of 180 days immediately following the date of commencement
of sales of the offering pursuant to which this Warrant is being issued, except the transfer of any security:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.75in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify">(i)</TD>
    <TD STYLE="text-align: justify">by operation of law or by reason of reorganization of the Company;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(ii)</TD>
    <TD STYLE="text-align: justify">to any FINRA member firm participating in the offering and the officers, partners, registered persons or affiliates thereof, if all securities so transferred remain subject to the lock-up restriction in this Section 4(a) for the remainder of the time period;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(iii)</TD>
    <TD STYLE="text-align: justify">if the aggregate amount of securities of the Company held by the Holder or related person does not exceed 1% of the securities being offered;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(iv)</TD>
    <TD STYLE="text-align: justify">that is beneficially owned on a pro-rata basis by all equity owners of an investment fund, provided that no participating member manages or otherwise directs investments by the fund, and participating members in the aggregate do not own more than 10% of the equity in the fund; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(v)</TD>
    <TD STYLE="text-align: justify">the exercise or conversion of any security, if all securities received remain subject to the lock-up restriction in this Section 4(a) for the remainder of the time period;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(vi)</TD>
    <TD STYLE="text-align: justify">if the Company meets the registration requirements of Forms S-3, F-3 or F-10; or</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(vii)</TD>
    <TD STYLE="text-align: justify">back to the Company in a transaction exempt from registration with the Commission.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Subject to the foregoing restriction,
this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part,
upon surrender of this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this
Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to pay any
transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute
and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the denomination or denominations
specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so
assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary, the Holder shall not be required
to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall
surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers an assignment form to the
Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for
the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;<U>New Warrants</U>.
This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company, together
with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent
or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination, the Company
shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance with
such notice. All Warrants issued on transfers or exchanges shall be dated the initial issuance date of this Warrant and shall be identical
with this Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;<U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 5</U>.&nbsp;<U>Demand
Registrations</U>. To the extent the Company does not maintain an effective registration statement for the Warrant Shares, then for a
period commencing on the Initial Exercise Date and terminating on the Termination Date, the Holder is entitled to one &ldquo;demand&rdquo;
registration right at the Company&rsquo;s expense and one &ldquo;demand&rdquo; registration right at the Holder&rsquo;s expense, each
such right to be exercised not later than the Termination Date. Upon receipt of a demand registration request from the registered Holder,
the Company shall file a registration statement on Form S-3 (&ldquo;Form S-3&rdquo;) or, if Form S-3 is not available, on any other appropriate
form, including Form S-1, within 60 days of demand thereof registering the Warrant Shares and cause such registration statement to become
effective within 120 days thereof. A registration requested pursuant to this Section 5 shall not be deemed to have been effected: (i)
unless a registration statement with respect thereto has become effective or (ii) if, after it has become effective, such registration
is interfered with by any stop order, injunction or other order or requirement of the Commission or other governmental agency or court
of competent jurisdiction for any reason, other than by reason of some act or omission by the Holder. The Company shall use its commercially
reasonable efforts to cause any registration statement filed pursuant to the demand rights granted under this Section 5 to remain effective
for a period of at least nine (9) consecutive months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 6</U>.&nbsp;<U>Piggy-Back
Registrations</U>. If, at any time while this Warrant is outstanding, there is not an effective registration statement covering all of
the Warrant Shares and the Company shall determine to prepare and file with the Commission a registration statement relating to an offering
for its own account or the account of others under the Securities Act of any of its equity securities, other than on Form S-4 or Form
S-8 (each as promulgated under the Securities Act) or their then equivalents relating to equity securities to be issued solely in connection
with any acquisition of any entity or business or equity securities issuable in connection with the Company&rsquo;s stock option or other
employee benefit plans, then the Company shall deliver to each Holder a written notice of such determination and, if within fifteen days
after the date of the delivery of such notice, any such Holder shall so request in writing, the Company shall include in such registration
statement all or any part of such Warrant Shares such Holder requests to be registered;&nbsp;<U>provided</U>,&nbsp;<U>however</U>, that
the Company shall not be required to register any Warrant Shares pursuant to this Section 6 that are eligible for resale pursuant to Rule
144 (without volume restrictions or current public information requirements) or that are the subject of a then effective registration
statement that is available for resales or other dispositions by such Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><U>Section 7</U>.&nbsp;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">a)&nbsp;<U>No Rights
as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends or
other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set forth
in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant to Section
2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required to
net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">b)&nbsp;<U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">c)&nbsp;<U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">d)&nbsp;<U>Authorized
Shares</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Except and to the
extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate
of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or
any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all
times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate
to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i) not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior
to such increase in par value, (ii) take all such action as may be necessary or appropriate in order that the Company may validly and
legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii) use commercially reasonable efforts
to obtain all such authorizations, exemptions or consents from any public regulatory body having jurisdiction thereof, as may be, necessary
to enable the Company to perform its obligations under this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">e)&nbsp;<U>Governing
Law</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be governed by and
construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of
law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of the transactions
contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York.
Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough
of Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed
herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim that it is not personally
subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding.
Each party hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding
by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address
in effect for notices to it under this Warrant and agrees that such service shall constitute good and sufficient service of process and
notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted
by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in
such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&rsquo; fees and other costs and
expenses incurred with the investigation, preparation and prosecution of such action or proceeding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">f)&nbsp;<U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">g)&nbsp;<U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages
to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and expenses including, but
not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts
due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">h)&nbsp;<U>Notices</U>.
Any and all notices or other communications or deliveries to be provided by the Holders hereunder including, without limitation, any Notice
of Exercise, shall be in writing and delivered personally, by facsimile or e-mail, or sent by a nationally recognized overnight courier
service, addressed to the Company, at Intensity Therapeutics, Inc., 61 Wilton Road, 3rd Floor, Westport, CT 06880, Attention: Lew Bender,
facsimile number: 203-557-3023, email address: lbender@intensitytherapeutics.com, or such other facsimile number, email address or address
as the Company may specify for such purposes by notice to the Holders. Any and all notices or other communications or deliveries to be
provided by the Company hereunder shall be in writing and delivered personally, by facsimile or e-mail, or sent by a nationally recognized
overnight courier service addressed to each Holder at the facsimile number, e-mail address or address of such Holder appearing on the
books of the Company. Any notice or other communication or deliveries hereunder shall be deemed given and effective on the earliest of
(i) the time of transmission, if such notice or communication is delivered via facsimile at the facsimile number or via e-mail at the
e-mail address set forth in this Section prior to 5:30 p.m. (New York City time) on any date, (ii) the next Trading Day after the time
of transmission, if such notice or communication is delivered via facsimile at the facsimile number or via e-mail at the e-mail address
set forth in this Section on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (iii) the
second Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service, or (iv) upon actual
receipt by the party to whom such notice is required to be given. To the extent that any notice provided hereunder constitutes, or contains,
material, non-public information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice with the
Commission pursuant to a Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">i)&nbsp;<U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">j)&nbsp;<U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">k)&nbsp;<U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">l)&nbsp;<U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and
the Holder, on the other hand.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">m)&nbsp;<U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">n)&nbsp;<U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">IN WITNESS WHEREOF, the Company has caused this
Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="text-transform: uppercase"><B>intensity therapeutics, INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt">By:</TD>
    <TD STYLE="border-bottom: black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8239;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">TO: intensity
therapeutics, INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(1) The undersigned hereby elects
to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders
herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(2) Payment shall take the form
of (check applicable box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">[&nbsp;&nbsp;] in lawful money of the
United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">[&nbsp;&nbsp;] if permitted the cancellation
of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c), to exercise this Warrant
with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(3) Please issue said Warrant
Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Warrant Shares shall be delivered to the following
DWAC Account Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.5in">_______________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">[SIGNATURE
OF HOLDER]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Investing Entity: ________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Signature of Authorized Signatory of Investing
Entity</I>: _________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Name of Authorized Signatory: ___________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Title of Authorized Signatory: ____________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: ________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ASSIGNMENT FORM</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">FOR VALUE RECEIVED, the foregoing
Warrant and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 10.5pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">Name:</TD>
    <TD STYLE="width: 50%; text-align: justify">______________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">(Please Print)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Address:</TD>
    <TD STYLE="text-align: justify">______________________________________</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Phone Number:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Email Address:</P></TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">(Please Print)</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________________</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">______________________________________</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Dated: _______________ __, ______</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Holder&rsquo;s Signature:&nbsp;_________________</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Holder&rsquo;s Address:&nbsp;_________________</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>ea181296ex10-1_intensity.htm
<DESCRIPTION>UNDERWRITING AGREEMENT, DATED JUNE 29, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDERWRITING AGREEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>between</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Intensity Therapeutics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>and</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The Benchmark Company, LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>as Representative of the Several Underwriters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Intensity Therapeutics, Inc.</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>UNDERWRITING AGREEMENT</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">New York, New York<BR>
June 29, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Benchmark Company, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As Representative of the several Underwriters named on Schedule 1 attached
hereto<BR>
150 East 58th St, 17th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10155</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned, Intensity
Therapeutics, Inc., a corporation formed under the laws of the State of Delaware (collectively with its subsidiaries and affiliates, including,
without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being subsidiaries or
affiliates of Intensity Therapeutics, Inc., the &ldquo;<B>Company</B>&rdquo;), hereby confirms its agreement (this &ldquo;<B>Agreement</B>&rdquo;)
with The Benchmark Company, LLC (hereinafter referred to as &ldquo;you&rdquo; (including its correlatives) or the &ldquo;<B>Representative</B>&rdquo;)
and with the other underwriters named on <U>Schedule 1</U> hereto for which the Representative is acting as representative (the Representative
and such other underwriters being collectively called the &ldquo;<B>Underwriters</B>&rdquo; or, individually, an &ldquo;<B>Underwriter</B>&rdquo;)
as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-weight: normal">1.</FONT> <U>Purchase and Sale of Shares</U>.</P>



<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">1.1&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Firm
Shares</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">1.1.1.&nbsp;<U>Nature
and Purchase of Firm Shares</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(i)&nbsp;<FONT STYLE="font-size: 10pt">On
the basis of the representations and warranties herein contained, but subject to the terms and conditions herein set forth, the Company
agrees to issue and sell to the several Underwriters, an aggregate of 3,900,000 shares (&ldquo;</FONT></FONT><FONT STYLE="font-size: 10pt">Firm
Shares<FONT STYLE="font-weight: normal">&rdquo;) of the Company&rsquo;s common stock, par value $0.0001 per share (the &ldquo;</FONT>Common
Stock<FONT STYLE="font-weight: normal">&rdquo;).</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(ii)&nbsp;<FONT STYLE="font-size: 10pt">The
Underwriters, severally and not jointly, agree to purchase from the Company the number of Firm Shares set forth opposite their respective
names on <U>Schedule 1</U> attached hereto and made a part hereof at a purchase price of $4.65 per share (93% of the per Firm Share offering
price). The Firm Shares are to be offered initially to the public at the offering price set forth on the cover page of the Prospectus
(as defined in Section 2.1.1 hereof).</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">1.1.2.&nbsp;<U>Shares
Payment and Delivery</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(i)&nbsp;<FONT STYLE="font-size: 10pt">Delivery
and payment for the Firm Shares shall be made at 10:00 a.m., Eastern time, on the second (2nd) Business Day following the effective date
(the &ldquo;</FONT></FONT><FONT STYLE="font-size: 10pt">Effective Date<FONT STYLE="font-weight: normal">&rdquo;) of the Registration Statement
(as defined in Section 2.1.1 below) (or the third (3rd) Business Day following the Effective Date if the Registration Statement is declared
effective after 4:01 p.m., Eastern time) or at such earlier time as shall be agreed upon by the Representative and the Company, at the
offices of Mintz, Levin, Cohn, Ferris and Popeo, P.C., Chrysler Center, 919 Third Avenue, New York, NY 10022 (&ldquo;</FONT>Representative
Counsel<FONT STYLE="font-weight: normal">&rdquo;), or at such other place (or remotely by facsimile or other electronic transmission)
as shall be agreed upon by the Representative and the Company. The hour and date of delivery and payment for the Firm Shares is called
the &ldquo;</FONT>Closing Date<FONT STYLE="font-weight: normal">.&rdquo;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(ii)&nbsp;<FONT STYLE="font-size: 10pt">Payment
for the Firm Shares shall be made on the Closing Date by wire transfer in Federal (same day) funds, payable to the order of the Company
upon delivery of the Firm Shares, which shall be delivered through the facilities of the Depository Trust Company (&ldquo;</FONT></FONT><FONT STYLE="font-size: 10pt">DTC<FONT STYLE="font-weight: normal">&rdquo;)
for the account of the Underwriters. The Firm Shares shall be registered in such name or names and in such authorized denominations as
the Representative may request in writing. The Company shall not be obligated to sell or deliver the Firm Shares except upon tender of
payment by the Representative for all of the Firm Shares. The term &ldquo;</FONT>Business Day<FONT STYLE="font-weight: normal">&rdquo;
means any day other than a Saturday, a Sunday or a legal holiday or a day on which banking institutions are authorized or obligated by
law to close in New York, New York.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">1.2&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Over-allotment
Option</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">1.2.1.&nbsp;<U>Option
Shares</U>. For the purposes of covering any over-allotments in connection with the distribution and sale of the Firm Shares, the Company
hereby grants to the Underwriters an option to purchase up to 585,000 additional shares of Common Stock, representing fifteen percent
(15%) of the Firm Shares sold in the offering, from the Company (the &ldquo;</FONT>Over-allotment Option<FONT STYLE="font-weight: normal">&rdquo;).
Such 585,000 additional shares of Common Stock, the net proceeds of which will be deposited with the Company&rsquo;s account, are hereinafter
referred to as &ldquo;</FONT>Option Shares<FONT STYLE="font-weight: normal">.&rdquo; The purchase price to be paid per Option Share shall
be equal to the price per Firm Share set forth in Section 1.1.1 hereof. The offering and sale of the Firm Shares and the Option Shares
is hereinafter referred to as the &ldquo;</FONT>Offering<FONT STYLE="font-weight: normal">.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">1.2.2.&nbsp;<U>Exercise
of Option</U>. The Over-allotment Option granted pursuant to Section 1.2.1 hereof may be exercised by the Representative as to all (at
any time) or any part (from time to time) of the Option Shares within forty-five (45) days after the Effective Date. The Underwriters
shall not be under any obligation to purchase any Option Shares prior to the exercise of the Over-allotment Option. The Over-allotment
Option granted hereby may be exercised by the giving of oral notice to the Company from the Representative, which must be confirmed in
writing by overnight mail or facsimile or other electronic transmission setting forth the number of Option Shares to be purchased and
the date and time for delivery of and payment for the Option Shares (the &ldquo;</FONT>Option Closing Date<FONT STYLE="font-weight: normal">&rdquo;),
which shall not be later than two (2) full Business Days after the date of the notice or such other time as shall be agreed upon by the
Company and the Representative, at the offices of Representative Counsel or at such other place (including remotely by facsimile or other
electronic transmission) as shall be agreed upon by the Company and the Representative. If such delivery and payment for the Option Shares
does not occur on the Closing Date, the Option Closing Date will be as set forth in the notice. Upon exercise of the Over-allotment Option
with respect to all or any portion of the Option Shares, subject to the terms and conditions set forth herein, (i) the Company shall become
obligated to sell to the Underwriters the number of Option Shares specified in such notice and (ii) each of the Underwriters, acting severally
and not jointly, shall purchase that portion of the total number of Option Shares then being purchased as set forth in <U>Schedule 1</U>
opposite the name of such Underwriter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">1.2.3.&nbsp;<U>Payment
and Delivery</U>. Payment for the Option Shares shall be made on the Option Closing Date by wire transfer in Federal (same day) funds,
payable to the order of the Company upon delivery to you of certificates (in form and substance satisfactory to the Underwriters) representing
the Option Shares (or through the facilities of DTC) for the account of the Underwriters. The Option Shares shall be registered in such
name or names and in such authorized denominations as the Representative may request in writing at least two (2) full Business Days prior
to the Option Closing Date. The Company shall not be obligated to sell or deliver the Option Shares except upon tender of payment by the
Representative for applicable Option Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-weight: normal">1.2.4.&nbsp;<U>Underwriters&rsquo;
Warrants</U>. At the Closing Date, and each Option Closing Date, if any, the Company shall deliver to the Underwriters warrants (the &ldquo;</FONT>Underwriter
Warrants<FONT STYLE="font-weight: normal">&rdquo;) to purchase a number of shares of Common Stock (the &ldquo;</FONT>Underwriter Warrant
Shares<FONT STYLE="font-weight: normal">&rdquo;) equal to 7.0% of the sum of the number of Firm Shares and Option Shares issued on such
Closing Date and Option Closing Date, as applicable, in certificated form registered in the name of the Underwriters (or their designees),
which Underwriters Warrants shall have an exercise price of $6.00 (120% of the price per Firm Share set forth in Section 1.1.1 hereof)
subject to adjustment therein, in the form attached hereto as <U>Exhibit A</U>. The Firm Shares, the Option Shares and the Underwriter
Warrant Shares are hereinafter referred to together as the &ldquo;</FONT>Shares<FONT STYLE="font-weight: normal">.&rdquo; The Shares and
Underwriter Warrants are hereinafter referred to together as the &ldquo;</FONT>Public&nbsp;Securities<FONT STYLE="font-weight: normal">.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">2.&nbsp;</FONT><U>Representations
and Warranties of the Company</U><FONT STYLE="font-weight: normal">. The Company represents and warrants to the Underwriters as of the
Applicable Time (as defined below), as of the Closing Date and as of the Option Closing Date, if any, as follows:</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.1&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Filing
of Registration Statement</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.1.1.&nbsp;<U>Pursuant
to the Securities Act</U>. The Company has filed with the U.S. Securities and Exchange Commission (the &ldquo;</FONT>Commission<FONT STYLE="font-weight: normal">&rdquo;)
a registration statement, and an amendment or amendments thereto, on Form S-1 (File No. 333-260565), including any related prospectus
or prospectuses, for the registration of the Shares under the Securities Act of 1933, as amended (the &ldquo;</FONT>Securities Act<FONT STYLE="font-weight: normal">&rdquo;),
which registration statement and amendment or amendments have been prepared by the Company in all material respects in conformity with
the requirements of the Securities Act and the rules and regulations of the Commission under the Securities Act (the &ldquo;</FONT>Securities
Act Regulations<FONT STYLE="font-weight: normal">&rdquo;) and will contain all material statements that are required to be stated therein
in accordance with the Securities Act and the Securities Act Regulations. Except as the context may otherwise require, such registration
statement, as amended, on file with the Commission at the time the registration statement became effective (including the Preliminary
Prospectus included in the registration statement, financial statements, schedules, exhibits and all other documents filed as a part thereof
or incorporated therein and all information deemed to be a part thereof as of the Effective Date pursuant to paragraph (b) of Rule 430A
of the Securities Act Regulations (the &ldquo;</FONT>Rule 430A Information<FONT STYLE="font-weight: normal">&rdquo;)), is referred to
herein as the &ldquo;</FONT>Registration Statement<FONT STYLE="font-weight: normal">.&rdquo; If the Company files any registration statement
pursuant to Rule 462(b) of the Securities Act Regulations, then after such filing, the term &ldquo;Registration Statement&rdquo; shall
include such registration statement filed pursuant to Rule 462(b). The Registration Statement has been declared effective by the Commission
on the date hereof. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">Each
prospectus used prior to the effectiveness of the Registration Statement, and each prospectus that omitted the Rule 430A Information that
was used after such effectiveness and prior to the execution and delivery of this Agreement, is herein called a &ldquo;</FONT>Preliminary
Prospectus<FONT STYLE="font-weight: normal">.&rdquo; The Preliminary Prospectus, subject to completion, dated June 23, 2023, that was
included in the Registration Statement immediately prior to the Applicable Time is hereinafter called the &ldquo;</FONT>Pricing Prospectus<FONT STYLE="font-weight: normal">.&rdquo;
The final prospectus in the form first furnished to the Underwriters for use in the Offering is hereinafter called the &ldquo;</FONT>Prospectus<FONT STYLE="font-weight: normal">.&rdquo;
Any reference to the &ldquo;</FONT>most recent Preliminary Prospectus<FONT STYLE="font-weight: normal">&rdquo; shall be deemed to refer
to the latest Preliminary Prospectus included in the Registration Statement. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Applicable
Time<FONT STYLE="font-weight: normal">&rdquo; means 4:30 p.m., Eastern time, on the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Issuer
Free Writing Prospectus<FONT STYLE="font-weight: normal">&rdquo; means any &ldquo;issuer free writing prospectus,&rdquo; as defined in
Rule 433 of the Securities Act Regulations (&ldquo;</FONT>Rule 433<FONT STYLE="font-weight: normal">&rdquo;), including without limitation
any &ldquo;free writing prospectus&rdquo; (as defined in Rule 405 of the Securities Act Regulations) relating to the Public Securities
that is (i)&nbsp;required to be filed with the Commission by the Company, (ii)&nbsp;a &ldquo;road show that is a written communication&rdquo;
within the meaning of Rule 433(d)(8)(i), whether or not required to be filed with the Commission, or (iii)&nbsp;exempt from filing with
the Commission pursuant to Rule 433(d)(5)(i) because it contains a description of the Public Securities or of the Offering that does not
reflect the final terms, in each case in the form filed or required to be filed with the Commission or, if not required to be filed, in
the form retained in the Company&rsquo;s records pursuant to Rule 433(g).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Issuer
General Use Free Writing Prospectus<FONT STYLE="font-weight: normal">&rdquo; means any Issuer Free Writing Prospectus that is intended
for general distribution to prospective investors (other than a &ldquo;<I>bona fide</I> electronic road show,&rdquo; as defined in Rule
433 (the &ldquo;</FONT>Bona Fide Electronic Road Show<FONT STYLE="font-weight: normal">&rdquo;)), as evidenced by its being specified
in <U>Schedule 2-B</U> hereto. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Issuer
Limited Use Free Writing Prospectus<FONT STYLE="font-weight: normal">&rdquo; means any Issuer Free Writing Prospectus that is not an
Issuer General Use Free Writing Prospectus.</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-weight: normal">&ldquo;</FONT>Pricing
Disclosure Package<FONT STYLE="font-weight: normal">&rdquo; means any Issuer General Use Free Writing Prospectus issued at or prior to
the Applicable Time, the Pricing Prospectus and the information included on <U>Schedule 2-A</U> hereto, all considered together.</FONT>&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.1.2.&nbsp;</FONT><U>Pursuant
to the Exchange Act</U><FONT STYLE="font-weight: normal">. The Company has filed with the Commission a Form 8-A (File Number 000-41109)
providing for the registration pursuant to Section 12(b) under the Securities Exchange Act of 1934, as amended (the &ldquo;</FONT>Exchange
Act<FONT STYLE="font-weight: normal">&rdquo;), of the Common Stock. The registration of the Common Stock under the Exchange Act has been
declared effective by the Commission on or prior to the date hereof. The Company has taken no action designed to, or likely to have the
effect of, terminating the registration of the Common Stock under the Exchange Act, nor has the Company received any notification that
the Commission is contemplating terminating such registration.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.2&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Stock
Exchange Listing</U><FONT STYLE="font-weight: normal">. As of as of the Closing Date and as of each Option Closing Date, the Common Stock
has been approved for listing and is listed on The Nasdaq Capital Market (the &ldquo;</FONT>Exchange<FONT STYLE="font-weight: normal">&rdquo;),
and the Company has taken no action designed to, or likely to have the effect of, delisting the Common Stock from the Exchange, nor has
the Company received any notification that the Exchange is contemplating terminating such listing except as described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.3&nbsp;</FONT><FONT STYLE="font-style: normal"><U>No
Stop Orders, etc</U><FONT STYLE="font-weight: normal">. Neither the Commission nor, to the Company&rsquo;s knowledge, any state regulatory
authority has issued any order preventing or suspending the use of the Registration Statement, any Preliminary Prospectus or the Prospectus
or has instituted or, to the Company&rsquo;s knowledge, threatened to institute, any proceedings with respect to such an order. The Company
has complied with each request (if any) from the Commission for additional information.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.4&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Disclosures
in Registration Statement</U></FONT><FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.1.&nbsp;<U>Compliance
with Securities Act and 10b-5 Representation</U>. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(i)&nbsp;<FONT STYLE="font-size: 10pt">Each
of the Registration Statement and any post-effective amendment thereto, at the time it became effective, complied in all material respects
with the requirements of the Securities Act and the Securities Act Regulations. Each Preliminary Prospectus, including the prospectus
filed as part of the Registration Statement as originally filed or as part of any amendment or supplement thereto, and the Prospectus,
at the time each was filed with the Commission, complied in all material respects with the requirements of the Securities Act and the
Securities Act Regulations. Each Preliminary Prospectus delivered to the Underwriters for use in connection with this Offering and the
Prospectus was or will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except
to the extent permitted by Regulation S-T.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(ii)&nbsp;<FONT STYLE="font-size: 10pt">Neither
the Registration Statement nor any amendment thereto, at its effective time, as of the Applicable Time, at the Closing Date or at any
Option Closing Date (if any), contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit
to state a material fact required to be stated therein or necessary to make the statements therein not misleading; provided, however,
that this representation and warranty shall not apply to statements made or statements omitted in reliance upon and in conformity with
the Underwriters&rsquo; Information (as defined in Section 2.4.1(iii) below). </FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(iii)&nbsp;<FONT STYLE="font-size: 10pt">The
Pricing Disclosure Package, as of the Applicable Time, at the Closing Date or at any Option Closing Date (if any), did not, does not and
will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances under which they were made, not misleading; and each Issuer Limited Use Free Writing Prospectus hereto
does not conflict with the information contained in the Registration Statement, any Preliminary Prospectus, the Pricing Prospectus or
the Prospectus, and each such Issuer Limited Use Free Writing Prospectus, as supplemented by and taken together with the Pricing Prospectus
as of the Applicable Time, did not include an untrue statement of a material fact or omit to state a material fact necessary in order
to make the statements therein, in light of the circumstances under which they were made, not misleading; provided, however, that this
representation and warranty shall not apply to statements made or statements omitted in reliance upon and in conformity with written information
furnished to the Company with respect to the Underwriters by the Representative expressly for use in the Registration Statement, the Pricing
Prospectus or the Prospectus or any amendment thereof or supplement thereto. The parties acknowledge and agree that such information provided
by or on behalf of any Underwriter consists solely of the following disclosure contained in the &ldquo;Underwriting&rdquo; section of
the Prospectus: </FONT></FONT><FONT STYLE="font-size: 10pt">&nbsp;<FONT STYLE="font-weight: normal">(a) the first two sentences set forth
under the sub-caption &ldquo;Discount, Commissions and Expenses&rdquo;, (b) the information set forth under the sub-captions &ldquo;Stabilization,&rdquo;
and &ldquo;Passive Market Making&rdquo; and (c) the table showing the number of securities to be purchased by each Underwriter</FONT>
(<FONT STYLE="font-weight: normal">the &ldquo;</FONT>Underwriters&rsquo; Information<FONT STYLE="font-weight: normal">&rdquo;); and</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-weight: normal">(iv)&nbsp;<FONT STYLE="font-size: 10pt">Neither
the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its issue date, at the time of any filing
with the Commission pursuant to Rule 424(b), at the Closing Date or at any Option Closing Date, included, includes or will include an
untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading; provided, however, that this representation and
warranty shall not apply to the&nbsp;Underwriters&rsquo; Information.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.2.&nbsp;<U>Disclosure
of Agreements</U>. The agreements and documents described in the Registration Statement, the Pricing Disclosure Package and the Prospectus
conform in all material respects to the descriptions thereof contained therein and there are no agreements or other documents required
by the Securities Act and the Securities Act Regulations to be described in the Registration Statement, the Pricing Disclosure Package
and the Prospectus or to be filed with the Commission as exhibits to the Registration Statement, that have not been so described or filed.
Each agreement or other instrument (however characterized or described) to which the Company is a party or by which it is or may be bound
or affected and (i)&nbsp;that is referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus, or (ii)&nbsp;is
material to the Company&rsquo;s business, has been duly authorized and validly executed by the Company, is in full force and effect in
all material respects and is enforceable against the Company and, to the Company&rsquo;s knowledge, the other parties thereto, in accordance
with its terms, except (x)&nbsp;as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar laws affecting
creditors&rsquo; rights generally, (y)&nbsp;as enforceability of any indemnification or contribution provision may be limited under the
federal and state securities laws, and (z)&nbsp;that the remedy of specific performance and injunctive and other forms of equitable relief
may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may be brought. None
of such agreements or instruments has been assigned by the Company, and neither the Company nor, to the Company&rsquo;s knowledge, any
other party is in default thereunder and, to the Company&rsquo;s knowledge, no event has occurred that, with the lapse of time or the
giving of notice, or both, would constitute a default thereunder except for a default or event which would not reasonably be expected
to result in a Material Adverse Change (as such term is defined in Section 2.5.1 below). To the Company&rsquo;s knowledge, performance
by the Company of the material provisions of such agreements or instruments will not result in a violation of any existing applicable
law, rule, regulation, judgment, order or decree of any governmental agency or court, domestic or foreign, having jurisdiction over the
Company or any of its assets or businesses (each, a &ldquo;</FONT>Governmental Entity<FONT STYLE="font-weight: normal">&rdquo;), including,
without limitation, those relating to environmental laws and regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.3.&nbsp;<U>Prior
Securities Transactions</U>. During the period starting three (3) years prior to the date of this Agreement, no securities of the Company
have been sold by the Company or by or on behalf of, or for the benefit of, any person or persons controlling, controlled by or under
common control with the Company, except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Preliminary
Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.4.4.&nbsp;<U>Regulations</U>.
The disclosures in the Registration Statement, the Pricing Disclosure Package and the Prospectus concerning the effects of federal, state,
local and all foreign regulation on the Offering and the Company&rsquo;s business as currently contemplated are correct in all material
respects and no other such regulations are required to be disclosed in the Registration Statement, the Pricing Disclosure Package and
the Prospectus which are not so disclosed.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.5&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Changes
After Dates in Registration Statement</U></FONT><FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.5.1.&nbsp;<U>No
Material Adverse Change</U>. Since the respective dates as of which information is given in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, except as otherwise specifically stated therein and except in accordance with its ordinary business operations:
(i)&nbsp;there has been no material adverse change in the financial position or results of operations of the Company, nor any change or
development that, singularly or in the aggregate, involves a material adverse change, in or affecting the condition (financial or otherwise),
results of operations, business, assets or prospects of the Company (a &ldquo;</FONT>Material Adverse Change<FONT STYLE="font-weight: normal">&rdquo;);
(ii)&nbsp;there have been no material transactions entered into by the Company, other than as contemplated pursuant to this Agreement;
and (iii)&nbsp;no officer or director of the Company has resigned from any position with the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.5.2.&nbsp;<U>Recent
Securities Transactions, etc</U>. Subsequent to the respective dates as of which information is given in the Registration Statement, the
Pricing Disclosure Package and the Prospectus, and except as may otherwise be indicated or contemplated herein or disclosed in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, the Company has not: (i)&nbsp;issued any securities, other than upon exercise
or conversion of outstanding securities described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, or
incurred any liability or obligation, direct or contingent, for borrowed money except as described in the Registration Statement, the
Pricing Disclosure Package and the Prospectus; or (ii)&nbsp;declared or paid any dividend or made any other distribution on or in respect
to its capital stock.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.6&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Independent
Accountants</U>. <FONT STYLE="font-weight: normal">To the knowledge of the Company, EisnerAmper LLP (the &ldquo;</FONT>Auditor<FONT STYLE="font-weight: normal">&rdquo;),
whose report is filed with the Commission as part of the Registration Statement, the Pricing Disclosure Package and the Prospectus, is
an independent registered public accounting firm as required by the Securities Act and the Securities Act Regulations and the Public Company
Accounting Oversight Board. The Auditor has not, during the periods covered by the financial statements included in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, provided to the Company any non-audit services, as such term is used in Section 10A(g)
of the Exchange Act.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.7&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Financial
Statements, etc</U><FONT STYLE="font-weight: normal">. The financial statements, including the notes thereto and supporting schedules
included in the Registration Statement, the Pricing Disclosure Package and the Prospectus, fairly present in all material respects the
financial position and the results of operations of the Company at the dates and for the periods to which they apply; and such financial
statements have been prepared in conformity with U.S. generally accepted accounting principles (&ldquo;</FONT>GAAP<FONT STYLE="font-weight: normal">&rdquo;),
consistently applied throughout the periods involved (provided that unaudited interim financial statements are subject to year-end audit
adjustments that are not expected to be material in the aggregate and do not contain all footnotes required by GAAP); and the supporting
schedules included in the Registration Statement present fairly the information required to be stated therein. Except as included therein,
no historical or pro forma financial statements are required to be included in the Registration Statement, the Pricing Disclosure Package
or the Prospectus under the Securities Act or the Securities Act Regulations. The pro forma and pro forma as adjusted financial information
and the related notes, if any, included in the Registration Statement, the Pricing Disclosure Package and the Prospectus have been properly
compiled and prepared in accordance with the applicable requirements of the Securities Act and the Securities Act Regulations and present
fairly the information shown therein, and the assumptions used in the preparation thereof are reasonable and the adjustments used therein
are appropriate to give effect to the transactions and circumstances referred to therein. All disclosures contained in the Registration
Statement, the Pricing Disclosure Package or the Prospectus regarding &ldquo;non-GAAP financial measures&rdquo; (as such term is defined
by the rules and regulations of the Commission), if any, comply in all material respects with Regulation G of the Exchange Act and Item
10 of Regulation S-K of the Securities Act, to the extent applicable. Each of the Registration Statement, the Pricing Disclosure Package
and the Prospectus discloses all material off-balance sheet transactions, arrangements, obligations (including contingent obligations),
and other relationships of the Company with unconsolidated entities or other persons that may have a material current or future effect
on the Company&rsquo;s financial condition, changes in financial condition, results of operations, liquidity, capital expenditures, capital
resources, or significant components of revenues or expenses. Except as disclosed in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, (a) neither the Company nor any of its direct and indirect subsidiaries, including each entity disclosed or
described in the Registration Statement, the Pricing Disclosure Package and the Prospectus as being a subsidiary of the Company (each,
a &ldquo;</FONT>Subsidiary<FONT STYLE="font-weight: normal">&rdquo; and, collectively, the &ldquo;</FONT>Subsidiaries<FONT STYLE="font-weight: normal">&rdquo;),
has incurred any material liabilities or obligations, direct or contingent, or entered into any material transactions other than in the
ordinary course of business, (b) the Company has not declared or paid any dividends or made any distribution of any kind with respect
to its capital stock, (c) there has not been any change in the capital stock of the Company or any of its Subsidiaries, other than in
the course of business or pursuant to any grants under any stock compensation plan, and (d) there has not been any Material Adverse Change
in the Company&rsquo;s long-term or short-term debt.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.8&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Authorized
Capital; Options, etc</U><FONT STYLE="font-weight: normal">. The Company had, at the date or dates indicated in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, the duly authorized, issued and outstanding capitalization as set forth therein. Based
on the assumptions stated in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company will have on the
Closing Date the adjusted stock capitalization set forth therein. Except as set forth in, or contemplated by, the Registration Statement,
the Pricing Disclosure Package and the Prospectus, on the Effective Date, as of the Applicable Time and on the Closing Date and any Option
Closing Date, there will be no stock options, warrants, or other rights to purchase or otherwise acquire any authorized, but unissued
shares of Common Stock of the Company or any security convertible or exercisable into shares of Common Stock of the Company, or any contracts
or commitments to issue or sell shares of Common Stock or any such options, warrants, rights or convertible securities.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.9&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Valid
Issuance of Securities, etc<FONT STYLE="font-weight: normal">.</FONT></U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.9.1.&nbsp;</FONT><U>Outstanding
Securities</U><FONT STYLE="font-weight: normal">. All issued and outstanding securities of the Company issued prior to the transactions
contemplated by this Agreement have been duly authorized and validly issued and are fully paid and non-assessable; the holders thereof
have no rights of rescission with respect thereto, and are not subject to personal liability by reason of being such holders; and none
of such securities were issued in violation of the preemptive rights of any holders of any security of the Company or similar contractual
rights granted by the Company. The authorized shares of Common Stock conform in all material respects to all statements relating thereto
contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus. The offers and sales of the outstanding shares
of Common Stock were at all relevant times either registered under the Securities Act and the applicable state securities or &ldquo;blue
sky&rdquo; laws or, based in part on the representations and warranties of the purchasers of such Shares, exempt from such registration
requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.9.2.&nbsp;</FONT><U>Securities
Sold Pursuant to this Agreement</U><FONT STYLE="font-weight: normal">. The Shares have been duly authorized for issuance and sale and,
when issued and paid for, will be validly issued, fully paid and non-assessable; the Underwriter Warrants have been duly authorized for
issuance and, when issued in accordance with their terms and the terms of this Agreement, will be valid and binding obligations of the
Company, enforceable against the Company in accordance with their terms, except (x)&nbsp;as such enforceability may be limited by bankruptcy,
insolvency, reorganization or similar laws affecting creditors&rsquo; rights generally, (y)&nbsp;as enforceability of any indemnification
or contribution provision may be limited under the federal and state securities laws, and (z)&nbsp;that the remedy of specific performance
and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before
which any proceeding therefor may be brought. The Company has reserved from its duly authorized capital stock the maximum number of shares
of Common Stock issuable pursuant to this Agreement and the Underwriter Warrants. The holders of the Public Securities are not and will
not be subject to personal liability by reason of being such holders; the Public Securities are not and will not be subject to the preemptive
rights of any holders of any security of the Company or similar contractual rights granted by the Company; and all corporate action required
to be taken for the authorization, issuance and sale of the Public Securities has been duly and validly taken. The Public Securities conform
in all material respects to all statements with respect thereto contained in the Registration Statement, the Pricing Disclosure Package
and the Prospectus. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.10&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Registration
Rights of Third Parties</U><FONT STYLE="font-weight: normal">. Except as set forth in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, no holders of any securities of the Company or any rights exercisable for or convertible or exchangeable into
securities of the Company have the right to require the Company to register any such securities of the Company under the Securities Act
or to include any such securities in a registration statement to be filed by the Company.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.11&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Validity
and Binding Effect of Agreements</U><FONT STYLE="font-weight: normal">. This Agreement has been duly and validly authorized by the Company,
and, when executed and delivered, will constitute, the valid and binding agreements of the Company, enforceable against the Company in
accordance with its terms, except: (i)&nbsp;as such enforceability may be limited by bankruptcy, insolvency, reorganization or similar
laws affecting creditors&rsquo; rights generally; (ii)&nbsp;as enforceability of any indemnification or contribution provision may be
limited under the federal and state securities laws; and (iii)&nbsp;that the remedy of specific performance and injunctive and other forms
of equitable relief may be subject to the equitable defenses and to the discretion of the court before which any proceeding therefor may
be brought.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.12&nbsp;</FONT><FONT STYLE="font-style: normal"><U>No
Conflicts, etc</U><FONT STYLE="font-weight: normal">. The execution, delivery and performance by the Company of this Agreement and all
ancillary documents, the consummation by the Company of the transactions herein and therein contemplated and the compliance by the Company
with the terms hereof and thereof do not and will not, with or without the giving of notice or the lapse of time or both: (i)&nbsp;result
in a material breach of, or conflict with any of the terms and provisions of, or constitute a material default under, or result in the
creation, modification, termination or imposition of any lien, charge or encumbrance upon any property or assets of the Company pursuant
to the terms of any agreement or instrument to which the Company is a party; (ii)&nbsp;result in any violation of the provisions of the
Company&rsquo;s Certificate of Incorporation (as the same may be amended or restated from time to time, the &ldquo;</FONT>Charter<FONT STYLE="font-weight: normal">&rdquo;)
or the by-laws of the Company; or (iii)&nbsp;violate any existing applicable law, rule, regulation, judgment, order or decree of any Governmental
Entity as of the date hereof (including, without limitation, those enforced by the Food and Drug Administration of the U.S. Department
of Health and Human Services (the &ldquo;</FONT>FDA<FONT STYLE="font-weight: normal">&rdquo;) or by any foreign, federal, state or local
regulatory authority performing functions similar to those performed by the FDA) except in the case of clause (iii) above, for such violations
which would not reasonably be expected to result in a Material Adverse Change.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.13&nbsp;</FONT><FONT STYLE="font-style: normal"><U>No
Defaults; Violations</U><FONT STYLE="font-weight: normal">. No material default exists in the due performance and observance of any term,
covenant or condition of any material license, contract, indenture, mortgage, deed of trust, note, loan or credit agreement, or any other
agreement or instrument evidencing an obligation for borrowed money, or any other material agreement or instrument to which the Company
is a party or by which the Company may be bound or to which any of the properties or assets of the Company is subject. The Company is
not in violation of (i) any term or provision of its Charter or by-laws, or (ii) in violation of any franchise, license, permit, applicable
law, rule, regulation, judgment or decree of any Governmental Entity, except in the case of clause (ii) above, for such violations which
would not reasonably be expected to result in a Material Adverse Change.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.14&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Corporate
Power; Licenses; Consents</U></FONT><FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.14.1.&nbsp;<U>Conduct
of Business</U>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has
all requisite corporate power and authority, and has all necessary authorizations, approvals, orders, licenses, certificates and permits
of and from all governmental regulatory officials and bodies that it needs as of the date hereof to conduct its business purpose in all
material respects as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.14.2.&nbsp;<U>Transactions
Contemplated Herein</U>. The Company has all corporate power and authority to enter into this Agreement and to carry out the provisions
and conditions hereof, and all consents, authorizations, approvals and orders required in connection therewith have been obtained. No
consent, authorization or order of, and no filing with, any court, government agency or other body is required for the valid issuance,
sale and delivery of the Public Securities and the consummation of the transactions and agreements contemplated by this Agreement and
as contemplated by the Registration Statement, the Pricing Disclosure Package and the Prospectus, except with respect to applicable federal
and state securities laws and the rules and regulations of the Financial Industry Regulatory Authority, Inc. (&ldquo;</FONT>FINRA<FONT STYLE="font-weight: normal">&rdquo;).</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.15&nbsp;</FONT><FONT STYLE="font-style: normal"><U>D&amp;O
Questionnaires</U><FONT STYLE="font-weight: normal">. To the Company&rsquo;s knowledge, all information contained in the questionnaires
(the &ldquo;</FONT>Questionnaires<FONT STYLE="font-weight: normal">&rdquo;) completed by each of the Company&rsquo;s directors and officers
immediately prior to the Offering (the &ldquo;</FONT>Insiders<FONT STYLE="font-weight: normal">&rdquo;) as supplemented by all information
concerning the Company&rsquo;s directors, officers and principal shareholders as described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, as well as in the Lock-Up Agreement (as defined in Section 2.25 below), provided to the Underwriters,
is true and correct in all material respects and the Company has not become aware of any information which would cause the information
disclosed in the Questionnaires to become materially inaccurate and incorrect.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.16&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Litigation;
Governmental Proceedings</U><FONT STYLE="font-weight: normal">. There is no action, suit, proceeding, inquiry, arbitration, investigation,
litigation or governmental proceeding pending or, to the Company&rsquo;s knowledge, threatened against, or involving the Company or, to
the Company&rsquo;s knowledge, any executive officer or director which is required to be disclosed and has not been disclosed in the Registration
Statement, the Pricing Disclosure Package and the Prospectus or in connection with the Company&rsquo;s listing application for the listing
of the Common Stock on the Exchange. </FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.17&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Good
Standing</U><FONT STYLE="font-weight: normal">. The Company has been duly organized and is validly existing as a corporation and is in
good standing under the laws of the State of Delaware as of the date hereof, and is duly qualified to do business and is in good standing
in each other jurisdiction in which its ownership or lease of property or the conduct of business requires such qualification, except
where the failure to qualify, singularly or in the aggregate, would not have or reasonably be expected to result in a Material Adverse
Change.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.18&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Insurance</U><FONT STYLE="font-weight: normal">.
The Company carries or is entitled to the benefits of insurance, with reputable insurers, in such amounts and covering such risks which
the Company believes are adequate, and all such insurance is in full force and effect. The Company has no reason to believe that it will
not be able (i) to renew its existing insurance coverage as and when such policies expire or (ii) to obtain comparable coverage from similar
institutions as may be necessary or appropriate to conduct its business as now conducted and at a cost that would not result in a Material
Adverse Change.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.19&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Transactions
Affecting Disclosure to FINRA</U></FONT><FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.19.1.&nbsp;<U>Finder&rsquo;s
Fees</U>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no claims, payments,
arrangements, agreements or understandings relating to the payment of a finder&rsquo;s, consulting or origination fee by the Company or
any Insider with respect to the sale of the Public Securities hereunder or any other arrangements, agreements or understandings of the
Company or, to the Company&rsquo;s knowledge, any of its shareholders that may affect the Underwriters&rsquo; compensation, as determined
by FINRA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.19.2.&nbsp;<U>Payments
Within Twelve (12) Months</U>. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the
Company has not made any direct or indirect payments (in cash, securities or otherwise) to: (i)&nbsp;any person, as a finder&rsquo;s fee,
consulting fee or otherwise, in consideration of such person raising capital for the Company or introducing to the Company persons who
raised or provided capital to the Company; (ii) any FINRA member; or (iii)&nbsp;any person or entity that has any direct or indirect affiliation
or association with any FINRA member, within the twelve (12) months prior to the Effective Date, other than the payment to the Underwriters
as provided hereunder in connection with the Offering.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.19.3.&nbsp;<U>Use
of Proceeds</U>. None of the net proceeds of the Offering will be paid by the Company to any participating FINRA member or its affiliates,
except as specifically authorized herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.19.4.&nbsp;<U>FINRA
Affiliation</U>. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there is no (i)
officer or director of the Company, (ii) beneficial owner of 5% or more of any class of the Company&rsquo;s securities or (iii) beneficial
owner of the Company&rsquo;s unregistered equity securities which were acquired during the 180-day period immediately preceding the filing
of the Registration Statement that is an affiliate or associated person of a FINRA member participating in the Offering (as determined
in accordance with the rules and regulations of FINRA).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.19.5.&nbsp;<U>Information</U>.
All information provided by the Company in its FINRA questionnaire to Representative Counsel specifically for use by Representative Counsel
in connection with its Public Offering System filings (and related disclosure) with FINRA is true, correct and complete in all material
respects.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.20&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Foreign
Corrupt Practices Act</U><FONT STYLE="font-weight: normal">. None of the Company and its Subsidiaries or, to the Company&rsquo;s knowledge,
any director, officer, agent, employee or affiliate of the Company and its Subsidiaries or any other person acting on behalf of the Company
and its Subsidiaries, has, directly or indirectly, given or agreed to give any money, gift or similar benefit (other than legal price
concessions to customers in the ordinary course of business) to any customer, supplier, employee or agent of a customer or supplier, or
official or employee of any governmental agency or instrumentality of any government (domestic or foreign) or any political party or candidate
for office (domestic or foreign) or other person who was, is, or may be in a position to help or hinder the business of the Company (or
assist it in connection with any actual or proposed transaction) that (i)&nbsp;might subject the Company to any damage or penalty in any
civil, criminal or governmental litigation or proceeding, (ii)&nbsp;if not given in the past, might have had a Material Adverse Change
or (iii)&nbsp;if not continued in the future, might adversely affect the assets, business, operations or prospects of the Company. The
Company has taken reasonable steps to ensure that its accounting controls and procedures are sufficient to cause the Company to comply
in all material respects with the Foreign Corrupt Practices Act of 1977, as amended.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.21&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Compliance
with OFAC</U><FONT STYLE="font-weight: normal">. None of the Company and its Subsidiaries or, to the Company&rsquo;s knowledge, any director,
officer, agent, employee or affiliate of the Company and its Subsidiaries or any other person acting on behalf of the Company and its
Subsidiaries, is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Department of
the Treasury (&ldquo;</FONT>OFAC<FONT STYLE="font-weight: normal">&rdquo;), and the Company will not, directly or indirectly, use the
proceeds of the Offering hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner
or other person or entity, for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered
by OFAC.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.22&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Money
Laundering Laws</U><FONT STYLE="font-weight: normal">. The operations of the Company and its Subsidiaries are and have been conducted
at all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions
Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions, the rules and regulations thereunder and any related
or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the &ldquo;</FONT>Money
Laundering Laws<FONT STYLE="font-weight: normal">&rdquo;); and no action, suit or proceeding by or before any Governmental Entity involving
the Company with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.23&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Regulatory</U></FONT>.
<FONT STYLE="font-style: normal; font-weight: normal">All preclinical studies and clinical trials conducted by or on behalf of the Company
that are material to the Company and its Subsidiaries, taken as a whole, are or have been adequately and accurately described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus in all material respects.&nbsp; The clinical trials and preclinical studies
conducted by or on behalf of the Company and its Subsidiaries that are described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus or the results of which are referred to in the Registration Statement, the Pricing Disclosure Package and the
Prospectus were and,&nbsp;if still ongoing, are being conducted in material compliance with all laws and regulations applicable thereto
in the jurisdictions in which they are being conducted and with all laws and regulations applicable to preclinical studies and clinical
trials from which data will be submitted to support marketing approval.&nbsp; The descriptions in the Registration Statement, the Pricing
Disclosure Package and the Prospectus of the results of such studies and trials are accurate and complete in all material respects and
fairly present the data derived from such studies and trials, and the Company has no knowledge of, or reason to believe that, any clinical
trial the aggregate results of which are inconsistent with or otherwise call into question in any material respect the results of any
clinical trial conducted by or on behalf of the Company that are described in the Registration Statement, the Pricing Disclosure Package
and the Prospectus or the results of which are referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus.&nbsp;
Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has not received any
written notices or statements from the FDA, the European Medicines Agency (&ldquo;</FONT><FONT STYLE="font-style: normal">EMA<FONT STYLE="font-weight: normal">&rdquo;)
or any other governmental agency or authority imposing, requiring, requesting or suggesting a clinical hold, termination, suspension or
material modification for or of any clinical trial that is described in the Registration Statement, the Pricing Disclosure Package and
the Prospectus or the results of which are referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus.&nbsp;
Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has not received any
written notices or statements from the EMA or any other national, federal or other governmental authority with jurisdiction over clinical
trials, and otherwise has no knowledge of, or reason to believe that, (i) any clinical trial application or similar submission for a potential
product of the Company is or has been rejected or placed on clinical hold; and (ii) any license, approval, permit or authorization to
conduct any clinical trial of any potential product of the Company has been, will be or may be suspended, revoked, modified or limited.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.24&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Officers&rsquo;
Certificate</U>. <FONT STYLE="font-weight: normal">Any certificate signed by any duly authorized officer of the Company and delivered
to you or to Representative Counsel shall be deemed a representation and warranty by the Company to the Underwriters as to the matters
covered thereby.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.25&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Lock-Up
Agreements. <FONT STYLE="font-weight: normal">Schedule 3</FONT></U><FONT STYLE="font-weight: normal"> hereto contains a complete and accurate
list of the Company&rsquo;s officers, directors and each holder of more than five percent (5%) of the Company&rsquo;s outstanding shares
of Common Stock (or securities convertible or exercisable into shares of Common Stock) (collectively, the &ldquo;</FONT>Lock-Up Parties<FONT STYLE="font-weight: normal">&rdquo;).
The Company has caused each of the Lock-Up Parties to deliver an executed Lock-Up Agreement, in the form attached hereto as <U>Exhibit
B</U> (the &ldquo;</FONT>Lock-Up Agreement<FONT STYLE="font-weight: normal">&rdquo;), each of which shall be assigned to the Representative
prior to the execution of this Agreement. </FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.26&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Subsidiaries</U>.
<FONT STYLE="font-weight: normal">All direct and indirect Subsidiaries of the Company are duly organized and in good standing under the
laws of the place of organization or incorporation, and each Subsidiary is in good standing in each jurisdiction in which its ownership
or lease of property or the conduct of business requires such qualification, except where the failure to qualify would not have a Material
Adverse Change. The Company&rsquo;s ownership and control of each Subsidiary is as described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus. </FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.27&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Related
Party Transactions</U>. <FONT STYLE="font-weight: normal">There are no business relationships or related party transactions involving
the Company or any other person required to be described in the Registration Statement, the Pricing Disclosure Package and the Prospectus
that have not been described as required.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.28&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Board
of Directors</U>. <FONT STYLE="font-weight: normal">The Board of Directors of the Company is comprised of the persons set forth under
the heading of the Pricing Prospectus and the Prospectus captioned &ldquo;Management.&rdquo; The qualifications of the persons serving
as board members and the overall composition of the board comply with the Exchange Act, the Exchange Act Regulations, the Sarbanes-Oxley
Act of 2002 and the rules promulgated thereunder (the &ldquo;</FONT>Sarbanes-Oxley Act<FONT STYLE="font-weight: normal">&rdquo;) applicable
to the Company and the listing rules of the Exchange. At least one member of the Audit Committee of the Board of Directors of the Company
qualifies as an &ldquo;audit committee financial expert,&rdquo; as such term is defined under Regulation S-K and the listing rules of
the Exchange. In addition, at least a majority of the persons serving on the Board of Directors qualify as &ldquo;independent,&rdquo;
as defined under the listing rules of the Exchange.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.29&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Sarbanes-Oxley
Compliance</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.29.1.&nbsp;<U>Disclosure
Controls</U>. Except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company has developed
and currently maintains disclosure controls and procedures that will comply with Rule 13a-15 or 15d-15 under the Exchange Act Regulations,
and such controls and procedures are effective to ensure that all material information concerning the Company will be made known on a
timely basis to the individuals responsible for the preparation of the Company&rsquo;s Exchange Act filings and other public disclosure
documents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">2.29.2.&nbsp;<U>Compliance</U>.
Except as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is, or at the Applicable
Time and on the Closing Date will be, in material compliance with the provisions of the Sarbanes-Oxley Act applicable to it, and has implemented
or will implement such programs and taken reasonable steps to ensure the Company&rsquo;s future compliance (not later than the relevant
statutory and regulatory deadlines therefor) with all of the material provisions of the Sarbanes-Oxley Act.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.30&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Accounting
Controls</U>. <FONT STYLE="font-weight: normal">Except as set forth in the Registration Statement, the Pricing Disclosure Package and
the Prospectus, the Company and its Subsidiaries maintain systems of &ldquo;internal control over financial reporting&rdquo; (as defined
under Rules 13a-15 and 15d-15 under the Exchange Act Regulations) that comply with the requirements of the Exchange Act and have been
designed by, or under the supervision of, their respective principal executive and principal financial officers, or persons performing
similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with GAAP, including, but not limited to, internal accounting controls sufficient to provide reasonable
assurance that (i) transactions are executed in accordance with management&rsquo;s general or specific authorizations; (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability;
(iii) access to assets is permitted only in accordance with management&rsquo;s general or specific authorization; and (iv) the recorded
accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to
any differences. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is
not aware of any material weaknesses in its internal controls. The Company&rsquo;s auditors and the Audit Committee of the Board of Directors
of the Company have been advised of: (i) all significant deficiencies and material weaknesses in the design or operation of internal controls
over financial reporting which are known to the Company&rsquo;s management and that have adversely affected or are reasonably likely to
adversely affect the Company&rsquo; ability to record, process, summarize and report financial information; and (ii) any fraud known to
the Company&rsquo;s management, whether or not material, that involves management or other employees who have a significant role in the
Company&rsquo;s internal controls over financial reporting.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.31&nbsp;</FONT><FONT STYLE="font-style: normal"><U>No
Investment Company Status</U>. <FONT STYLE="font-weight: normal">The Company is not and, after giving effect to the Offering and the application
of the proceeds thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be, required
to register as an &ldquo;investment company,&rdquo; as defined in the Investment Company Act of 1940, as amended.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.32&nbsp;</FONT><FONT STYLE="font-style: normal"><U>No
Labor Disputes</U>. <FONT STYLE="font-weight: normal">No labor dispute with the employees of the Company or any of its Subsidiaries exists
or, to the knowledge of the Company, is imminent. </FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.33&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Intellectual
Property Rights</U>. <FONT STYLE="font-weight: normal">The Company and each of its Subsidiaries owns or possesses or has valid rights
to use all patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations,
copyrights, licenses, inventions, trade secrets and similar rights (&ldquo;</FONT>Intellectual Property Rights<FONT STYLE="font-weight: normal">&rdquo;)
necessary for the conduct of the business of the Company and its Subsidiaries as currently carried on and as described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus. To the knowledge of the Company, no action or use by the Company or any
of its Subsidiaries necessary for the conduct of its business as currently carried on and as described in the Registration Statement and
the Prospectus will involve or give rise to any infringement of, or license or similar fees for, any Intellectual Property Rights of others.
Neither the Company nor any of its Subsidiaries has received any notice alleging any such infringement, fee or conflict with asserted
Intellectual Property Rights of others. Except as would not reasonably be expected to result, individually or in the aggregate, in a Material
Adverse Change (A) to the knowledge of the Company, there is no infringement, misappropriation or violation by third parties of any of
the Intellectual Property Rights owned by the Company; (B) there is no pending or, to the knowledge of the Company, threatened action,
suit, proceeding or claim by others challenging the rights of the Company in or to any such Intellectual Property Rights, and the Company
is unaware of any facts which would form a reasonable basis for any such claim, that would, individually or in the aggregate, together
with any other claims in this Section 2.33, reasonably be expected to result in a Material Adverse Change; (C) the Intellectual Property
Rights owned by the Company and, to the knowledge of the Company, the Intellectual Property Rights licensed to the Company have not been
adjudged by a court of competent jurisdiction invalid or unenforceable, in whole or in part, and there is no pending or, to the Company&rsquo;s
knowledge, threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property
Rights, and the Company is unaware of any facts which would form a reasonable basis for any such claim that would, individually or in
the aggregate, together with any other claims in this Section 2.33, reasonably be expected to result in a Material Adverse Change; (D)
there is no pending or, to the Company&rsquo;s knowledge, threatened action, suit, proceeding or claim by others that the Company infringes,
misappropriates or otherwise violates any Intellectual Property Rights or other proprietary rights of others, the Company has not received
any written notice of such claim and the Company is unaware of any other facts which would form a reasonable basis for any such claim
that would, individually or in the aggregate, together with any other claims in this Section 2.33, reasonably be expected to result in
a Material Adverse Change; and (E) to the Company&rsquo;s knowledge, no employee of the Company is in or has ever been in violation in
any material respect of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition
agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or with a former employer where the basis
of such violation relates to such employee&rsquo;s employment with the Company, or actions undertaken by the employee while employed with
the Company and could reasonably be expected to result, individually or in the aggregate, in a Material Adverse Change. To the Company&rsquo;s
knowledge, all material technical information developed by and belonging to the Company which has not been patented has been kept confidential.
The Company is not a party to or bound by any options, licenses or agreements with respect to the Intellectual Property Rights of any
other person or entity that are required to be set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus
and are not described therein. The Registration Statement, the Pricing Disclosure Package and the Prospectus contain in all material respects
the same description of the matters set forth in the preceding sentence. None of the technology employed by the Company has been obtained
or is being used by the Company in violation of any contractual obligation binding on the Company or, to the Company&rsquo;s knowledge,
any of its officers, directors or employees, or otherwise in violation of the rights of any persons. </FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.34&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Taxes</U>.
<FONT STYLE="font-weight: normal">Each of the Company and its Subsidiaries has filed all returns (as hereinafter defined) required to
be filed with taxing authorities prior to the date hereof or has duly obtained extensions of time for the filing thereof. Each of the
Company and its Subsidiaries has paid all taxes (as hereinafter defined) shown as due on such returns that were filed and has paid all
taxes imposed on or assessed against the Company or such respective Subsidiary. The provisions for taxes payable, if any, shown on the
financial statements filed with or as part of the Registration Statement are sufficient for all accrued and unpaid taxes, whether or not
disputed, and for all periods to and including the dates of such consolidated financial statements. Except as disclosed in writing to
the Underwriters, (i) no issues have been raised (and are currently pending) by any taxing authority in connection with any of the returns
or taxes asserted as due from the Company or its Subsidiaries, and (ii) no waivers of statutes of limitation with respect to the returns
or collection of taxes have been given by or requested from the Company or its Subsidiaries. The term &ldquo;taxes&rdquo; mean all federal,
state, local, foreign and other net income, gross income, gross receipts, sales, use, ad valorem, transfer, franchise, profits, license,
lease, service, service use, withholding, payroll, employment, excise, severance, stamp, occupation, premium, property, windfall profits,
customs, duties or other taxes, fees, assessments or charges of any kind whatever, together with any interest and any penalties, additions
to tax or additional amounts with respect thereto. The term &ldquo;returns&rdquo; means all returns, declarations, reports, statements
and other documents required to be filed in respect to taxes.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.35&nbsp;</FONT><FONT STYLE="font-style: normal"><U>ERISA
Compliance</U>. <FONT STYLE="font-weight: normal">The Company and any &ldquo;employee benefit plan&rdquo; (as defined under the Employee
Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &ldquo;</FONT>ERISA<FONT STYLE="font-weight: normal">&rdquo;))
established or maintained by the Company or its &ldquo;ERISA Affiliates&rdquo; (as defined below) are in compliance in all material respects
with ERISA. &ldquo;ERISA Affiliate&rdquo; means, with respect to the Company, any member of any group of organizations described in Sections
414(b),(c),(m) or (o) of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the
&ldquo;</FONT>Code<FONT STYLE="font-weight: normal">&rdquo;) of which the Company is a member. No &ldquo;reportable event&rdquo; (as defined
under ERISA) has occurred or is reasonably expected to occur with respect to any &ldquo;employee benefit plan&rdquo; established or maintained
by the Company or any of its ERISA Affiliates. No &ldquo;employee benefit plan&rdquo; established or maintained by the Company or any
of its ERISA Affiliates, if such &ldquo;employee benefit plan&rdquo; were terminated, would have any &ldquo;amount of unfunded benefit
liabilities&rdquo; (as defined under ERISA). Neither the Company nor any of its ERISA Affiliates has incurred or reasonably expects to
incur any material liability under (i) Title IV of ERISA with respect to termination of, or withdrawal from, any &ldquo;employee benefit
plan&rdquo; or (ii) Sections 412, 4971, 4975 or 4980B of the Code. Each &ldquo;employee benefit plan&rdquo; established or maintained
by the Company or any of its ERISA Affiliates that is intended to be qualified under Section 401(a) of the Code is so qualified and, to
the knowledge of the Company, nothing has occurred, whether by action or failure to act, which would cause the loss of such qualification.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.36&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Compliance
with Laws</U>. <FONT STYLE="font-weight: normal">The Company: (A) is and at all times has been in compliance with all statutes, rules,
or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, labeling,
promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by the Company (&ldquo;</FONT>Applicable
Laws<FONT STYLE="font-weight: normal">&rdquo;), except as could not, individually or in the aggregate, reasonably be expected to have
a Material Adverse Change; (B) has not received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other
correspondence or notice from the U.S. Food and Drug Administration or any other governmental authority alleging or asserting noncompliance
with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations, permits and supplements or amendments thereto
required by any such Applicable Laws (&ldquo;</FONT>Authorizations<FONT STYLE="font-weight: normal">&rdquo;); (C) possesses all material
Authorizations and such Authorizations are valid and in full force and effect and are not in material violation of any term of any such
Authorizations; (D) has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or
other action from any governmental authority or third party alleging that any product operation or activity is in violation of any Applicable
Laws or Authorizations and has no knowledge that any such governmental authority or third party is considering any such claim, litigation,
arbitration, action, suit, investigation or proceeding; (E) has not received written notice that any governmental authority has taken,
is taking or intends to take action to limit, suspend, modify or revoke any Authorizations and has no knowledge that any such governmental
authority is considering such action; (F) has filed, obtained, maintained or submitted all material reports, documents, forms, notices,
applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that
all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and
correct in all material respects on the date submitted (or were corrected or supplemented by a subsequent submission); and (G) has not,
either voluntarily or involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued, any recall, market
withdrawal or replacement, safety alert, post-sale warning, &ldquo;dear doctor&rdquo; letter, or other notice or action relating to the
alleged lack of safety or efficacy of any product or any alleged product defect or violation and, to the Company&rsquo;s knowledge, no
third party has initiated, conducted or intends to initiate any such notice or action.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.37&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Ineligible
Issuer</U>.&nbsp; <FONT STYLE="font-weight: normal">At the time of filing the Registration Statement and any post-effective amendment
thereto, at the time of effectiveness of the Registration Statement and any amendment thereto, at the earliest time thereafter that the
Company or another offering participant made a bona fide offer (within the meaning of Rule 164(h)(2) of the Securities Act Regulations)
of the Public Securities and at the date hereof, the Company was not and is not an &ldquo;ineligible issuer,&rdquo; as defined in Rule
405, without taking account of any determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered
an ineligible issuer.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.38&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Smaller
Reporting Company</U>.&nbsp; <FONT STYLE="font-weight: normal">As of the time of filing of the Registration Statement, the Company was
a &ldquo;smaller reporting company,&rdquo; as defined in Rule&nbsp;12b-2 of the Exchange Act Regulations.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.39&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Industry
Data</U>.&nbsp; <FONT STYLE="font-weight: normal">The statistical and market-related data included in each of the Registration Statement,
the Pricing Disclosure Package and the Prospectus are based on or derived from sources that the Company reasonably and in good faith believes
are reliable and accurate or represent the Company&rsquo;s good faith estimates that are made on the basis of data derived from such sources.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.40&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Emerging
Growth Company</U>. <FONT STYLE="font-weight: normal">From the time of the initial confidential submission of the Registration Statement
to the Commission (or, if earlier, the first date on which the Company engaged directly in or through any Person authorized to act on
its behalf in any Testing-the-Waters Communication) through the date hereof, the Company has been and is an &ldquo;emerging growth company,&rdquo;
as defined in Section 2(a) of the Securities Act (an &ldquo;</FONT>Emerging Growth Company<FONT STYLE="font-weight: normal">&rdquo;).
&ldquo;Testing-the-Waters Communication&rdquo; means any oral or written communication with potential investors undertaken in reliance
on Section 5(d) of the Securities Act.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.41&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Testing-the-Waters
Communications</U>. <FONT STYLE="font-weight: normal">The Company has not (i) alone engaged in any Testing-the-Waters Communications,
other than Testing-the-Waters Communications with the written consent of the Representative and with entities that are qualified institutional
buyers within the meaning of Rule 144A under the Securities Act or institutions that are accredited investors within the meaning of Rule
501 under the Securities Act and (ii) authorized anyone other than the Representative to engage in Testing-the-Waters Communications.
The Company confirms that the Representative has been authorized to act on its behalf in undertaking Testing-the-Waters Communications.
The Company has not distributed any Written Testing-the-Waters Communications other than those listed on <U>Schedule 2-C</U> hereto. &ldquo;Written
Testing-the-Waters Communication&rdquo; means any Testing-the-Waters Communication that is a written communication within the meaning
of Rule 405 under the Securities Act.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.42&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Margin
Securities</U>. <FONT STYLE="font-weight: normal">The Company owns no &ldquo;margin securities&rdquo; as that term is defined in Regulation
U of the Board of Governors of the Federal Reserve System (the &ldquo;</FONT>Federal Reserve Board<FONT STYLE="font-weight: normal">&rdquo;),
and none of the proceeds of Offering will be used, directly or indirectly, for the purpose of purchasing or carrying any margin security,
for the purpose of reducing or retiring any indebtedness which was originally incurred to purchase or carry any margin security or for
any other purpose which might cause any of the shares of Common Stock to be considered a &ldquo;purpose credit&rdquo; within the meanings
of Regulation T, U or X of the Federal Reserve Board. </FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.43&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Environmental
Laws</U></FONT>. <FONT STYLE="font-style: normal; font-weight: normal">The Company is in compliance with all foreign, federal, state and
local rules, laws and regulations relating to the use, treatment, storage and disposal of hazardous or toxic substances or waste and protection
of health and safety or the environment which are applicable to their businesses (&ldquo;</FONT><FONT STYLE="font-style: normal">Environmental
Laws<FONT STYLE="font-weight: normal">&rdquo;), except where the failure to comply would not, singularly or in the aggregate, result in
a Material Adverse Change. There has been no storage, generation, transportation, handling, treatment, disposal, discharge, emission,
or other release of any kind of toxic or other wastes or other hazardous substances by, due to, or caused by the Company (or, to the Company&rsquo;s
knowledge, any other entity for whose acts or omissions the Company is or may otherwise be liable) upon any of the property now or previously
owned or leased by the Company, or upon any other property, in violation of any law, statute, ordinance, rule, regulation, order, judgment,
decree or permit or which would, under any law, statute, ordinance, rule (including rule of common law), regulation, order, judgment,
decree or permit, give rise to any liability, except for any violation or liability which would not have, singularly or in the aggregate
with all such violations and liabilities, a Material Adverse Change; and there has been no disposal, discharge, emission or other release
of any kind onto such property or into the environment surrounding such property of any toxic or other wastes or other hazardous substances
with respect to which the Company has knowledge, except for any such disposal, discharge, emission, or other release of any kind which
would not have, singularly or in the aggregate with all such discharges and other releases, a Material Adverse Change. In the ordinary
course of business, the Company conducts periodic reviews of the effect of Environmental Laws on their business and assets, in the course
of which they identify and evaluate associated costs and liabilities (including, without limitation, any capital or operating expenditures
required for clean-up, closure of properties or compliance with Environmental Laws or governmental permits issued thereunder, any related
constraints on operating activities and any potential liabilities to third parties). On the basis of such reviews, the Company has reasonably
concluded that such associated costs and liabilities would not have, singularly or in the aggregate, a Material Adverse Change.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.44&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Real
Property</U><FONT STYLE="font-weight: normal">. Except as set forth in the Registration Statement, the Pricing Disclosure Package and
the Prospectus, the Company has good and marketable title in fee simple to, or have valid rights to lease or otherwise use, all items
of real or personal property which are material to the business of the Company, in each case free and clear of all liens, encumbrances,
security interests, claims and defects that do not, singly or in the aggregate, materially affect the value of such property and do not
materially interfere with the use made and proposed to be made of such property by the Company; and all of the leases and subleases material
to the business of the Company, and under which the Company holds properties described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, are in full force and effect, and the Company has not received any notice of any material claim of any sort
that has been asserted by anyone adverse to the rights of the Company under any of the leases or subleases mentioned above, or affecting
or questioning the rights of the Company to the continued possession of the leased or subleased premises under any such lease or sublease.</FONT></FONT></P>

<P STYLE="text-align: justify; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.45&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Contracts
Affecting Capital</U><FONT STYLE="font-weight: normal">. There are no transactions, arrangements or other relationships between and/or
among the Company, any of its affiliates (as such term is defined in Rule 405 of the Securities Act Regulations) and any unconsolidated
entity, including, but not limited to, any structured finance, special purpose or limited purpose entity that could reasonably be expected
to materially affect the Company&rsquo;s liquidity or the availability of or requirements for their capital resources required to be described
or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus which have not been described
or incorporated by reference as required.</FONT></FONT></P>

<P STYLE="text-align: justify; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.46&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Loans
to Directors or Officers</U><FONT STYLE="font-weight: normal">. There are no outstanding loans, advances (except normal advances for business
expenses in the ordinary course of business) or guarantees or indebtedness by the Company to or for the benefit of any of the officers
or directors of the Company, or any of their respective family members, except as disclosed in the Registration Statement, the Pricing
Disclosure Package and the Prospectus.</FONT></FONT></P>

<P STYLE="text-align: justify; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.47&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Electronic
Road Show</U><FONT STYLE="font-weight: normal">. The Company has made available a Bona Fide Electronic Road Show in compliance with Rule
433(d)(8)(ii) of the Securities Act Regulations such that no filing of any &ldquo;road show&rdquo; (as defined in Rule 433(h) of the Securities
Act Regulations) is required in connection with the Offering.</FONT></FONT></P>

<P STYLE="text-align: justify; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.48&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Minute
Books</U><FONT STYLE="font-weight: normal">. The minute books of the Company have been made available to the Underwriters and counsel
for the Underwriters, and such books (i) contain a complete summary of all material meetings and actions of the board of directors (including
each board committee) and stockholders of the Company (or analogous governing bodies and interest holders, as applicable), since the time
of its respective incorporation or organization through the date of the latest meeting and action, and (ii) accurately in all material
respects reflect all material transactions referred to in such minutes. There are no material transactions, agreements, dispositions or
other actions of the Company that are not properly approved and/or accurately and fairly recorded in the minute books of the Company,
as applicable.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-weight: normal">3.</FONT> <U>Covenants of the Company</U>. <FONT STYLE="font-weight: normal">The Company covenants and agrees as follows</FONT>:</P>



<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.1&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Amendments
to Registration Statement</U></FONT>. <FONT STYLE="font-style: normal; font-weight: normal">The Company shall deliver to the Representative,
prior to filing, any amendment or supplement to the Registration Statement or Prospectus proposed to be filed after the Effective Date
and not file any such amendment or supplement to which the Representative shall reasonably object in writing. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.2&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Federal
Securities Laws</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.1.&nbsp;<U>Compliance</U>.
The Company, subject to Section 3.2.2, shall comply with the requirements of Rule 430A of the Securities Act Regulations, and will notify
the Representative promptly, and confirm the notice in writing, (i)&nbsp;when any post-effective amendment to the Registration Statement
shall become effective or any amendment or supplement to the Prospectus shall have been filed; (ii)&nbsp;of the receipt of any comments
from the Commission; (iii)&nbsp;of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement
to the Prospectus or for additional information; (iv)&nbsp;of the issuance by the Commission of any stop order suspending the effectiveness
of the Registration Statement or any post-effective amendment or of any order preventing or suspending the use of any Preliminary Prospectus
or the Prospectus, or of the suspension of the qualification of the Public Securities for offering or sale in any jurisdiction, or of
the initiation or threatening of any proceedings for any of such purposes or of any examination pursuant to Section&nbsp;8(d) or 8(e)
of the Securities Act concerning the Registration Statement and (v)&nbsp;if the Company becomes the subject of a proceeding under Section&nbsp;8A
of the Securities Act in connection with the Offering of the Public Securities. The Company shall effect all filings required under Rule
424(b) of the Securities Act Regulations, in the manner and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)),
and shall take such steps as it deems necessary to ascertain promptly whether the form of prospectus transmitted for filing under Rule
424(b) was received for filing by the Commission and, in the event that it was not, it will promptly file such prospectus. The Company
shall use its commercially reasonable efforts to prevent the issuance of any stop order, prevention or suspension and, if any such order
is issued, to obtain the lifting thereof at the earliest possible moment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.2.&nbsp;<U>Continued
Compliance</U>. The Company shall comply with the Securities Act, the Securities Act Regulations, the Exchange Act and the Exchange Act
Regulations so as to permit the completion of the distribution of the Public Securities as contemplated in this Agreement and in the Registration
Statement, the Pricing Disclosure Package and the Prospectus. If at any time when a prospectus relating to the Public Securities is (or,
but for the exception afforded by Rule 172 of the Securities Act Regulations (&ldquo;</FONT>Rule 172<FONT STYLE="font-weight: normal">&rdquo;),
would be) required by the Securities Act to be delivered in connection with sales of the Public Securities, any event shall occur or condition
shall exist as a result of which it is necessary, in the opinion of counsel for the Underwriters or for the Company, to (i)&nbsp;amend
the Registration Statement in order that the Registration Statement will not include an untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary to make the statements therein not misleading; (ii)&nbsp;amend or supplement
the Pricing Disclosure Package or the Prospectus in order that the Pricing Disclosure Package or the Prospectus, as the case may be, will
not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein
not misleading in the light of the circumstances existing at the time it is delivered to a purchaser or (iii)&nbsp;amend the Registration
Statement or amend or supplement the Pricing Disclosure Package or the Prospectus, as the case may be, in order to comply with the requirements
of the Securities Act or the Securities Act Regulations, the Company will promptly (A)&nbsp;give the Representative notice of such event;
(B)&nbsp;prepare any amendment or supplement as may be necessary to correct such statement or omission or to make the Registration Statement,
the Pricing Disclosure Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed
filing or use, furnish the Representative with copies of any such amendment or supplement and (C)&nbsp;file with the Commission any such
amendment or supplement; provided that the Company shall not file or use any such amendment or supplement to which the Representative
or counsel for the Underwriters shall reasonably object. The Company will furnish to the Underwriters such number of copies of such amendment
or supplement as the Underwriters may reasonably request. The Company has given the Representative notice of any filings made pursuant
to the Exchange Act or the Exchange Act Regulations within forty-eight (48) hours prior to the Applicable Time. The Company shall give
the Representative notice of its intention to make any such filing from the Applicable Time until the later of the Closing Date and the
exercise in full or expiration of the Over-allotment Option specified in Section 1.2 hereof and will furnish the Representative with copies
of the related document(s) a reasonable amount of time prior to such proposed filing, as the case may be, and will not file or use any
such document to which the Representative or counsel for the Underwriters shall reasonably object. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.3.&nbsp;<U>Exchange
Act Registration</U>. For a period of three (3) years after the date of this Agreement, the Company shall use its commercially reasonable
efforts to maintain the registration of the Common Stock under the Exchange Act, unless the Company is taken private in a bona fide acquisition
transaction. The Company shall not deregister the Common Stock under the Exchange Act without the prior written consent of the Representative,
which consent shall not be unreasonably withheld.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.4.&nbsp;<U>Free
Writing Prospectuses</U>. The Company agrees that, unless it obtains the prior written consent of the Representative, it shall not make
any offer relating to the Public Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute
a &ldquo;free writing prospectus,&rdquo; or a portion thereof, required to be filed by the Company with the Commission or retained by
the Company under Rule 433; provided that the Representative shall be deemed to have consented to each Issuer General Use Free Writing
Prospectus hereto and any &ldquo;road show that is a written communication&rdquo; within the meaning of Rule 433(d)(8)(i) that has been
reviewed by the Representative. The Company represents that it has treated or agrees that it will treat each such free writing prospectus
consented to, or deemed consented to, by the Underwriters as an &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433,
and that it has complied and will comply with the applicable requirements of Rule 433 with respect thereto, including timely filing with
the Commission where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing Prospectus there
occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or would conflict with
the information contained in the Registration Statement or included or would include an untrue statement of a material fact or omitted
or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at
that subsequent time, not misleading, the Company will promptly notify the Underwriters and will promptly amend or supplement, at its
own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.2.5.&nbsp;<U>Testing-the-Waters
Communications</U>. If at any time following the distribution of any Written Testing-the-Waters Communication there occurred or occurs
an event or development as a result of which such Written Testing-the-Waters Communication included or would include an untrue statement
of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of
the circumstances existing at that subsequent time, not misleading, the Company shall promptly notify the Representative and shall promptly
amend or supplement, at its own expense, such Written Testing-the-Waters Communication to eliminate or correct such untrue statement or
omission.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.3&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Delivery
to the Underwriters of Registration Statements</U><FONT STYLE="font-weight: normal">. The Company has delivered or made available or shall
deliver or make available to the Representative and counsel for the Representative, without charge, signed copies of the Registration
Statement as originally filed and each amendment thereto (including exhibits filed therewith) and signed copies of all consents and certificates
of experts, and will also deliver to the Underwriters, without charge, a conformed copy of the Registration Statement as originally filed
and each amendment thereto (without exhibits) for each of the Underwriters. The copies of the Registration Statement and each amendment
thereto furnished to the Underwriters will be identical to the electronically transmitted copies thereof filed with the Commission pursuant
to EDGAR, except to the extent permitted by Regulation S-T.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.4&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Delivery
to the Underwriters of Prospectuses</U><FONT STYLE="font-weight: normal">. The Company has delivered or made available or will deliver
or make available to each Underwriter, without charge, as many copies of each Preliminary Prospectus as such Underwriter reasonably requested,
and the Company hereby consents to the use of such copies for purposes permitted by the Securities Act. The Company will furnish to each
Underwriter, without charge, during the period when a prospectus relating to the Public Securities is (or, but for the exception afforded
by Rule 172, would be) required to be delivered under the Securities Act, such number of copies of the Prospectus (as amended or supplemented)
as such Underwriter may reasonably request. The Prospectus and any amendments or supplements thereto furnished to the Underwriters will
be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted
by Regulation S-T.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.5&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Review
of Financial Statements<FONT STYLE="font-weight: normal">.</FONT></U><FONT STYLE="font-weight: normal"> For a period of two (2) years
after the date of this Agreement, the Company, at its expense, shall cause its regularly engaged independent registered public accounting
firm to review (but not audit) the Company&rsquo;s financial statements for each of the three fiscal quarters immediately preceding the
announcement of any quarterly financial information.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.6&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Listing</U><FONT STYLE="font-weight: normal">.
The Company shall use its commercially reasonable efforts to maintain the listing of the Common Stock (including the Shares) on the Exchange
for at least three (3) years from the date of this Agreement.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.7&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Financial
Public Relations Firm</U>. <FONT STYLE="font-weight: normal">As of the Effective Date, the Company shall have retained a financial public
relations firm reasonably acceptable to the Representative and the Company, which shall initially be Rx Communications Group LLC, which
firm shall be experienced in assisting issuers in initial public offerings of securities and in their relations with their security holders,
and shall retain such firm or another firm reasonably acceptable to the Representative for a period of not less than two (2) years after
the Effective Date.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.8&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Reports
to the Representative</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">3.8.1.&nbsp;</FONT><U>Transfer
Agent; Transfer Sheets</U>. <FONT STYLE="font-weight: normal">For a period of three (3) years after the date of this Agreement, the Company
shall retain a transfer agent and registrar acceptable to the Representative (the&nbsp;</FONT>&ldquo;Transfer Agent<FONT STYLE="font-weight: normal">&rdquo;)
and, for a period of one (1) year after the date of this Agreement, the Company shall furnish to the Representative at the Company&rsquo;s
sole cost and expense such transfer sheets of the Company&rsquo;s securities as the Representative may reasonably request, including the
daily and monthly consolidated transfer sheets of the Transfer Agent and DTC. Continental Stock Transfer &amp; Trust Company is acceptable
to the Representative to act as Transfer Agent for the shares of Common Stock. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.9&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Payment
of Expenses</U><FONT STYLE="font-weight: normal">. </FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-weight: normal">3.9.1.&nbsp;The
Company hereby agrees to pay on each of the Closing Date and the Option Closing Date, if any, to the extent not paid at the Closing Date,
all expenses incident to the performance of the obligations of the Company under this Agreement, including, but not limited to: (a) all
filing fees and communication expenses relating to the registration of the shares of Common Stock to be sold in the Offering (including
the Option Shares) with the Commission; (b) all Public Filing System filing fees associated with the review of the Offering by FINRA;
(c) all fees and expenses relating to the listing of Common Stock on the Exchange and such other stock exchanges as the Company and the
Representative together determine; (d) all fees, expenses and disbursements relating to the registration or qualification of the Public
Securities under the &ldquo;blue sky&rdquo; securities laws of such states and other jurisdictions as the Representative may reasonably
designate (including, without limitation, all filing and registration fees, and the reasonable fees and disbursements of &ldquo;blue sky&rdquo;
counsel; (e) all fees, expenses and disbursements relating to the registration, qualification or exemption of the Public Securities under
the securities laws of such foreign jurisdictions as the Representative may reasonably designate; (f) the costs of all mailing and printing
of the underwriting documents (including, without limitation, the Underwriting Agreement, any Blue Sky Surveys and, if appropriate, any
Agreement Among Underwriters, Selected Dealers&rsquo; Agreement, Underwriters&rsquo; Questionnaire and Power of Attorney), Registration
Statements, Prospectuses and all amendments, supplements and exhibits thereto and as many preliminary and final Prospectuses as the Representative
may reasonably deem necessary; (g) the costs and expenses of a public relations firm; (h) the costs of preparing, printing and delivering
certificates representing the Public Securities; (i) fees and expenses of the transfer agent for the shares of Common Stock; (j) stock
transfer and/or stamp taxes, if any, payable upon the transfer of securities from the Company to the Underwriters; (k) the fees and expenses
of the Company&rsquo;s accountants; (l) the fees and expenses of the Company&rsquo;s legal counsel and other agents and representatives.
The Company hereby agrees to pay on each of the Closing Date and the Option Closing Date, if any, to the extent not paid at the Closing
Date, to the Representative, from the gross proceeds of the Offering, for accountable expenses actually incurred by the Representative
in connection with the transaction in an amount of up to $175,000. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-weight: normal">3.9.2.&nbsp;The
Company further agrees that, on the Closing Date, in addition to the expenses payable pursuant to Section 3.9.1, it shall pay to the Representative
a non-accountable expense allowance equal to one percent (1.0%) of the gross proceeds received by the Company from the Offering.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.10&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Application
of Net Proceeds</U><FONT STYLE="font-weight: normal">. The Company shall apply the net proceeds from the Offering received by it in a
manner consistent with the application thereof described under the caption &ldquo;Use of Proceeds&rdquo; in the Registration Statement,
the Pricing Disclosure Package and the Prospectus.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.11&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Delivery
of Earnings Statements to Security Holder<FONT STYLE="font-weight: normal">s</FONT></U><FONT STYLE="font-weight: normal">. The Company
shall make generally available to its security holders as soon as practicable, but not later than the first (1<SUP>st</SUP>) day of the
fifteenth (15<SUP>th</SUP>) full calendar month following the date of this Agreement, an earnings statement (which need not be certified
by independent registered public accounting firm unless required by the Securities Act or the Securities Act Regulations, but which shall
satisfy the provisions of Rule 158(a) under Section 11(a) of the Securities Act) covering a period of at least twelve (12) consecutive
months beginning after the date of this Agreement.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.12&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Stabilization</U><FONT STYLE="font-weight: normal">.
Neither the Company nor, to its knowledge, any of its employees, directors or shareholders (without the consent of the Representative)
has taken or shall take, directly or indirectly, any action designed to or that has constituted or that might reasonably be expected to
cause or result in, under Regulation M of the Exchange Act, or otherwise, stabilization or manipulation of the price of any security of
the Company to facilitate the sale or resale of the Public Securities.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.13&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Internal
Controls</U><FONT STYLE="font-weight: normal">. The Company shall maintain a system of internal accounting controls sufficient to provide
reasonable assurances that: (i)&nbsp;transactions are executed in accordance with management&rsquo;s general or specific authorization;
(ii)&nbsp;transactions are recorded as necessary in order to permit preparation of financial statements in accordance with GAAP and to
maintain accountability for assets; (iii)&nbsp;access to assets is permitted only in accordance with management&rsquo;s general or specific
authorization; and (iv)&nbsp;the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate
action is taken with respect to any differences.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.14&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Accountants</U><FONT STYLE="font-weight: normal">.
As of the date of this Agreement, the Company shall continue to retain a nationally recognized independent registered public accounting
firm for a period of at least three (3) years after the date of this Agreement. The Representative acknowledges that the Auditor is acceptable
to the Representative.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.15&nbsp;</FONT><FONT STYLE="font-style: normal"><U>FINRA</U><FONT STYLE="font-weight: normal">.
The Company shall advise the Representative (who shall make an appropriate filing with FINRA) if it is or becomes aware that (i) any officer
or director of the Company, (ii) any beneficial owner of 5% or more of any class of the Company&rsquo;s securities or (iii) any beneficial
owner of the Company&rsquo;s unregistered equity securities which were acquired during the one hundred and eighty (180) days immediately
preceding the filing of the Registration Statement is or becomes an affiliate or associated person of a FINRA member participating in
the Offering (as determined in accordance with the rules and regulations of FINRA).</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.16&nbsp;</FONT><FONT STYLE="font-style: normal"><U>No
Fiduciary Duties</U><FONT STYLE="font-weight: normal">. The Company acknowledges and agrees that the Underwriters&rsquo; responsibility
to the Company is solely contractual in nature and that none of the Underwriters or their affiliates or any selling agent shall be deemed
to be acting in a fiduciary capacity, or otherwise owes any fiduciary duty to the Company or any of its affiliates in connection with
the Offering and the other transactions contemplated by this Agreement.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.17&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Company
Lock-Up Agreements</U><FONT STYLE="font-weight: normal">. The Company, on behalf of itself and any successor entity, agrees that, without
the prior written consent of the Representative, it will not, for a period of 180 days after the date of this Agreement (the &ldquo;Lock-Up
Period&rdquo;), (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to
sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of
capital stock of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company;
(ii) file or cause to be filed any registration statement with the Commission relating to the offering of any shares of capital stock
of the Company or any securities convertible into or exercisable or exchangeable for shares of capital stock of the Company; or (iii)
enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership
of capital stock of the Company, whether any such transaction described in clause (i), (ii) or (iii) above is to be settled by delivery
of shares of capital stock of the Company or such other securities, in cash or otherwise. </FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">The
restrictions contained in this Section 3.17.1 shall not apply to (i) the shares of Common Stock to be sold hereunder, (ii) the issuance
by the Company of shares of Common Stock upon the exercise of a stock option or warrant or the conversion of a security outstanding on
the date hereof, which is disclosed in the Registration Statement, or (iii) the issuance by the Company of stock options or other stock-based
awards or the issuance by the Company of shares of capital stock of the Company under any equity compensation plan of the Company; provided
that, prior to the issuance of any such stock options or shares of capital stock of the Company that vest within the Lock-Up Period, each
recipient thereof shall sign and deliver a Lock-Up Agreement. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.18&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Release
of D&amp;O Lock-up Period</U><FONT STYLE="font-weight: normal">. If the Representative, in its sole discretion, agrees to release or waive
the restrictions set forth in the Lock-Up Agreements described in Section 2.26 hereof for an officer or director of the Company and provide
the Company with notice of the impending release or waiver at least three (3) Business Days before the effective date of the release or
waiver, the Company agrees to announce the impending release or waiver by a press release substantially in the form of <U>Exhibit C</U>
hereto through a major news service at least two (2) Business Days before the effective date of the release or waiver.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.19&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Blue
Sky Qualifications</U><FONT STYLE="font-weight: normal">. The Company shall use its commercially reasonable efforts, in cooperation with
the Underwriters, if necessary, to qualify the Public Securities for offering and sale under the applicable securities laws of such states
and other jurisdictions (domestic or foreign) as the Representative may designate with the consent of the Company and to maintain such
qualifications in effect so long as required to complete the distribution of the Public Securities; provided, however, that the Company
shall not be obligated to file any general consent to service of process or to qualify as a foreign corporation or as a dealer in securities
in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of doing business in any jurisdiction
in which it is not otherwise so subject.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.20&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Reporting
Requirements</U><FONT STYLE="font-weight: normal">. The Company, during the period when a prospectus relating to the Public Securities
is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the Securities Act, will file all documents
required to be filed with the Commission pursuant to the Exchange Act within the time periods required by the Exchange Act and Exchange
Act Regulations. Additionally, the Company shall report the use of proceeds from the issuance of the Public Securities as may be required
under Rule 463 under the Securities Act Regulations.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.21&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Emerging
Growth Company Status</U><FONT STYLE="font-weight: normal">. The Company shall promptly notify the Representative if the Company ceases
to be an Emerging Growth Company at any time prior to the later of (i) completion of the distribution of the Public Securities within
the meaning of the Securities Act and (ii) fifteen (15) days following the completion of the Lock-Up Period.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.22&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Right
of Participation</U><FONT STYLE="font-weight: normal">. The Company agrees that the Representative and Prime Executions, Inc., dba Freedom
Capital Markets, shall have an irrevocable right of participation for a period of nine months following the Closing to act as co-managers
on any public or private offering of equity securities for the Company.</FONT></FONT></P>

<P STYLE="text-align: justify; font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.23&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Reservation
of Common Stock</U><FONT STYLE="font-weight: normal">. As of the date hereof, the Company has reserved and the Company shall continue
to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of
enabling the Company to issue Option Shares pursuant to the Over-allotment Option and shares of Common Stock pursuant to any exercise
of the Underwriter Warrants.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><FONT STYLE="font-weight: normal">4.&nbsp;</FONT><U>Conditions
of Underwriters&rsquo; Obligations</U>. <FONT STYLE="font-weight: normal">The obligations of the Underwriters to purchase and pay for
the Public Securities, as provided herein, shall be subject to (i) the continuing accuracy in all material respects of the representations
and warranties of the Company as of the date hereof and as of each of the Closing Date and the Option Closing Date, if any; (ii) the accuracy
of the statements of officers of the Company made pursuant to the provisions hereof; (iii) the performance by the Company of its obligations
hereunder; and (iv) the following conditions</FONT>:</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.1&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Regulatory
Matters</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.1.1.&nbsp;<U>Effectiveness
of Registration Statement; Rule 430A Information</U>. The Registration Statement has become effective not later than 5:00 p.m., Eastern
time, on the date of this Agreement or such later date and time as shall be consented to in writing by you, and, at each of the Closing
Date and any Option Closing Date, no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment
thereto has been issued under the Securities Act, no order preventing or suspending the use of any Preliminary Prospectus or the Prospectus
has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company&rsquo;s knowledge,
contemplated by the Commission. The Company has complied with each request (if any) from the Commission for additional information. The
Prospectus containing the Rule 430A Information shall have been filed with the Commission in the manner and within the time frame required
by Rule 424(b) (without reliance on Rule 424(b)(8)) or a post-effective amendment providing such information shall have been filed with,
and declared effective by, the Commission in accordance with the requirements of Rule 430A.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.1.2.&nbsp;<U>FINRA
Clearance</U>. On or before the date of this Agreement, the Representative shall have received clearance from FINRA as to the amount of
compensation allowable or payable to the Underwriters as described in the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.1.3.&nbsp;<U>Exchange
Stock Market Clearance</U>. On the Closing Date, (i) the Company&rsquo;s Common Stock, including the Firm Shares and the Underwriter Warrant
Shares, shall have been approved for listing on the Exchange, (ii) the Common Stock shall have been continuously trading on the Exchange
following the date of this Agreement to the Closing Date, and (iii) the Exchange shall have raised no objection to the transactions contemplated
hereby. On the first Option Closing Date (if any), the Company&rsquo;s Common Stock, including the Option Shares and Underwriter Warrant
Shares, shall have been approved for listing on the Exchange, subject only to official notice of issuance.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.2&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Company
Counsel Matters</U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.2.1.&nbsp;<U>Closing
Date Opinion of Counsel</U>. On the Closing Date, the Representative shall have received the favorable opinion of McDermott Will &amp;
Emery LLP, counsel to the Company, dated the Closing Date and addressed to the Representative, in a form reasonably acceptable to the
Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.2.2.&nbsp;<U>Opinion
of Special Intellectual Property Counsels for the Company</U>. On the Closing Date, the Representative shall have received the opinion
of Cooley LLP, special intellectual property counsel for the Company, dated the Closing Date, addressed to the Representative in a form
reasonably acceptable to the Representative.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.2.3.&nbsp;<U>Option
Closing Date Opinions of Counsel</U>. On the Option Closing Date, if any, the Representative shall have received the favorable opinions
of each counsel listed in Sections 4.2.1 and 4.2.2, dated the Option Closing Date, addressed to the Representative and in form and substance
reasonably satisfactory to the Representative, confirming as of the Option Closing Date, the statements made by such counsels in their
respective opinions delivered on the Closing Date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.2.4.&nbsp;<U>Reliance</U>.
In rendering such opinions, such counsel may rely: (i)&nbsp;as to matters involving the application of laws other than the laws of the
United States and jurisdictions in which they are admitted, to the extent such counsel deems proper and to the extent specified in such
opinion, if at all, upon an opinion or opinions (in form and substance reasonably satisfactory to the Representative) of other counsel
reasonably acceptable to the Representative, familiar with the applicable laws; and (ii)&nbsp;as to matters of fact, to the extent they
deem proper, on certificates or other written statements of officers of the Company and officers of departments of various jurisdictions
having custody of documents respecting the corporate existence or good standing of the Company, provided that copies of any such statements
or certificates shall be delivered to Representative Counsel if requested. The opinion of McDermott Will &amp; Emery LLP and any opinion
relied upon by McDermott Will &amp; Emery LLP shall include a statement to the effect that it may be relied upon by Representative Counsel
in its opinion, if any, delivered to the Underwriters.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.3&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Comfort
Letters</U><FONT STYLE="font-weight: normal">. </FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.3.1.&nbsp;<U>Cold
Comfort Letter</U>. At the time this Agreement is executed you shall have received a cold comfort letter containing statements and information
of the type customarily included in accountants&rsquo; comfort letters with respect to the financial statements and certain financial
information contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus, addressed to the Representative
and in form and substance satisfactory in all respects to you and to the Auditor, dated as of the date of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.3.2.&nbsp;<U>Bring-down
Comfort Letter</U>. At each of the Closing Date and the Option Closing Date, if any, the Representative shall have received from the Auditor
a letter, dated as of the Closing Date or the Option Closing Date, as applicable, to the effect that the Auditor reaffirms the statements
made in the letter furnished pursuant to Section 4.3.1, except that the specified date referred to shall be a date not more than three
(3) business days prior to the Closing Date or the Option Closing Date, as applicable. </FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.4&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Officers&rsquo;
Certificates</U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.4.1.&nbsp;<U>Officers&rsquo;
Certificate</U>. The Company shall have furnished to the Representative a certificate, dated the Closing Date and any Option Closing Date
(if such date is other than the Closing Date), of its Executive Chairman of the Board, its Chief Executive Officer, its President and
its Chief Financial Officer stating that (i) such officers have carefully examined the Registration Statement, the Pricing Disclosure
Package, any Issuer Free Writing Prospectus and the Prospectus and, in their opinion, the Registration Statement and each amendment thereto,
as of the Applicable Time and as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date) did not
include any untrue statement of a material fact and did not omit to state a material fact required to be stated therein or necessary to
make the statements therein not misleading, and the Pricing Disclosure Package, as of the Applicable Time and as of the Closing Date (or
any Option Closing Date if such date is other than the Closing Date), any Issuer Free Writing Prospectus as of its date and as of the
Closing Date (or any Option Closing Date if such date is other than the Closing Date), the Prospectus and each amendment or supplement
thereto, as of the respective date thereof and as of the Closing Date, did not include any untrue statement of a material fact and did
not omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances in which they were
made, not misleading, (ii) since the effective date of the Registration Statement, no event has occurred which should have been set forth
in a supplement or amendment to the Registration Statement, the Pricing Disclosure Package or the Prospectus, (iii) to the best of their
knowledge after reasonable investigation, as of the Closing Date (or any Option Closing Date if such date is other than the Closing Date),
the representations and warranties of the Company in this Agreement are true and correct and the Company has complied with all agreements
and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date (or any Option Closing
Date if such date is other than the Closing Date), and (iv) there has not been, subsequent to the date of the most recent audited financial
statements included or incorporated by reference in the Pricing Disclosure Package, any material adverse change in the financial position
or results of operations of the Company, or any change or development that, singularly or in the aggregate, involves a Material Adverse
Change in or affecting the condition (financial or otherwise), results of operations, business, assets or prospects of the Company, except
as set forth in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.4.2.&nbsp;<U>Secretary&rsquo;s
Certificate</U>. At each of the Closing Date and the Option Closing Date, if any, the Representative shall have received a certificate
of the Company signed by the Secretary of the Company, dated the Closing Date or the Option Date, as the case may be, respectively, certifying:
(i)&nbsp;that each of the Charter and Bylaws is true and complete, has not been modified and is in full force and effect; (ii)&nbsp;that
the resolutions of the Company&rsquo;s Board of Directors relating to the Offering are in full force and effect and have not been modified;
(iii) as to the accuracy and completeness of all correspondence between the Company or its counsel and the Commission; and (iv)&nbsp;as
to the incumbency of the officers of the Company. The documents referred to in such certificate shall be attached to such certificate.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.5&nbsp;</FONT><FONT STYLE="font-style: normal"><U>No
Material Changes</U><FONT STYLE="font-weight: normal">. Prior to and on each of the Closing Date and each Option Closing Date, if any:
(i)&nbsp;there shall have been no Material Adverse Change in the condition or prospects or the business activities, financial or otherwise,
of the Company from the latest dates as of which such condition is set forth in the Registration Statement, the Pricing Disclosure Package
and the Prospectus; (ii)&nbsp;no action, suit or proceeding, at law or in equity, shall have been pending or threatened against the Company
or any Insider before or by any court or federal or state commission, board or other administrative agency wherein an unfavorable decision,
ruling or finding may reasonably be expected to result in a Material Adverse Change, except as set forth in the Registration Statement,
the Pricing Disclosure Package and the Prospectus; (iii)&nbsp;no stop order shall have been issued under the Securities Act and no proceedings
therefor shall have been initiated or threatened by the Commission; and (iv)&nbsp;the Registration Statement, the Pricing Disclosure Package
and the Prospectus and any amendments or supplements thereto shall contain all material statements which are required to be stated therein
in accordance with the Securities Act and the Securities Act Regulations and shall conform in all material respects to the requirements
of the Securities Act and the Securities Act Regulations, and neither the Registration Statement, the Pricing Disclosure Package nor the
Prospectus nor any amendment or supplement thereto shall contain any untrue statement of a material fact or omit to state any material
fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made,
not misleading.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.6&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Delivery
of Agreements</U><FONT STYLE="font-weight: normal">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">4.6.1.&nbsp;<U>Lock-Up
Agreements</U>. On or before the date of this Agreement, the Company shall have delivered to the Representative executed copies of the
Lock-Up Agreements from each of the persons listed in <U>Schedule 3</U> hereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in"><FONT STYLE="font-weight: normal">4.6.2.&nbsp;<U>Underwriter
Warrants</U>. At the Closing Date, the Underwriter Warrants and, as to each Option Closing Date, if any, the additional Underwriter Warrants,
in definitive form, in such denominations and registered in such names as the Underwriters or their designees request, shall have been
delivered to the several Underwriters.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.7&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Additional
Documents</U><FONT STYLE="font-weight: normal">. At the Closing Date and at each Option Closing Date (if any) Representative Counsel shall
have been furnished with such documents and opinions as they may require for the purpose of enabling Representative Counsel to deliver
an opinion to the Underwriters, or in order to evidence the accuracy of any of the representations or warranties, or the fulfillment of
any of the conditions, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Public
Securities as herein contemplated shall be satisfactory in form and substance to the Representative and Representative Counsel. </FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-weight: normal">5.</FONT> <U>Indemnification</U>.</P>



<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">5.1&nbsp;<U>Indemnification
of the Underwriters</U></FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">5.1.1.&nbsp;<U>General</U>.
Subject to the conditions set forth below, the Company agrees to indemnify and hold harmless each Underwriter, its affiliates and each
of its and their respective directors, officers, members, employees, representatives and agents and each person, if any, who controls
any such Underwriter within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act (collectively the &ldquo;Underwriter
Indemnified Parties,&rdquo; and each an &ldquo;Underwriter Indemnified Party&rdquo;), against any and all loss, liability, claim, damage
and expense whatsoever (including but not limited to any and all legal or other expenses reasonably incurred in investigating, preparing
or defending against any litigation, commenced or threatened, or any claim whatsoever, whether arising out of any action between any of
the Underwriter Indemnified Parties and the Company or between any of the Underwriter Indemnified Parties and any third party, or otherwise)
to which they or any of them may become subject under the Securities Act, the Exchange Act or any other statute or at common law or otherwise
or under the laws of foreign countries, arising out of or based upon any untrue statement or alleged untrue statement of a material fact
contained in (i) the Registration Statement, the Pricing Disclosure Package, the Preliminary Prospectus, the Prospectus, or in any Issuer
Free Writing Prospectus or in any Written Testing-the-Waters Communication (as from time to time each may be amended and supplemented);
(ii) any materials or information provided to investors by, or with the approval of, the Company in connection with the marketing of the
Offering, including any &ldquo;road show&rdquo; or investor presentations made to investors by the Company (whether in person or electronically);
or (iii) any application or other document or written communication (in this Section 5, collectively called &ldquo;application&rdquo;)
executed by the Company or based upon written information furnished by the Company in any jurisdiction in order to qualify the Public
Securities under the securities laws thereof or filed with the Commission, any state securities commission or agency, the Exchange or
any other national securities exchange; or the omission or alleged omission therefrom of a material fact required to be stated therein
or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading, unless such
statement or omission was made in reliance upon, and in conformity with, the Underwriters&rsquo; Information. With respect to any untrue
statement or omission or alleged untrue statement or omission made in the Pricing Disclosure Package, the indemnity agreement contained
in this Section 5.1.1 shall not inure to the benefit of any Underwriter Indemnified Party to the extent that any loss, liability, claim,
damage or expense of such Underwriter Indemnified Party results from the fact that a copy of the Prospectus was not given or sent to the
person asserting any such loss, liability, claim or damage at or prior to the written confirmation of sale of the Public Securities to
such person as required by the Securities Act and the Securities Act Regulations, and if the untrue statement or omission has been corrected
in the Prospectus, unless such failure to deliver the Prospectus was a result of non-compliance by the Company with its obligations under
Section 3.3 hereof. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">5.1.2.&nbsp;<U>Procedure</U>.
If any action is brought against an Underwriter Indemnified Party in respect of which indemnity may be sought against the Company pursuant
to Section 5.1.1, such Underwriter Indemnified Party shall promptly notify the Company in writing of the institution of such action and
the Company shall assume the defense of such action, including the employment and fees of counsel (subject to the reasonable approval
of such Underwriter Indemnified Party) and payment of actual expenses. Such Underwriter Indemnified Party shall have the right to employ
its or their own counsel in any such case, but the fees and expenses of such counsel shall be at the expense of such Underwriter Indemnified
Party unless (i) the employment of such counsel at the expense of the Company shall have been authorized in writing by the Company in
connection with the defense of such action, or (ii) the Company shall not have employed counsel to have charge of the defense of such
action, or (iii) such indemnified party or parties shall have reasonably concluded that there may be defenses available to it or them
which are different from or additional to those available to the Company (in which case the Company shall not have the right to direct
the defense of such action on behalf of the indemnified party or parties), in any of which events the reasonable fees and expenses of
not more than one additional firm of attorneys selected by the Underwriter Indemnified Party (in addition to local counsel) shall be borne
by the Company. Notwithstanding anything to the contrary contained herein, if any Underwriter Indemnified Party shall assume the defense
of such action as provided above, the Company shall have the right to approve the terms of any settlement of such action, which approval
shall not be unreasonably withheld.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">5.2&nbsp;<U>Indemnification
of the Company</U>. Each Underwriter, severally and not jointly, agrees to indemnify and hold harmless the Company, its directors, its
officers who signed the Registration Statement and persons who control the Company within the meaning of Section 15 of the Securities
Act or Section 20 of the Exchange Act against any and all loss, liability, claim, damage and expense described in the foregoing indemnity
from the Company to the several Underwriters, as incurred, but only with respect to untrue statements or omissions, or alleged untrue
statements or omissions made in the Registration Statement, any Preliminary Prospectus, the Pricing Disclosure Package or Prospectus or
any amendment or supplement thereto or in any application, in reliance upon, and in strict conformity with, the Underwriters&rsquo; Information.
In case any action shall be brought against the Company or any other person so indemnified based on any Preliminary Prospectus, the Registration
Statement, the Pricing Disclosure Package or Prospectus or any amendment or supplement thereto or any application, and in respect of which
indemnity may be sought against any Underwriter, such Underwriter shall have the rights and duties given to the Company, and the Company
and each other person so indemnified shall have the rights and duties given to the several Underwriters by the provisions of Section 5.1.2.
The Company agrees promptly to notify the Representative of the commencement of any litigation or proceedings against the Company or any
of its officers, directors or any person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section
20 of the Exchange Act, in connection with the issuance and sale of the Public Securities or in connection with the Registration Statement,
the Pricing Disclosure Package, the Prospectus, or any Issuer Free Writing Prospectus or any Written Testing-the-Waters Communication.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">5.3&nbsp;<U>Contribution</U></FONT><FONT STYLE="font-weight: normal">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">5.3.1.&nbsp;<U>Contribution
Rights</U>. If the indemnification provided for in this Section 5 shall for any reason be unavailable to or insufficient to hold harmless
an indemnified party under Section 5.1 or 5.2 in respect of any loss, claim, damage or liability, or any action in respect thereof, referred
to therein, then each indemnifying party shall, in lieu of indemnifying such indemnified party, contribute to the amount paid or payable
by such indemnified party as a result of such loss, claim, damage or liability, or action in respect thereof, (i) in such proportion as
shall be appropriate to reflect the relative benefits received by the Company, on the one hand, and the Underwriters, on the other, from
the Offering of the Public Securities, or (ii) if the allocation provided by clause (i) above is not permitted by applicable law, in such
proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of
the Company, on the one hand, and the Underwriters, on the other, with respect to the statements or omissions that resulted in such loss,
claim, damage or liability, or action in respect thereof, as well as any other relevant equitable considerations. The relative benefits
received by the Company, on the one hand, and the Underwriters, on the other, with respect to such Offering shall be deemed to be in the
same proportion as the total net proceeds from the Offering of the Public Securities purchased under this Agreement (before deducting
expenses) received by the Company, as set forth in the table on the cover page of the Prospectus, on the one hand, and the total underwriting
discounts and commissions received by the Underwriters with respect to the shares of the Common Stock purchased under this Agreement,
as set forth in the table on the cover page of the Prospectus, on the other hand. The relative fault shall be determined by reference
to whether the untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates
to information supplied by the Company or the Underwriters, the intent of the parties and their relative knowledge, access to information
and opportunity to correct or prevent such statement or omission. The Company and the Underwriters agree that it would not be just and
equitable if contributions pursuant to this Section 5.3.1 were to be determined by pro rata allocation (even if the Underwriters were
treated as one entity for such purpose) or by any other method of allocation that does not take into account the equitable considerations
referred to herein. The amount paid or payable by an indemnified party as a result of the loss, claim, damage or liability, or action
in respect thereof, referred to above in this Section 5.3.1 shall be deemed to include, for purposes of this Section 5.3.1, any legal
or other expenses reasonably incurred by such indemnified party in connection with investigating or defending any such action or claim.
Notwithstanding the provisions of this Section 5.3.1 in no event shall an Underwriter be required to contribute any amount in excess of
the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the Offering of the
Public Securities exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue
or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section
11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-weight: normal">5.3.2.&nbsp;<U>Contribution
Procedure</U>. Within fifteen (15) days after receipt by any party to this Agreement (or its representative) of notice of the commencement
of any action, suit or proceeding, such party will, if a claim for contribution in respect thereof is to be made against another party
(&ldquo;contributing party&rdquo;), notify the contributing party of the commencement thereof, but the failure to so notify the contributing
party will not relieve it from any liability which it may have to any other party other than for contribution hereunder. In case any such
action, suit or proceeding is brought against any party, and such party notifies a contributing party or its representative of the commencement
thereof within the aforesaid fifteen (15) days, the contributing party will be entitled to participate therein with the notifying party
and any other contributing party similarly notified. Any such contributing party shall not be liable to any party seeking contribution
on account of any settlement of any claim, action or proceeding affected by such party seeking contribution on account of any settlement
of any claim, action or proceeding affected by such party seeking contribution without the written consent of such contributing party.
The contribution provisions contained in this Section 5.3.2 are intended to supersede, to the extent permitted by law, any right to contribution
under the Securities Act, the Exchange Act or otherwise available. Each Underwriter&rsquo;s obligations to contribute pursuant to this
Section 5.3 are several and not joint.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-weight: normal">6.</FONT> <U>Default by an Underwriter</U>.</P>



<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">6.1&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Default
Not Exceeding 10% of Firm Shares or Option Shares</U><FONT STYLE="font-weight: normal">. If any Underwriter or Underwriters shall default
in its or their obligations to purchase the Firm Shares or the Option Shares, if the Over-allotment Option is exercised hereunder, and
if the number of the Firm Shares or Option Shares with respect to which such default relates does not exceed in the aggregate 10% of the
number of Firm Shares or Option Shares that all Underwriters have agreed to purchase hereunder, then such Firm Shares or Option Shares
to which the default relates shall be purchased by the non-defaulting Underwriters in proportion to their respective commitments hereunder.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">6.2&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Default
Exceeding 10% of Firm Shares or Option Shares</U><FONT STYLE="font-weight: normal">. In the event that the default addressed in Section
6.1 relates to more than 10% of the Firm Shares or Option Shares, you may in your discretion arrange for yourself or for another party
or parties to purchase such Firm Shares or Option Shares to which such default relates on the terms contained herein. If, within one (1)
Business Day after such default relating to more than 10% of the Firm Shares or Option Shares, you do not arrange for the purchase of
such Firm Shares or Option Shares, then the Company shall be entitled to a further period of one (1) Business Day within which to procure
another party or parties satisfactory to you to purchase said Firm Shares or Option Shares on such terms. In the event that neither you
nor the Company arrange for the purchase of the Firm Shares or Option Shares to which a default relates as provided in this Section 6,
this Agreement will automatically be terminated by you or the Company without liability on the part of the Company (except as provided
in Sections 3.10 and 5 hereof) or the several Underwriters (except as provided in Section 5 hereof); provided, however, that if such default
occurs with respect to the Option Shares, this Agreement will not terminate as to the Firm Shares; and provided, further, that nothing
herein shall relieve a defaulting Underwriter of its liability, if any, to the other Underwriters and to the Company for damages occasioned
by its default hereunder.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">6.3&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Postponement
of Closing Date</U><FONT STYLE="font-weight: normal">. In the event that the Firm Shares or Option Shares to which the default relates
are to be purchased by the non-defaulting Underwriters, or are to be purchased by another party or parties as aforesaid, you or the Company
shall have the right to postpone the Closing Date or Option Closing Date for a reasonable period, but not in any event exceeding five
(5) Business Days, in order to effect whatever changes may thereby be made necessary in the Registration Statement, the Pricing Disclosure
Package or the Prospectus or in any other documents and arrangements, and the Company agrees to file promptly any amendment to the Registration
Statement, the Pricing Disclosure Package or the Prospectus that in the opinion of counsel for the Underwriter may thereby be made necessary.
The term &ldquo;Underwriter&rdquo; as used in this Agreement shall include any party substituted under this Section 6 with like effect
as if it had originally been a party to this Agreement with respect to such shares of Common Stock.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-weight: normal">7.</FONT> <U>Additional Covenants</U>.</P>



<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">7.1&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Board
Composition and Board Designations</U><FONT STYLE="font-weight: normal">. The Company shall ensure that: (i)&nbsp;the qualifications of
the persons serving as members of the Board of Directors and the overall composition of the Board comply with the Sarbanes-Oxley Act,
with the Exchange Act and with the listing rules of the Exchange or any other national securities exchange, as the case may be, in the
event the Company seeks to have its Common Stock listed on another exchange or quoted on an automated quotation system, and (ii)&nbsp;if
applicable, at least one member of the Audit Committee of the Board of Directors qualifies as an &ldquo;audit committee financial expert,&rdquo;
as such term is defined under Regulation S-K and the listing rules of the Exchange.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">7.2&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Prohibition
on Press Releases and Public Announcements</U><FONT STYLE="font-weight: normal">. For a period ending at 5:00 p.m., Eastern time, on the
first (1<SUP>st</SUP>) Business Day following the fortieth (40<SUP>th</SUP>) day after the Closing Date, the Company shall not issue press
releases or engage in any other publicity without the Representative&rsquo;s prior written consent, which consent shall not unreasonable
be withheld or delayed; provided that the Representative&rsquo;s consent shall not be required with regard to any press release or other
public disclosure that is required by law or any normal and customary press release or any other publicity issued in the ordinary course
of the Company&rsquo;s business.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-weight: normal">8.</FONT> <U>Effective Date of this Agreement and Termination Thereof</U><FONT STYLE="font-weight: normal">.</FONT></P>



<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.1&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Effective
Date</U><FONT STYLE="font-weight: normal">. This Agreement shall become effective when both the Company and the Representative have executed
the same and delivered counterparts of such signatures to the other party.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.2&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Termination</U></FONT>.
<FONT STYLE="font-style: normal; font-weight: normal">The Representative shall have the right to terminate this Agreement at any time
prior to any Closing Date, (i) if any domestic or international event or act or occurrence has materially disrupted, or in your reasonable
judgment will in the immediate future materially disrupt, general securities markets in the United States; or (ii) if trading on the New
York Stock Exchange or the Nasdaq Stock Market LLC shall have been suspended or materially limited, or minimum or maximum prices for trading
shall have been fixed, or maximum ranges for prices for securities shall have been required by FINRA or by order of the Commission or
any other government authority having jurisdiction; or (iii) if the United States shall have become involved in a new war or an increase
in major hostilities; or (iv) if a banking moratorium has been declared by a New York State or federal authority; or (v) if a moratorium
on foreign exchange trading has been declared which materially adversely impacts the United States securities markets; or (vi) if the
Company shall have sustained a material loss by fire, flood, accident, hurricane, earthquake, theft, sabotage or other calamity or malicious
act which, whether or not such loss shall have been insured, will, in your reasonable judgment, make it inadvisable to proceed with the
delivery of the Firm Shares or Option Shares; or (vii) if the Company is in material breach of any of its representations, warranties
or covenants hereunder; or (viii) if, prior to the Closing Date, the Common Stock has not been approved for listing on the Exchange, the
Company has taken any action designed to, or likely to have the effect of, delisting the Common Stock from the Exchange, or the Company
has received any notification that the Exchange is contemplating terminating such listing; or (ix) if the Representative shall have become
aware after the date hereof of such a material adverse change in the conditions or prospects of the Company, or such adverse material
change in the securities market, or any event, act or occurrence that has materially disrupted, or in the opinion of the Representative,
will in the future materially disrupt, the securities market, or there shall be such a material adverse change in general financial, political
or economic conditions or the effect of international conditions on the financial markets in the United States is such as to make it,
in the judgment of the Representative, inadvisable or impracticable to proceed with the offering, sale and/or delivery of the Public Securities
or to enforce contracts made by the Underwriters for the sale of the Public Securities.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.3&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Expenses</U><FONT STYLE="font-weight: normal">.
Notwithstanding anything to the contrary in this Agreement, except in the case of a default by the Underwriters, pursuant to Section 6.2
above, in the event that this Agreement shall be terminated for any reason whatsoever, within the time specified herein or any extensions
thereof pursuant to the terms herein, the Company shall be obligated to pay to the Underwriters their actual and accountable out-of-pocket
and documented expenses related to the transactions contemplated herein then due and payable (including the fees and disbursements of
Representative Counsel) up to $175,000, and upon demand the Company shall pay the full amount thereof to the Representative on behalf
of the Underwriters; provided, however, that such expense cap in no way limits or impairs the indemnification and contribution provisions
of this Agreement. Notwithstanding the foregoing, any advance received by the Representative will be reimbursed to the Company to the
extent not actually incurred in compliance with FINRA Rule 5110(g)(4)(A).</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.4&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Indemnification</U><FONT STYLE="font-weight: normal">.
Notwithstanding any contrary provision contained in this Agreement, any election hereunder or any termination of this Agreement, and whether
or not this Agreement is otherwise carried out, the provisions of Section 5 shall remain in full force and effect and shall not be in
any way affected by, such election or termination or failure to carry out the terms of this Agreement or any part hereof.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">8.5&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Representations,
Warranties, Agreements to Survive</U><FONT STYLE="font-weight: normal">. All representations, warranties and agreements contained in this
Agreement or in certificates of officers of the Company submitted pursuant hereto, shall remain operative and in full force and effect
regardless of (i)&nbsp;any investigation made by or on behalf of any Underwriter or its Affiliates or selling agents, any person controlling
any Underwriter, its officers or directors or any person controlling the Company or (ii)&nbsp;delivery of and payment for the Public Securities.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <FONT STYLE="font-weight: normal">9.</FONT> <U>Miscellaneous</U><FONT STYLE="font-weight: normal">.</FONT></P>



<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">9.1&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Notices</U><FONT STYLE="font-weight: normal">.
All communications hereunder, except as herein otherwise specifically provided, shall be in writing and shall be mailed (registered or
certified mail, return receipt requested), personally delivered or sent by facsimile transmission and confirmed and shall be deemed given
when so delivered or faxed and confirmed or if mailed, two (2) days after such mailing.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">If to the Representative:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">The Benchmark Company, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">150 East 58th St, 17th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">New York, NY 10155</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Attn: Michael Jacobs</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.1pt"><BR>
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.1pt">919 Third Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.1pt">New York, NY 10022</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.1pt">Attn: Ivan K. Blumenthal, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.1pt">Fax No.:&nbsp;212-983-3115</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">If to the Company:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Intensity Therapeutics, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">61 Wilton Road, 3rd Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Westport, CT 06880</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Attn: Lew Bender</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">Fax No: 203-557-3023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">with a copy (which shall not constitute notice) to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">McDermott Will &amp; Emery LLP</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">One Vanderbilt Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">New York, NY 10017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Attn: Robert Cohen, Esq.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Fax No: 212 547 5444</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">9.2&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Headings</U></FONT>.
<FONT STYLE="font-style: normal; font-weight: normal">The headings contained herein are for the sole purpose of convenience of reference,
and shall not in any way limit or affect the meaning or interpretation of any of the terms or provisions of this Agreement.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">9.3&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Amendment</U><FONT STYLE="font-weight: normal">.
This Agreement may only be amended by a written instrument executed by each of the parties hereto.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">9.4&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Entire
Agreement</U><FONT STYLE="font-weight: normal">. This Agreement (together with the other agreements and documents being delivered pursuant
to or in connection with this Agreement) constitutes the entire agreement of the parties hereto with respect to the subject matter hereof
and thereof, and supersedes all prior agreements and understandings of the parties, oral and written, with respect to the subject matter
hereof. </FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">9.5&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Binding
Effect</U><FONT STYLE="font-weight: normal">. This Agreement shall inure solely to the benefit of and shall be binding upon the Representative,
the Underwriters, the Company and the controlling persons, directors and officers referred to in Section 5 hereof, and their respective
successors, legal representatives, heirs and assigns, and no other person shall have or be construed to have any legal or equitable right,
remedy or claim under or in respect of or by virtue of this Agreement or any provisions herein contained. The term &ldquo;successors and
assigns&rdquo; shall not include a purchaser, in its capacity as such, of securities from any of the Underwriters.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">9.6&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Governing
Law; Consent to Jurisdiction; Trial by Jury</U>. <FONT STYLE="font-weight: normal">This Agreement shall be governed by and construed and
enforced in accordance with the laws of the State of New York, without giving effect to conflict of laws principles thereof. The Company
hereby agrees that any action, proceeding or claim against it arising out of, or relating in any way to this Agreement shall be brought
and enforced in the New York Supreme Court, County of New York, or in the United States District Court for the Southern District of New
York, and irrevocably submits to such jurisdiction, which jurisdiction shall be exclusive. The Company hereby waives any objection to
such exclusive jurisdiction and that such courts represent an inconvenient forum. Any such process or summons to be served upon the Company
may be served by transmitting a copy thereof by registered or certified mail, return receipt requested, postage prepaid, addressed to
it at the address set forth in Section 9.1 hereof. Such mailing shall be deemed personal service and shall be legal and binding upon the
Company in any action, proceeding or claim. The Company agrees that the prevailing party(ies) in any such action shall be entitled to
recover from the other party(ies) all of its reasonable attorneys&rsquo; fees and expenses relating to such action or proceeding and/or
incurred in connection with the preparation therefor. The Company (on its behalf and, to the extent permitted by applicable law, on behalf
of its stockholders and affiliates) and each of the Underwriters hereby irrevocably waives, to the fullest extent permitted by applicable
law, any and all right to trial by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated
hereby.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">9.7&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Execution
in Counterparts</U><FONT STYLE="font-weight: normal">. This Agreement may be executed in one or more counterparts, and by the different
parties hereto in separate counterparts, each of which shall be deemed to be an original, but all of which taken together shall constitute
one and the same agreement, and shall become effective when one or more counterparts has been signed by each of the parties hereto and
delivered to each of the other parties hereto. Delivery of a signed counterpart of this Agreement by facsimile or email/pdf transmission
shall constitute valid and sufficient delivery thereof.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">9.8&nbsp;</FONT><FONT STYLE="font-style: normal"><U>Waiver,
etc</U><FONT STYLE="font-weight: normal">. The failure of any of the parties hereto to at any time enforce any of the provisions of this
Agreement shall not be deemed or construed to be a waiver of any such provision, nor to in any way effect the validity of this Agreement
or any provision hereof or the right of any of the parties hereto to thereafter enforce each and every provision of this Agreement. No
waiver of any breach, non-compliance or non-fulfillment of any of the provisions of this Agreement shall be effective unless set forth
in a written instrument executed by the party or parties against whom or which enforcement of such waiver is sought; and no waiver of
any such breach, non-compliance or non-fulfillment shall be construed or deemed to be a waiver of any other or subsequent breach, non-compliance
or non-fulfillment.</FONT></FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">[Signature Page Follows]</P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;-</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">If
the foregoing correctly sets forth the understanding between the Underwriters and the Company, please so indicate in the space provided
below for that purpose, whereupon this letter shall constitute a binding agreement between us.</FONT></P>

<P STYLE="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">INTENSITY THERAPEUTICS, INC.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-size: 10pt">/s/ Lewis H. Bender</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="width: 31%"><FONT STYLE="font-size: 10pt">Lewis H. Bender</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President and Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Confirmed as of the date first written<BR>
above mentioned, on behalf of
itself and as <BR>
Representative of the several Underwriters <BR>
named on <U>Schedule 1</U> hereto:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">THE BENCHMARK COMPANY, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%"><FONT STYLE="font-size: 10pt">/s/ John J. Borer III</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: John J. Borer III</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:&nbsp;&nbsp; Senior Managing Director</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">ACKNOWLEDGED:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PRIME EXECUTIONS, INC. DBA FREEDOM CAPITAL MARKETS</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 36%"><FONT STYLE="font-size: 10pt">/s/ Duane Penfold</FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: Duane Penfold</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:&nbsp;&nbsp; COO</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">[Signature
Page]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps">Intensity
Therapeutics, Inc. &ndash; Underwriting Agreement</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE 1</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: normal">Underwriters</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Total Number of<BR> Firm Shares to be Purchased</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number of Option Shares to be Purchased if the Over-Allotment Option is Fully Exercised</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; font-weight: normal; text-align: left; text-indent: 0in">The Benchmark Company, LLC</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">1,950,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 14%; text-align: right">292,500</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 1.5pt; font-weight: normal; text-align: left; text-indent: 0in">Freedom Capital Markets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,950,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">292,500</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; font-weight: bold; text-indent: 0in">TOTAL</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">3,900,000</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font-weight: bold; text-align: right">585,000</TD><TD STYLE="padding-bottom: 4pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 34; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch. <!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE 2-A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><B>Pricing Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Number of Firm Shares: 3,900,000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Number of Option Shares: 585,000</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Public Offering Price per Share: $5.00</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Underwriting Discount per Share: $0.35</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Proceeds to Company per Share (before expenses): $4.65</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch. 2-<!-- Field: Sequence; Type: UpperLetter; Name: PageNo -->A<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE 2-B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Issuer General Use Free Writing Prospectuses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issuer Free Writing Prospectus filed on November 24, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issuer Free Writing Prospectus filed on December 16, 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issuer Free Writing Prospectus filed on January 7, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issuer Free Writing Prospectus filed on April 20, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issuer Free Writing Prospectus filed on September 20, 2022.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issuer Free Writing Prospectus filed on January 13, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issuer Free Writing Prospectus filed on February 9, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issuer Free Writing Prospectus filed on February 13, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issuer Free Writing Prospectus filed on June 1, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Issuer Free Writing Prospectus filed on June 23, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch. 2-<!-- Field: Sequence; Type: UpperLetter; Name: PageNo -->B<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE 2-C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Written Testing-the-Waters Communications</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch. 2-<!-- Field: Sequence; Type: UpperLetter; Name: PageNo -->C<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>SCHEDULE 3</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>List of Lock-Up Parties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Lewis H. Bender</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">John Wesolowski</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Emer Leahy</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dr. Mark A. Goldberg</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">James M. Ahlers</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Daniel Donovan</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LFP River West Investors, LLC &ndash; Series 21</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">LFP River West Investors, LLC &ndash; Series 38</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Craig J. Duchossois Revocable Trust UAD 9/11/1989</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Portage Biotech Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">VCapital Intensity, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">BVC-Intensity LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 38; Options: NewSection; Value: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">Sch. 3</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Underwriter Warrant</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Exhibit B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Lock-Up Agreement</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">______________, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Benchmark Company, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">150 East 58th St, 17th Floor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York, NY 10155</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Re: Intensity Therapeutics, Inc. (the &ldquo;<B>Company</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned is an owner of record or beneficially
of certain shares of the Company&rsquo;s common stock, $0.0001 par value per share (&ldquo;<B>Common Stock</B>&rdquo;), or securities
convertible into, exchangeable, or exercisable for Common Stock (&ldquo;<B>Securities</B>&rdquo;). The Company proposes to enter into
an underwriting agreement (the &ldquo;<B>Underwriting Agreement</B>&rdquo;) with you as representative of the underwriters, with respect
to a public offering of the Company&rsquo;s Common Stock and warrants to purchase the Company&rsquo;s Common Stock (the &ldquo;<B>Offering</B>&rdquo;).
The undersigned acknowledges that the Offering will be of benefit to the undersigned. The undersigned also acknowledges that you and each
underwriter to be named in the Underwriting Agreement will rely on the representations and agreements of the undersigned contained in
this letter in connection with entering into the Underwriting Agreement and performing your and their obligations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In consideration of the foregoing and as an inducement
to you as underwriter, the undersigned hereby agrees that the undersigned will not, without your prior written consent (which consent
may be withheld in your sole discretion), directly or indirectly, sell, offer to sell, contract to sell, or grant any option for the sale
(including without limitation any short sale), grant any security interest in, pledge, hypothecate, hedge, establish an open &ldquo;put
equivalent position&rdquo; within the meaning of Rule 16a-1(h) under the Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder (collectively, the &ldquo;<B>Exchange Act</B>&rdquo;) or otherwise dispose of or enter into any transaction
which is designed to, or could be expected to, result in the disposition (whether by actual disposition or effective economic disposition
due to cash settlement or otherwise by the Company or any affiliate of the Company or any person in privity with the Company or any affiliate
of the Company) (collectively, a &ldquo;<B>Disposition</B>&rdquo;) of any shares of Common Stock or any Securities currently or hereafter
owned either of record or beneficially (as defined in Rule 13d-3 under the Exchange Act) by the undersigned, or publicly announce the
undersigned&rsquo;s intention to do any of the foregoing, for a period commencing on the date hereof and continuing through the close
of trading on the date one hundred and eighty (180) days following the Closing Date, as defined in the Underwriting Agreement, subject
to adjustment as discussed below (the &ldquo;<B>Lock-up Period</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 40; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit B</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The restrictions set forth herein shall not apply to the registration
of the offer and sale of Common Stock as contemplated by the Underwriting Agreement and the sale of Common Stock to the Underwriters in
the Offering and/or participation of the undersigned in the Offering, and shall furthermore not apply to:</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.5in">i)</TD><TD STYLE="text-align: justify">transfers of Securities as a bona fide gift;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.5in">ii)</TD><TD STYLE="text-align: justify">transfers of Securities for bona fide estate planning purposes, including any such transfer to any member of the immediate family
(as defined below) of the undersigned or to a trust the beneficiaries of which are exclusively the undersigned or members of the undersigned&rsquo;s
immediate family;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.5in">iii)</TD><TD STYLE="text-align: justify">if the undersigned is a corporation, partnership, limited liability company or other business entity, transfers of Securities to any
direct or indirect shareholder, partner or member of, or owner of a similar equity interest in (including, with respect to trusts, beneficiaries),
the undersigned, as the case may be, if, in any such case, such transfer is not for value;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.5in">iv)</TD><TD STYLE="text-align: justify">if the undersigned is a corporation, partnership, limited liability company or other business entity, transfers of Securities (a)
in connection with the sale or other bona fide transfer in a single transaction of all or substantially all of the undersigned&rsquo;s
capital stock, partnership interests, membership interests or other similar equity interests, as the case may be, or all or substantially
all of the undersigned&rsquo;s assets, in any such case not undertaken for the purpose of avoiding the restrictions imposed by this Agreement
or (b) to another corporation, partnership, limited liability company or other business entity so long as the transferee is an affiliate
(as defined below) of the undersigned and such transfer is not for value,</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.5in">v)</TD><TD STYLE="text-align: justify">the exercise by the undersigned of any stock option(s) issued pursuant to the Company&rsquo;s existing stock option plans and/or tradable
options, including any exercise effected by the delivery of shares of Common Stock of the Company held by the undersigned; provided, that,
the shares of Common Stock of the Company received upon such exercise shall remain subject to the restrictions provided for in this Agreement,</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.5in">vi)</TD><TD STYLE="text-align: justify">the exercise by the undersigned of any warrant(s) issued by the Company prior to the date of this Agreement or the conversion or redemption
of outstanding convertible securities, including any exercise effected by the delivery of shares of Common Stock of the Company held by
the undersigned; provided, that, the shares of Common Stock of the Company received upon such exercise shall remain subject to the restrictions
provided for in this Agreement,</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.5in">vii)</TD><TD STYLE="text-align: justify">the occurrence after the date hereof of any of the following: (a) an acquisition by an individual or legal entity or &ldquo;group&rdquo;
(as described in Rule 13d-5(b)(1) promulgated under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;))
of effective control (whether through legal or beneficial ownership of capital stock of the Company, by contract or otherwise) of 100%
of the voting securities of the Company, (b) the Company merges into or consolidates with any other entity, or any entity merges into
or consolidates with the Company, or (c) the Company sells or transfers all or substantially all of its assets to another person, provided,
that, the shares of Common Stock of the Company received upon any of the events set forth in clauses (a) through (c) above shall remain
subject to the restrictions provided for in this Agreement;</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.5in">viii)</TD><TD STYLE="text-align: justify">transfers of Securities by will or intestate succession upon the death of the undersigned,</TD></TR></TABLE>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0 0pt 1in; text-indent: -0.75in"></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit B</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.5in">ix)</TD><TD STYLE="text-align: justify">transfers of Securities to the Company in connection with, and to the extent necessary to fund, the payment of taxes due with respect
to the vesting of restricted stock, restricted stock units, performance stock units, equity appreciation rights or similar rights to purchase
Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">x)</TD><TD>transfers of Securities by operation of law or pursuant to an order of a court or regulatory agency,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">xi)</TD><TD STYLE="text-align: justify">transactions relating to Common Stock or other securities acquired in the open market after the completion of the Offering, provided
that no filing under Section 16(a) of the Exchange Act, shall be required or shall be voluntarily made in connection with such transfers,</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.75in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">xii)</TD><TD>transfers of Securities consented to, in writing by you;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">provided, however, that in the case of any transfer described in clause
(i), (ii), (iii) or (iv) above, it shall be a condition to the transfer that the transferee executes and delivers to you not later than
one business day prior to such transfer, a written agreement, in substantially the form of this Agreement (it being understood that any
references to &ldquo;immediate family&rdquo; in the agreement executed by such transferee shall expressly refer only to the immediate
family of the undersigned and not to the immediate family of the transferee) and otherwise satisfactory in form and substance to you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In addition, the restrictions sets forth herein shall not prevent the
undersigned from entering into a sales plan pursuant to Rule 10b5-1 under the Exchange Act after the date hereof, provided that (i) a
copy of such plan is provided to you promptly upon entering into the same and (ii) no sales or transfers may be made under such plan until
the Lock-Up Period ends or this Agreement is terminated in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The foregoing restrictions have been expressly
agreed to preclude the holder of shares of Common Stock and/or the Securities from engaging in any hedging or other transaction which
is designed to or reasonably expected to lead to or result in a Disposition of shares of Common Stock or Securities during the Lock-up
Period, even if such shares of Common Stock or Securities would be disposed of by someone other than such holder. Such prohibited hedging
or other transactions would include, without limitation, any short sale (whether or not against the box) or any purchase, sale, or grant
of any right (including, without limitation, any put or call option) with respect to any shares of Common Stock or Securities or with
respect to any security (other than a broad-based market basket or index) that includes, relates to, or derives any significant part of
its value from shares of Common Stock or Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned also agrees and consents to the
entry of stop transfer instructions with the Company&rsquo;s transfer agent and registrar against the transfer of shares of Common Stock
or Securities held by the undersigned except in compliance with the foregoing restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The undersigned understands that the underwriters
are entering into the Underwriting Agreement and proceeding with the Offering in reliance upon this Lock-Up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This agreement is irrevocable and will be binding
on the undersigned and the respective successors, heirs, personal representatives, and assigns of the undersigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Lock-Up Agreement shall be governed by, and
construed in accordance with, the laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Nothing in this Lock-up Agreement shall constitute
an obligation to purchase shares of Common Stock, or Securities of the Company. Whether or not the Offering actually occurs depends on
a number of factors, including market conditions. Any Offering will only be made pursuant to the Underwriting Agreement, the terms of
which are subject to negotiation among the parties thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature Page Follows]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit B</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I></I>The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Lock-Up Agreement
and that, upon request, the undersigned will execute any additional documents necessary in connection with the enforcement hereof. All
authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns,
heirs or personal representatives of the undersigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Very truly yours,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Printed Name of Holder</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 3%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 37%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 60%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Signature</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">&nbsp;</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Printed Name of Person Signing</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">(<I>and indicate capacity of person signing if</I></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><I>signing as custodian, trustee, or on behalf</I></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><I>of an entity</I>)</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit B</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>EXHIBIT C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form of Press Release</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Intensity Therapeutics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>[Date]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intensity Therapeutics, Inc. (the &ldquo;Company&rdquo;)
announced today that The Benchmark Company, LLC, acting as representative for the underwriters in the Company&rsquo;s recent public offering
of _______ shares of the Company&rsquo;s common stock, is [waiving] [releasing] a lock-up restriction with respect to _________&nbsp;shares
of the Company&rsquo;s common stock held by [certain officers or directors] [an officer or director] of the Company.&nbsp; The [waiver]
[release] will take effect on _________, 20___, and the shares may be sold on or after such date.&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>This press release is not an offer or sale
of the securities in the United States or in any other jurisdiction where such offer or sale is prohibited, and such securities may not
be offered or sold in the United States absent registration or an exemption from registration under the Securities Act of 1933, as amended.</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">Exhibit C</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>6
<FILENAME>ea181296ex99-1_intensity.htm
<DESCRIPTION>PRESS RELEASE ISSUED JUNE 29, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Intensity Therapeutics, Inc. Announces Pricing
of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">WESTPORT, Conn. June 29, 2023, &ndash; Intensity
Therapeutics, Inc. (&ldquo;Intensity&rdquo; or the &ldquo;Company&rdquo;) (Nasdaq: INTS), a clinical-stage biotechnology company focused
on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase
immune system recognition of cancers, today announced the pricing of its upsized initial public offering of 3,900,000 shares of common
stock at a public offering price of $5.00 per share. In addition, Intensity has granted the underwriters a 45-day option to purchase an
additional 585,000 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the offering, the Company&rsquo;s
common stock is expected to begin trading on The Nasdaq Capital Market on June 30, 2023, under the ticker symbol &ldquo;INTS&rdquo; subject
to final approval by Nasdaq. The offering is expected to close on July 5, 2023, subject to the satisfaction of customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The net proceeds to Intensity from the offering
(prior to any exercise of the underwriter&rsquo;s over-allotment option), after deducting the underwriting discounts, commissions and
transaction expenses, are expected to be approximately $16.2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Benchmark Company and Freedom Capital Markets
are acting as the joint book-running managers for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The securities described above are being offered
by the Company pursuant to a registration statement on Form S-1 (Registration No. 333-260565) that was previously filed with the U.S.
Securities and Exchange (the &ldquo;SEC&rdquo;) and declared effective on June 29, 2023. This offering is being made only by means of
a prospectus forming part of the effective registration statement. Copies of the final prospectus relating to the initial public offering
can be obtained, when available, through the SEC&rsquo;s website at www.sec.gov or from: The Benchmark Company, LLC, Attention: Prospectus
Department, 150 E. 58<SUP>th</SUP>&nbsp;Street, 17<SUP>th&nbsp;</SUP>floor, New York, NY 10155 at 212-312-6700 or by email at prospectus@benchmarkcompany.com
and Freedom Capital Markets, 40 Wall Street, 58th Floor, New York, NY 10005, via email at EquitySyndicate@freedomcapmkts.com and via telephone
at (800) 786-1469.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Intensity Therapeutics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intensity Therapeutics, Inc. is a clinical-stage
biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. Intensity leverages its DfuseRx&#8480; technology
platform to create proprietary drug formulations that following direct injection rapidly disperse throughout a tumor and diffuse therapeutic
agents into cancer cells. Intensity&rsquo;s product candidates have the potential to induce an adaptive immune response that not only
attacks the injected tumor, but also non-injected tumors. The Company&rsquo;s lead product candidate, INT230-6, is in development for
the treatment of patients with solid tumors, such as sarcoma and breast cancer patients. Intensity has a clinical collaboration agreement
with Merck Sharpe &amp; Dohme (Merck) to evaluate INT230-6 with pembrolizumab. In addition, the Company has a clinical collaboration agreement
with Bristol-Myers Squibb to evaluate the combination INT230-6 with Bristol-Myers Squibb&rsquo;s anti-CTLA-4 antibody, ipilimumab. Intensity
has also executed agreements with the Ottawa Hospital Research Institute (OHRI) and the Ontario Institute of Cancer Research (OICR) to
study INT230-6 in a randomized controlled neoadjuvant phase 2 study in women with early stage breast cancer (the INVINCIBLE study) (NCT04781725).
Additionally, the Company executed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute&rsquo;s
(NCI) Vaccine Branch. For more information, please visit www.intensitytherapeutics.com and follow the Company on Twitter @IntensityInc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain statements in this press release may constitute
&ldquo;forward-looking statements&rdquo; within the meaning of the United States Private Securities Litigation Reform Act of 1995, as
amended to date. These statements include, but are not limited to, statements relating to the expected trading commencement, closing dates
and use of proceeds. We have based these forward-looking statements on our current expectations and projections about future events, nevertheless,
actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking
statements we make. These risks and uncertainties, many of which are beyond our control, include: the risk that the initial public offering
of common stock may not close, as well as other risks described in the section entitled &ldquo;Risk Factors&rdquo; in the prospectus,
which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements,
which speak only as of the date on which they are made and reflect management&rsquo;s current estimates, projections, expectations and
beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information
contained in this press release except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>INVESTOR RELATIONS CONTACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rx Communications Group</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Michael K. Miller<BR>
(917) 633-6086&nbsp;<BR>
mmiller@rxir.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>7
<FILENAME>ea181296ex99-2_intensity.htm
<DESCRIPTION>PRESS RELEASE ISSUED JULY 5, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Intensity Therapeutics, Inc. Announces Closing
of Upsized Initial Public Offering, Raising Approximately</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$19.5 Million in Gross Proceeds</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WESTPORT, Conn. July 5, 2023</B>, &ndash; Intensity
Therapeutics, Inc. (&ldquo;Intensity&rdquo; or the &ldquo;Company&rdquo;) (Nasdaq: INTS), a clinical-stage biotechnology company focused
on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase
immune system recognition of cancers, today announced the closing of its upsized initial public offering of 3,900,000 shares of common
stock at a public offering price of $5.00 per share. In addition, Intensity has granted the underwriters a 45-day option to purchase an
additional 585,000 shares of its common stock at the initial public offering price, less the underwriting discounts and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In connection with the offering, the Company&rsquo;s
common stock began trading on The Nasdaq Capital Market on June 30, 2023, under the ticker symbol &ldquo;INTS.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The net proceeds to Intensity from the offering
(prior to any exercise of the underwriter&rsquo;s over-allotment option), after deducting the underwriting discounts, commissions and
transaction expenses were approximately $16.2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Benchmark Company and Freedom Capital Markets
acted as the joint book-running managers for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The securities described above were being offered
by the Company pursuant to a registration statement on Form S-1 (Registration No. 333-260565) that was previously filed with the U.S.
Securities and Exchange (the &ldquo;SEC&rdquo;) and declared effective on June 29, 2023. This offering was made only by means of a prospectus
forming part of the effective registration statement. Copies of the final prospectus can be obtained through the SEC&rsquo;s website at
www.sec.gov or from: The Benchmark Company, LLC, Attention: Prospectus Department, 150 E. 58<SUP>th</SUP>&nbsp;Street, 17<SUP>th&nbsp;</SUP>floor,
New York, NY 10155 at 212-312-6700 or by email at prospectus@benchmarkcompany.com and Freedom Capital Markets, 40 Wall Street, 58th Floor,
New York, NY 10005, via email at EquitySyndicate@freedomcapmkts.com and via telephone at (800) 786-1469.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Intensity Therapeutics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Intensity Therapeutics, Inc. is a clinical-stage
biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. Intensity leverages its DfuseRx&#8480; technology
platform to create proprietary drug formulations that following direct injection rapidly disperse throughout a tumor and diffuse therapeutic
agents into cancer cells. Intensity&rsquo;s product candidates have the potential to induce an adaptive immune response that not only
attacks the injected tumor, but also non-injected tumors. The Company&rsquo;s lead product candidate, INT230-6, is in development for
the treatment of patients with solid tumors, such as sarcoma and breast cancer. Intensity has a clinical collaboration agreement with
Merck Sharpe &amp; Dohme (Merck) to evaluate INT230-6 with pembrolizumab. In addition, the Company has a clinical collaboration agreement
with Bristol-Myers Squibb to evaluate the combination INT230-6 with Bristol-Myers Squibb&rsquo;s anti-CTLA-4 antibody, ipilimumab. Intensity
has also executed agreements with the Ottawa Hospital Research Institute (OHRI) and the Ontario Institute of Cancer Research (OICR) to
study INT230-6 in a randomized controlled neoadjuvant phase 2 study in women with early stage breast cancer (the INVINCIBLE study) (NCT04781725).
Additionally, the Company executed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute&rsquo;s
(NCI) Vaccine Branch. For more information, please visit www.intensitytherapeutics.com and follow the Company on Twitter @IntensityInc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain statements in this press release may constitute
&ldquo;forward-looking statements&rdquo; within the meaning of the United States Private Securities Litigation Reform Act of 1995, as
amended to date. These statements include, but are not limited to, statements relating to the expected trading commencement, closing dates
and use of proceeds. We have based these forward-looking statements on our current expectations and projections about future events, nevertheless,
actual results or events could differ materially from the plans, intentions and expectations disclosed in, or implied by, the forward-looking
statements we make. These risks and uncertainties, many of which are beyond our control, include: the risk that the initial public offering
of common stock may not close, as well as other risks described in the section entitled &ldquo;Risk Factors&rdquo; in the prospectus,
which can be obtained on the SEC website at www.sec.gov. Readers are cautioned not to place undue reliance on the forward-looking statements,
which speak only as of the date on which they are made and reflect management&rsquo;s current estimates, projections, expectations and
beliefs. The Company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information
contained in this press release except as required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>INVESTOR RELATIONS CONTACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rx Communications Group</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Michael K. Miller<BR>
(917) 633-6086&nbsp;<BR>
mmiller@rxir.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>ints-20230629.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qpZs7xRiXgen8uBYXYsWaCFGaPtyJ1xCYkxuG97fVl6byYtXhbbBSujUXCm0b8M -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:INTS="http://intensitytherapeutics.com/20230629" elementFormDefault="qualified" targetNamespace="http://intensitytherapeutics.com/20230629">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://intensitytherapeutics.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="ints-20230629_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="ints-20230629_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>ints-20230629_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>ints-20230629_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.18a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://intensitytherapeutics.com/role/Cover" xlink:href="ints-20230629.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://intensitytherapeutics.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139754055212816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jun. 29, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 29,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Intensity Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001567264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-1488089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">61
    Wilton Road<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">3rd Floor<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Westport<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06880<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">203<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">221-7381<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">INTS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>ea181296-8k_intensity_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ints-20230629.xsd" xlink:type="simple"/>
    <context id="From2023-06-29to2023-06-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001567264</identifier>
        </entity>
        <period>
            <startDate>2023-06-29</startDate>
            <endDate>2023-06-29</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-06-29to2023-06-29">0001567264</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-06-29to2023-06-29">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2023-06-29to2023-06-29">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="From2023-06-29to2023-06-29">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2023-06-29to2023-06-29">2023-06-29</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2023-06-29to2023-06-29">Intensity Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-06-29to2023-06-29">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2023-06-29to2023-06-29">001-41109</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-06-29to2023-06-29">46-1488089</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-06-29to2023-06-29">61     Wilton Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-06-29to2023-06-29">3rd Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-06-29to2023-06-29">Westport</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-06-29to2023-06-29">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-06-29to2023-06-29">06880</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-06-29to2023-06-29">203</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-06-29to2023-06-29">221-7381</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2023-06-29to2023-06-29">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2023-06-29to2023-06-29">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2023-06-29to2023-06-29">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2023-06-29to2023-06-29">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2023-06-29to2023-06-29">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-06-29to2023-06-29">INTS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-06-29to2023-06-29">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-06-29to2023-06-29">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2023-06-29to2023-06-29">true</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
M" #FA>56 <LB*:T$  !L$@  &    'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;(V887/B-A"&O_=7:-Q.IYT)P1($2 K,$,*U].YR-'#-M)U^$+; FMB6*\DA
M^?==&6+3U*S)AV ;[^O'N]*[0L.=TD\F$L*2ER1.S<B+K,UNVFT31"+AYE)E
M(H5O-DHGW,*IWK9-I@4/BZ D;C/?[[43+E-O/"RN+?1XJ'(;RU0L-#%YDG#]
M>BMBM1MYU'N[\""WD747VN-AQK=B*>S7;*'AK%VJA#(1J9$J)5IL1MZ$WMRR
MO@LH[OA=BITY.B;N5=9*/;F3>3CR?$<D8A%8)\'AXUE,11P[)>#XYR#JE<]T
M@<?';^H?BI>'EUES(Z8J?I2AC4;>P".AV/ \M@]J]XLXO-"5TPM4;(K_9+>_
M]\KW2) ;JY)#,! D,MU_\I=#(HX"NNQ$ #L$L()[_Z""\HY;/AYJM2/:W0UJ
M[J!XU2(:X&3JJK*T&KZ5$&?'4_4L]+!M0<I=: >'L-M]&#L1]FN>7A)V?4&8
MSSK_#6\#08G!2@Q6Z'4P#/+79&VLAD+]74>T5^C6*[C1>V,R'HB1!\/3"/TL
MO/'WW]*>_Q/"URGY.ICZ^$X%.8Q%2U:OF:B#P\,'K8\(1+>$Z*(J$R ("XH/
M,=_64>#Q&QX;@7!<E1Q7YR5C(;14(9FE(8'!5YL77*D<1DWCJ%>B]5#!::YU
MD2!I AZ3/P37*!ZNUFI1UNI0A*M?<O51I5EJI7T%K%B0^SQ9U\\Y7,/W::M+
MJ7^-\ Q*GL$Y/ ]B*]V,@XS=\Z0V0[C./+7.H4%J%0G-,Y%;&9@+,D^#2P3S
MNL2\/@=S"B754,YY&HH7\E&\UH'B2CYD[ZK79[TN@D7]RC7]<\!6_(7,0Z"3
M&QGPHLV<KFZ#9+?7HMW!P!]@]:5'OD[/(81"*)TI7<!=D*6%B4"4)E.50TXA
MM2JL+7N#^MT,@ZQ<GZ*F_08Y"4.P;!@VAP/R">XC7])Z,ERR1[\A\/<H8PO5
M>% \Q$@K_Z>X@Z.DJYVJ)<4E.SH$(U=*8X!5;Z"XN;\'G+HS*/1*[=):.%SN
M41@+P\9B;%6_H+C-OV<K1^%"JV>9!O5UQC6G*PRMZA<4M_CW: ME+#C-GS([
M/35P1;\'DQACJWH&Q0V_*.$$UMJG47 !YF,]E5;-@N(N_TFY9KJ(5(IUKP81
MQFBKWQE@W916?8'B=OZHI87. XE)DCP]>*^II<*%FM9$K&H)#/?OI8IE(*U,
MM^0S#&\M>5R[BL55&GFJ!L!PBUYHT0H@/0+FUW[I"JM'6&1_V6SJZ]>@UTAV
MM-;'+?I_9'-C<B!K!,1E&P$KLV>X,Z^DA76:VA#*?EC_2)8BR&&\U:XZ&I3<
M^(0VM+0J>+H@W_F7;AU",EB5/O,X%R2#]S41URAWU0,8;MHKS4,W_I:OR5K5
MCSY<8'Z_6F(DE>,SW)W?4D9F+T'$TZTXN;YL$+J?+.\FOV%,E=6SLZQ^E@B]
M=5GZ&11LY"PDXVE]<7%!JW.T;I71LX9?!VZ/0H3D7L$L5>2K$<1& G)GW8P(
M"=35+;+=\G+_DZL6%G_&*=CVT=Z!VX?YS%UV#(G%!G3\RS[41^^W-O8G5F7%
M=L):6:N2XC 2'":NNP&^WRAEWT[<#D6YP33^%U!+ P04    " #FA>56GZ ;
M\+$"  #B#   #0   'AL+W-T>6QE<RYX;6S=5VUKVS 0_BM"/V!N8FKBD1BV
M0&&PC4+S85^56'8$>O%DN7/ZZZ>S;"=I=67=A['-H<G=/;J[1W<GF:Y;=Y+\
MX<BY([V2NMW0HW/-^R1I#T>N6/O.-%Q[I#)6,>=56R=M8SDK6W!2,EG>W&2)
M8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-?RA0GCTQNZ)9)L;=B6,N4D*=@
M7H+A8*2QQ'DJ?$,78&F? KP(&K <XRBAC05C$C*$[_VX_!DP::U7A90SP24-
MAF+=,.>XU7=>&18/QA<0&>7=J?$,:\M.B^4M/3L,/S[)WMB2VSG-@DZF8BUY
M!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@#E_(!6OBMNHK=5R3TXE,);2"P
MU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\;O2@?^^,X_>65Z(?]+Z:\V/1
M%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/!I!R\@5M*'KEUXG!I^6%9L^.]
MFZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7
M>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]?\HIUTNUF<$//\A=>BD[E\ZI[
MJ,NXZBQ_AOMHD<VWL,\E=,E[7FY'U=;[021>\%G'!QR>(W?#$T<PGX#%$<"P
M/!@#S"=X87G^I_VLT/T$#..VBB(KU&>%^@2O&+(=/EB>N$_NG_A.\SQ-LPRK
MZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#Q
MNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q
M_F"G)$WS/(X %F>0IA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04
M    " #FA>56EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_
MQ=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+
MJ1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D
M5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@
M2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/
M['X 4$L#!!0    ( .:%Y5:JQ"(6,P$  "("   /    >&PO=V]R:V)O;VLN
M>&ULC5'1;L(P#/R5*A^P%K0A#5%>0-N0I@V-B??0NM0BB2O'A8VOG]NJ&M)>
M]I3<V;K<7187XM.!Z)1\>1=B;FJ19IZFL:C!VWA'#02=5,3>BD(^IK%AL&6L
M <2[=)IEL]1;#&:Y&+6VG-X"$B@$*2C9$7N$2_R==S Y8\0#.I3OW/1W!R;Q
M&-#C%<K<9":)-5U>B/%*0:S;%4S.Y68R#/; @L4?>M>9_+2'V#-B#Q]6C>1F
MEJE@A1REW^CUK7H\@RX/J!5Z0B? :ROPS-0V&(Z=C*9(;V+T/8SG4.*<_U,C
M5146L*:B]1!DZ)'!=09#K+&))@G60VY6= ;N\N@#FW+()FKJIBF>HPYX4P[V
M1D\E5!B@?%.9J+SV4VPYZ8Y>9WK_,'G4'EKG5LJ]AU>RY1AQ_)[E#U!+ P04
M    " #FA>56)!Z;HJT   #X 0  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QSM9$]#H,P#(6O$N4 -5"I0P5,75@K+A %\R,2$L6N"K<OA0&0.G1A
MLIXM?^_)3I]H%'=NH+;S)$9K!LIDR^SO *1;M(HNSN,P3VH7K.)9A@:\TKUJ
M$)(HND'8,V2>[IFBG#S^0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!
M4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%0
M2P,$%     @ YH7E5F60>9(9 0  SP,  !,   !;0V]N=&5N=%]4>7!E<UTN
M>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%
M3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#W
MR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?
ME.I$J+EST&!G(BY84(JKA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH9
M0]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTC
MR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_
M/[&\UDX:?^:+X3]>?P%02P$"% ,4    " #FA>56!T%-8H$   "Q    $
M            @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( .:%
MY5:<_<[H[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E
M+GAM;%!+ 0(4 Q0    ( .:%Y5:97)PC$ 8  )PG   3              "
M <T!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ YH7E5@'+(BFM
M!   ;!(  !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q
M+GAM;%!+ 0(4 Q0    ( .:%Y5:?H!OPL0(  .(,   -              "
M ?$,  !X;"]S='EL97,N>&UL4$L! A0#%     @ YH7E5I>*NQS     $P(
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9>&UL4$L%!@     )  D /@(  $44      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>25</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea181296-8k_intensity.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intensitytherapeutics.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ea181296-8k_intensity.htm">ea181296-8k_intensity.htm</File>
    <File>ea181296ex10-1_intensity.htm</File>
    <File>ea181296ex3-1_intensity.htm</File>
    <File>ea181296ex3-2_intensity.htm</File>
    <File>ea181296ex4-1_intensity.htm</File>
    <File>ea181296ex99-1_intensity.htm</File>
    <File>ea181296ex99-2_intensity.htm</File>
    <File>ints-20230629.xsd</File>
    <File>ints-20230629_lab.xml</File>
    <File>ints-20230629_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="25">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ea181296-8k_intensity.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 25
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ea181296-8k_intensity.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ints-20230629_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ints-20230629_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ints-20230629.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 25,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "INTS",
   "nsuri": "http://intensitytherapeutics.com/20230629",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea181296-8k_intensity.htm",
      "contextRef": "From2023-06-29to2023-06-29",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://intensitytherapeutics.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea181296-8k_intensity.htm",
      "contextRef": "From2023-06-29to2023-06-29",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://intensitytherapeutics.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001213900-23-054818-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-23-054818-xbrl.zip
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M%UR,&=S*$86(>\SC=85L9G\?8E;7,OPRN?^3YFC%;SYRBE:\T+:G2/S=IVC
MF1J\0M'UP:J5S02V.[RNZ?LW+MSHX$)?B$LFNSS-(^.'E%>$'::KUMCSIM98
MTC2^5QPB#P7K>(H?''%?[P4^& BX7MYTP(%ZBXC![NZ]-8<KPB] B.Y2B@5B
MX2[Q_5BZP5QTLQDUC&[$J4?JE\# T T^\=UI> U0^J)PGACQX\SYX'S+1%(H
MWO"#.0VVE/C"$;;G%77DNS'*XZHR-?EE[RZK>:&?ZP3>2A3$6X"WY5X&+Z\6
M8%7+?\L"T&,YD.V[F'MZ\KMIB1_+[//]KR?^J81L)@@YK; Z;+G ^9,Q:T?9
M#1BQ120>2NZ+G$]/QF4K!]>'CSZ:_*"K.WU+W3.*&X^F^[0^[DQU N(^@N6'
M8-CFV9KIUM*_Y6I.%Z%DW#=^F726.O$4ZJ,.6&^@OE(4'GXVMGDH$?>-DE02
M]@1QOT[GE8*P?'=M<6Q/-O'[B?7Y/'<T2G01H!C@+J6?1W\@#Z]=G7XXX\1O
M99SX.,:M*0LLF;.,>;?)FZ?+5_5;Y:OZ6/E:OQ3['24&UWN_C1="^;',2-L@
M$M(E/XW],>0%X_MO8]+^_F.9%"EP^,GAL_$F)C68P3R=UI@12:$F8AB^YPP+
MY>IC)G@MK!;NI>?K-?R $Y/<2G);LB7W_18[;GYI>^^<TK&B1?XZOCK;+6ZX
MGB#^.@AO?2F^NA0+!-<LLU5^\Q4U\;=947LZ6U]@4U;X=:W=M[VCP<>K%WD]
M[,NLS*V>9&(@9BKSLN4'UFZBJSS>;0,*FE%9<BR^L*-:WAL?O:4LO@V;'SK$
M?2A#.I:TD;\3EI==O 98+''P_"0')SGVV&!@U)0?>@\!O@T2U"+L2'Z/^][6
M.,;<!N^%P-#)O,E5'I"%KG^I8WI:^@T(;L!:S#TA/]TXYGI&'"\.DBL$(:P>
MZC4W,;UDE<@9G8$>OROB>6,%=W1]"Y-7RACU\H8ZAO\*E(<UJVVL97!ON[*J
MNP9@!>LL9#W(K?+G$861]5CQV]0.2'(@N2%F'*MT%'OI20IAS_V6D1=YP\-_
M^5[&6UVR'4;=:-ESC/Y>8EQ^^-_/[/JW/<@37D2W/7>8$JI]U^MHPJG(#W;A
M3(Q!I:&A+%!G2Y 0:\THR_K4]K.2N3)_3;IM_L=->>_XAM\:Y;[K@J/*^]'W
M\Y.[3^73V=W1AW&G].%B,:^=3 2I='HRO=8&G5/M?6?4%<33O8YX_?=PWBC?
MT;)]JY[=3L_.IY>]5J\SZ O,:(TG%];?B_:E\J5G7LU;=^K'Q>2N5[]JF-+[
M/X^G=V/%?M>?WHE3^9WI?/BR?[Z8G2UD_:PQN'8:7SZ_/VY='(N=/?7MZ8=S
M0WMWWA.[U5-'_](Q%>/=B?1).CX_&CB3\=W'^ES:<SY+?](OI^,_[4\?WWTY
MG;Y_WVHW/O=IJ?O!U(Y/G/K7V6@N?#R]-OMGAGUUT7VO7-A_*D.9G9Y+M?%?
MUU/+%NOO_FRWYQ\N^A\[;UR6_#]02P,$%     @ YH7E5@8IYRL)O0  H8$$
M !P   !E83$X,3(Y-F5X,3 M,5]I;G1E;G-I='DN:'1M[+UI<]M(LC;ZG1'\
M#[ASSTQ($9!&DNW>W'<BU%YZ?%]WV\=VG[GG(TB"$MHDP % R9Q??W.MRL+"
M198MM9KOTF-))%!+5E8N3S[YXS\__/+Z'\/!C_]\<?X<_C?"__/CAU<?7K_X
MQX]_Y_^%O_Y=_OSC3V^>_V_T_L/_OG[Q__QE6N3U#]'IR:*./F3SM(I^3:^C
M=\4\R6/^11R]3\ML^A?X(GSUK7ZO3C_51\DLN\A_B,KLXK)^&LV3\B*#'T_^
M\H\??_K'BT^7V2BKX=''IS_^_2<8R-O&([9]M7DR?/3D:63?/4[S.BWIC7_+
M1]7BZ==YUV^_/G_Q[E_O7GUX]>O/T?G/[UZ\^.7%KQ^BAS?145I?IVG^\";V
M"OZ55UF]BCY<IF6R2)=U-H:'O,K'QP]OMDD^>7B3@HV+?DKS\25\_&/TK)@O
MDGP51Z]?/WMX<TVJZ%VZ*-,*?I74V54:%=.HA@5XGUZ!^,ZBW_))6EZ7&7RA
M^@I#TKGO7W*#E\!K_J^CH^AEELXF/T1ODXOT*3SKWTN0Y11>&1T=R2W^X_-7
M_Z/CX;<<U<4"/G*V<!?NT:BHZV+^0_0-_FY4E" '[G<_S9+QQ^CT^ D,K2IF
MV02$Z6WX1!JW'>&/?X>W=@Q@5*;)QZ-1.BU*&.6"1FT']4W'F'"@N[[2+,W?
M<6UX.1[*0;[IO3,J9I.O(_*W^:8??^LQE7[\^V]?:K')'/W"YUK>@5_]WZ+\
M&$?ZKQ]_>@?O^W^7>1J=?1]'9R=GCVYM"+<^I[^LO4)O[27G?7=7U7%W17DR
M3R=1D4?OQY?I9#E+02$F=9W@3\,!G)FT+GB53Y^<1"^2JHZ>?%=?1N_K.#K]
M%O[Q<E84Y2T.WVSR_\+W3Y\\N<\[^CJ99/!Q,/BBGV&]9^D\S7_X0J?@]V55
M9].5_#*#7<2'GAP_R?(O?/[6OAF%>HDB5<%GTPGJ5M&YPT%;Z<91$HV+<E&4
M()L@=G"]H0#2 TA*9\EUY:PM$& 2W^<I_#HIT^A@7,QFZ1C%>K:*KC,0P*RN
MHFHYJK))EI2Z&<ETFLTR^#:\-LO'L^4DRR_BX0"_42SK:);-LYI&  .:S2*8
M4%;CER=9-9X5%9Z),IJDU;C,1O!#EM. WJ47657+T&ETL-]U= #V(AZ5+$^F
M<*K@>],,EN(P@M^/X+<7X0"+<CCP \3YK;NF8GKSWV:3?R^+IW"EB=K V^MO
M)?WR,*:WCU:PLODT*^<5+4IR4:8ROOHRJ\PCSO4O]B&\.%&_CHH.[!S+=)J6
M)2Q-7> TY>&K8BG/BP[<NM-H8--+V$7<N>H0%S><5:BRPG'AAM+8\"L%_*=D
M>6GI,+C_O!K#.R]B!892%EU?9N-+V<5 /<+2)"!1,$Z81QG^[:#]>1Y/M82'
M=8R%MSN0TC$(&*Y3,-^F Z&K5I0HL)/L*ILLX7NP\DG>_;7&&E4PR=FLN*YN
M3_WP?_&4;Z,.CD0?_/CRS:\?[)N/KE.\OW^(<CCKR<SK*OS@;5E@;!2?=!C%
M9/Q&FT=U>BPC0C%ZNRS'ETF5DC)YG\Q("[V_!!54H5P=>]^B/7)0++-L_$5U
M;GLV5;V:I3J9I]'-UUU&?QMFZ1>8PNGQ:3B+]4\AD_@E:,3AP&^>?/7XJUZ6
MI[=X-.YR@+ !\']EF+_]X]>D7I:B$MV9@:.":QZ>ESN8T5WJHR\QSH/L4(;:
MEOKL/RDOXU_^\28?#O"R&255YDPI>Z\5.1M)8%&524YF#]_L:#_42496W BL
M)+!:?H=K#*]X? 9<.G/^)GQNDO&#Y)M56N,M6U^RN2)V P@&FAH5/B&KJB7K
MTRH%BTN>V>64T)V77, W+\3^>Q1_?W(2GYR<1!7)5'2@5Z)N6I\V,.L2Z('-
M0B%7JRZ@S.AO986_1GMF/@>3HZJ+,?@JBZ2,KI(93/"_3HYAG*?1 BP#&BS;
M$.%XG]&783#X[>W'<MR8[A_W--WU0=KN)($M/!R$DBGR"F8=2G)>U-'O10:.
M'QIJ*.HHUPM5A-.RF%OAH7_GR_D(9"-4DO[\1,5B48 KD.*',[2SJP6;DL,!
M&KI5MZ&K/KM:O#BZ>3*! X>R6=.OX95)C;_0\2W*;$SGZ[\>'W_SQ(KL]X_^
MJH*/O_4CA=^"W0\V[G! WSX\)H_!3@4_!2,8R6?)>P)E08LFIWZQ'*&1 :,A
MDUX>*>,Q2\%>U[B -:<0J([I;5G0JBRKX0"=+W&XT$U[CXL%7SS#BTJF?;<'
MY]X?F^UO_C-_\_-F#P=ODQ7YF"APX*:#G):K_97_E:]\77@VQ!:R)5/QL@,]
M<XGA#CB;K!P0,? #7*O)\?PXIO!>6L*A@]G%>OJJ%&_[Z. LGQQ&/RTK.&A5
M%3U/5N)PXL'%SZ5PBDE/11.XM>%<MJ^]K:[I%^XYS^$YNU_4W3&:#7IBE,),
M#J,#6;'Z,BMARH_*]5,.AQIEZP: 889).I[!+DR& []8'$UY_ .:#*U-H$!)
M4G.T(4W*6891,O@#ABK<5M+%,XF6"WC?:-45XD"I,/=0+)IW. #5"RJ7K,1?
MX!K[3QR]3J\R$/!GQ27\]V5:EAF;?&^+15K$T=OC9S#&9Y?EJIK!6)Y1YB&.
MOC_]'NX!7+3SJS1?ICY$+W'<D[.SIM'6#*L\*Y8YF(;;[WAL5X=C,8M9 C<(
M;F.9SHL:PR^P(M-D7&7S#+WX4CZ88GRF+'*XA6"K\FH.YBGL%T=2;KZR?!M>
M%LN2_C(1^W4BYS/:=#QAL3E<Q"9\PVJ<@6$ HK?=N3B69=K;C+<RQ.;@UJ24
MS_8IY:^14O[3F #;V0!BB T'FZ]]N=FM/D'U=IVAY8[:$.QQO"-?IA-RS@\J
M<#Q F:T.H^DRGU3H[ZZ2T2Q5>YYDMN$I#P>D-IWJD[^:4<42DW>#D\]2L+PL
MEA<<K@?MG<TX.R//>)Z2BU3 4S^4L+K.O[I)6.#YAV?;7SE^=9/Q&.ZK6H=D
MO<2V2^1F6))M($X17USHU.&]Q,X=7A#ZEV197Q8E#!4NDC0OYEFNP9N*KX?&
M730' Z5$+00K L_ T<#V\FATA7@DZ+>B?P9>&(98*(E#41E*>M$FM$0H_31.
M0;AI4^LTYPT'+U!NL^[K$5<+7]C>?!X6AI0:MYRUM[;>F.%@GB84UEJAG,HE
M7U]B("EZCT%*^"WF'M^#_.+?85C1++T X;Y$K:J_HG_D(I>C)/](Z:L<#G"]
ME+6',V(V!@T*MXHC$/I9<HVK24E$W(4V:&%+9W2?1OB2:82SG=,(;^!0P)!F
M1<UJ]LT"!>)!)!2^X"VW;6SAS&85>&EMSN8X>BEZ=[$L0?GS74"!(4K<PK$O
M@OVI(@YGY^+FN?SQ!'VS;$2GF:/1DMUK74[!728)]@L,F%=Z[05(&E U!8T[
M" $N%_CCD^^>4/0ZF7#8'-2.!++AQ1P,CMYS)-D%ZG%>TPR\PS3'&-R8G=C3
M)W\][!@MVH8.I:#QM+@=@.QPRD.YCD2LMX])PS;A9;7#%"D*FM;1HBS&X%[1
M)UCC7F=J"' ,U.3]F_%WN7]C4L@&F# <=",3=+:\1=MF =2)HLNJ$3?E&.<B
MR284([5/YFMV.("_PWV<N&P'?[$14?7Q3A.6.#7A2[XJ791TC= Z=S28YG"0
MA?B4Q@IUR(2\ZP9>YEX%WEP%FO#JBT]PY+.*0C21OVI8%#J/+.LFV%00TVH)
M_\3=]>)TYL2)[$243'G%I"^T07H.K;>#I,;(XLK$I. 'RBL<L(K!D!3*./]]
MVI9!.L@9X;WJU=&4L#6/GQRBP55)#*P=4>/96BT[' 0&+,/&2/NS$=94O_BG
M<!QP!/$FX?.H2^"&W+6P76NNU[];=+D?^I;V(KO"HPNO*="A@N&+!K'*V6GK
M<"/439JCIS-*%>1%+L1P(%8^O@AOP!RE"H:1D2V_?> +M1!?.:2)PD15N(*B
M]V2))ZASV!VA:!=I(!2'J?<ER/GK"GV%#^ZZG/@#NT6^7'P05L<XF"(SLZ16
MUZ"^+J*#,W1JX<_6[[ BJ3$\6A+>-QB]B3EN$8_%X";OL2KHYA;[5)C&8QNG
M4:*CO2%/C[9;'_D<#OI"GYMBRNNG<!R]FO*PU@8[&Q?3I(#)XL84X_&R[ I,
MQ/9K0<1"C86D"J]0OU''T6\X_JU.N< ?)=VJFD]5'3P;W]^EV>*M8!)^A'P1
MQ[!CA\&RZM*/BSEJ_99KWF5SKCNF.(]LFME( TLOC@R#2E&:H!"UXQ>QXB%=
MLIOS2D&VFX?K%"V<I[JY3'51HZ[K4R.78-@R7-+HDL9>MA+=L#(F/R[!$Q$\
M,X>[R3[>^V#W]J;((V^*N,!B*\4;O5VKSSN#CETG>:?8(X6<-@4?HS#V")]<
M%4MR&5,04="QA+P^8(-DSB;U<E3528X !%!H%6A."C!V'+O#P$GCNZ]QD]%Z
M](4PGW]X=AAM'4?L6=-V))'Q(3N'$KM,O^Y((EX\LQ1+0-9<G&1?P9H4?;O]
M.?'(<"TZ(Y)1&) <#KHBDHO%#$0 92AXXI?2&K>K(#K/^2UX,3?0$H^]EK""
M*T[Z</ O1AA*".>\[KC=44KI(NH0E1A3ZI2O;E^43BPZKD4!-G9:E.:#9GS;
MHPP"[\)<;MW!C@TCB&0 -X ENKC"M\<G#JM5+>?.5.V$F>%JAX>(8)E4/<$Z
M)%#,YN.-7:O,(8HIUN85ZX25:JBA[&W=VC#!7614<H-E1&GEK??@D[IC(@67
M">7@O8GG(6W?')^<1 >G9WYU;A9].02?TQMXR02/'"F86BTYF1W?)$T<7A61
M-\_T'.?>AV^%&L-M42.[2UPMT*XOK%,7%RFY!YWQG1N%O_S( E"DWY*;C^<M
MX0%9E\ >+$NZ*^]W].GD#Q%]VG*4+O(DX_PM0.> H<#6W[\\8CRTMR@-LGF[
M@JO?&5$!&KTGN*XO' [._>6-:Q-97!?#N&+_\:BESOR?UEXX03W5P\_3W;_1
M[X"W>?14]K+Z 4<O2OQI]#\(R/^*<)QV2?Z6U6E' 69&)P9:=[6 \9^7R2@;
M/XU^A=N3)_]K@5,Z"X V^BW\"^_\T1\)"W1OY? !9+O/;E0T-R/?E@*177C6
M?>+[-D9Y%I;3O974C?.?O3$4G8]K;SWJ'7J)]U0VLXG2WX[?']OOX:7WXA,X
M+/D%?4\#_CUE2?S771!1B5CZ(B&52@C[=HC @9\F9#*C[ZT_5&Q UP4AS5^B
M\?S^Z#0Z>(G1ZE^+X^C1HT='9]^<//GFR:$IXH_8=)B1G[$P=2#P;/\C;IU&
M6(+1*;, V[*>=B!<:/S8Z?>/'K&C@R.&EW4L6&-[=L],=*\<+US/JI'+,R)4
M %A0""=O!NC!'T'?:(Z)C@R<1(EI*R0"_12D&D")X> 5AGJR,N7G.Z:K8$'4
M'RF7,Y$I&/IR)E$D;PRJ=/6N[-I5!.L./O+./WD'AYA9 F#>4L08KH%;VXI#
MU>BKR+0GDM&BCTS4K1L.\!'C,=S_%!1TYZMG81J_-G,XQN.'@2IQ?7!\H"HH
MR$8IF6MT7&4P,<?KK%R _VF.E)-'.C9X]@.,A*Z_Y),X,=L\!%[01ND8?7)?
MCF#R2/BUMW#2,HP68FV)K[J2X^@]^SX- &8YK%ZX 3!%">G#/U/VC(6U R-^
MY"5.BO&2=XNU&TZ;$\XU>^5TWF$40B7B]\T]*"-!YQ%-D.Y"]SE\D'$(&N4<
M-H\.WT@NRF1Q&1V,*,']#C,2CQ^=G-,5N5X NF3>?3]ZY<>YO;2C1JRL@\T(
M)9Q^EW_=<X5O[_^_"J/KN"F5:.*NC1\.[.+Q7+\YDZ5;OU@Q)X8X@D!G84JF
M2.QR:SJW[DGIB 6!(X+:/E7F$+"(]8R8[]N>FIY+(GA)<U?98TZ25\IR)D%2
M<I]15FC//G2QL\W;'.>+! .7_O*/EA79!A;HH=M"B8JUE6(F)&T>29=& ?>F
MJ)JH\P#3Q^!N3V0,1HK#$5!JO(%$&7M,8@B:AY/N&'OHW&NU/A/+),U@6K?.
MWC':9YYBRFV#9/<8M,$L91*E">E@9F)[Q$QL,2_:-:+5F_=%7XW<'-0TLB+-
M5N'R-(,^#4!;!\6.KD4VQKOL)LM ]%5T@\VL)-AH[S0K*] ?RS+/JDL)=#9#
M5VB&+AD+3E$GA?%M/X6;#/V<=#.67^<>:!0^>%[ V,L4(Q4]N[WU?61+./2F
MI;<[1P;M]:KO/2USHEL\]LKR%I1E* /^7(&TPPBVWW&NMWC\PZ.3CKI55SSL
MP5-6B=T).N-![^,KS.+!:7N)%!3_DG3]30ZR+Z.1%U!^L(RF^&#% 7AM&.OW
M@N+JX4!NQT>;[;U65;!\<Y<R8.^SM/G]&+@J[^B9A:.L"TO$>2@G3S9/XI C
M$N0UL;[CC%9D75NZ#3-$G4@]7\/_;,1QC#,7^O=QY$L"W=U?%LD$M'!Q'>EK
M$IIHG>9$5;/,,34+#W,WA !R\<&XZ0)/U>4_F!P>?'<(0T7T*6?N$%A2U$VO
MN7?45)T-(]6A@H4SAU- (%<VZ4T$PDRV;8?S:)[@:,AAI=NT5C\?9\I$C0L;
MX6EM "$@I^$=3&NE&$2J')B1;>/N?<+R48:7#,)QXB]R,0!F7 2V]5X2P=^T
M=R5C.C[N^67*?$SZTF85!%S?13FINA?MXO /KVCO<H [9* >/_ADTZ.'E&RZ
M]V)_;^V+G\%]);HVT(.W:&OPX_N>Z*ZT+">8WX2KL"]D+$%%'\;JY(O$[9I?
M@=M1$,2H-B7!.KM7_Q@5>0*J=Y+^^/=7_[#5$>Y&[;9Q2,T.!VCC=(3W?L*G
MOH2G1B_\$]_A$]_#$W>*\\%;TRMX$APWBO1CL%1(A17A3;%J"Y4^._K)T-_N
M_:8O=AY>HYT)^W(WYP&-B 3,!?GX%H=SDT%P'Q;Z#RD0$F@:#IXS@?BR!!,4
MKF^XA3Y# +;8405P)I0GU* 9FY"-J%DL*9UF2,SEL&S*Q(5DBJ9J.3>JA=G3
MP1*O0$.Q*<LX/Q6TO_W?WW]=5OH'!P]H0_-:* &7WA>,P*Y(O X4@4TE<G+^
MNZ-S3<XSM/CDY.3H\>GIR?>'%'R'.TKJ!]L9P<Z25,H'=>:)[7PD%?]X4RI>
MOT,IY)TXQ'SN6E';O#I=N($ V^W''@Q8DT+#P399H8A\PC#:'22(FAM5)Q_!
MI\\+*M*BW"8W7H@(25%&L^QCRDR;A!0@S"2_'R81DT=+U1^2X;WA+&-<21Y/
M .D<IS#+">DP+#>;2M1!$B.-J2/;&2;#YPL-GIC!M3)VF^ZN/83L2T+(=B=,
M(?$9#IS4O(:=1$Z!+174.>7I-B)Y^VM'FI(\'+AT;;) A<6%"G!@JEIY%4 B
M\4>^]O#D_9I4D^3?T;-D@1L4_9*4']-.$(M.<R<04(,]\(;G.S+'&S.'E3O<
MP4%VY>4Z5'>&W<'<XA"'FF#S"=;AI X#L[:K"G)BNT2L-5?:=I4S6[K,V[VF
MN#--\6AG3?%K053HB^@-QK\0%52/MU43OZ:9./;!U9)CG#7D5W!!TX]Y<0W&
MS@55GZT8"*)PMH)(=+E:LN8#J08VLDQ0J>FB3*^$H(>8 $#X<H>86OHZ\WY\
MP:HO$2K&T]L0UTBC$!(R"C=O,[7ZLDSAE:PY_-?Y]4*] X-F9@Y;]\X%HSE/
M-K _6(-2VC]38Y'TK]:*'G#YQ&% /*1;0I67GAW(.!O[8WOG4S@[?KSSL?4J
MF1 >FX'B6YSG>UP6?^_K]K$>UX#)G]$Y1?"J<%MT(%=/3T9'3Z*PUHM1YO>:
MC/</P!>\)7,[8]?67A@"HT<6DJH^,LSA#B#N@/06]9NUT;VQU]U]&'$1E1U1
MX6O!SWA!]*')0K2QA?,[W"^!=3<L$%Z<V05F;&<KGY,U7R;>&@NHKY:+Q2QM
MK%[+GD03W2PIW777ZX(E6ZQP=(,%!O/H9BML*7778]/:7(E@V[^QG',T#O/H
M:UIV1\.#*8H:/ 7'5.-S*=SZ@[F&"$ Y+A996CD(=G_LR0:.7CS_^?Q=+(Z$
MBWW!X<1-7*#?43,)JUF=Z/W1AWW7G*]+1"T6N5(4=Y[87(B5NG48IKB\GF-
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MOX9R['Y+6:)B69(_3H#T"T:,YS5)9)&KYB*NRR6O0"HEH_9F^TS@P?J<(E;
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M1(RWDYW_U!1AWAK3)@QC=T-?V/&S++M5KDTR>[^"J;^9:W,X,*;^7@O>]11
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MR?Y2JA W8:\'[WP*H =W9TC\!<WAX>!U0A*,,O(ZN=ZE*B*P!+;0203(HJ(
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M[T05?Z'E;(SG8$^3"K&Q:@ILVHHZ3*O[0N7GMG4'%:ZD$H[RO@5S[6 ;!.P
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MF>2KLCP>-^ES/1QLU^AM?P3OP1'<O<3N!9(*EF!ECH>#=T4RB=Y?%M<['+S
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MNJ6K.?7LRE.T$O >NLXY0?KDKV3G%J4S:<<SN#FVP']J.X;&HXDS+&V.PCT
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MHJ\!,T<L[R7T>^(F,"CK$=8JY]0<ZGV1,G"K;K?I2G!QN(J3FR#*C#)N(NE
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M2-S1%8F.PA9D59_65):ST WZSM<Y?DWM%%2-ND _1;<9UQ*!<CHO/+?;0E4
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M-+(49%B%M[,YV"(G>%>Z^]?5^UIKM5N>9^D%\Y ?]9]];YQ=,H05YQ)'SKF
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M.Q.XP89RZ\-&-UO!0>_ KN!6K['&T.(^.968Z*;A_?;#-!PY99D*Z\;*?5^
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MZ>?JZB<WJ/O S#D;[C$PIV#6S9M-K9+H)+CD8D$3N\/26U3UG%0;9E5><IB
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MM2@8124A5,=T3P#:A'X"@_9[J:\"'A?^E[ECTV>8="(!,!!+_B24]+MBA)S
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M 2KC"4WP*IJ"BIXR0P$S57_8F>29B.(,'@&UG0:LX@"9UHGDZ<!.R#.P J(
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MEQHY_ 4F^;*&1^YX/],(83V-H*ZP2V?IWY/F3YX+$[DOU+R2TMF$:I58O)U
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M#,]+8XX_C*[&0WZ('4(JK3NRUIXY1KI]]!NA]:$OR 'U(%*NEC7UEZ"*A9R
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M#[.9C*!)75B[9U4D-$@'">4/?$-V0TP@2#>@(H(93,71@WT5^2;^4;LBB?-
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MF:MHDUQ_I)\(?JY3A?NF 8P6GVM:'4?H>C5)UHR@)#GBD9\NCIRR;LPE!6%
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MX@2D9 1QYK-4&GC[%MGFZ2B=4^^KX5ZPP;9DRPU((L\%;>UK@.")A 5/&&Y
MH0H[7BB;&+>P4HK4X[!4*GH/DO4RTI1/E;F5U<7^^MRD%(:18AR,RA7^,#E3
M  F+YN7%%4)=EF$F+A%/TDN("J( E$+ $PSVV\Z6;!<:I-V6P'GXD\0=E41H
M/Z*4+\M>7A@"(CW'RV[6\\0%AKG'_"(OP1E_TI!XS+_S&AOFE5_Z/0\7T&V
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MOK=L*?2N)T!*U1QXV#@"54)D^!1F,JBZ$L6&<4Y#WXSDQ@F4U)1P?P#YVN=
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MMQX.ZRWW[A$@Q<(PF-]6R//0%06F@@WMUV-0*5G*"<"C\SAX7R6>+CF(9_&
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M-'-*^@XKKMK9&3G$<T000P[B<L-L"I6D':.9FR[B"5D>'G60!'LK-PBE.NS
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M?OO;\7]0I7G\S]-_?7CS_P!02P,$%     @ YH7E5DZ"S!0030  ,9T! !L
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MC \9#348Q=55-@=7N81GT<&62UBY+W+O$]#[!5C;_/V?"SB T36L:8%F!@D
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MF\]M,ELGO[BS4T84@*1!<+R,%@7C8B5:LBRQ-J604V!>S/2F6]62+K8E*2'
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M7?+Z,KC?RX$X]."*.,%K,QH$RGY?\:=/332^+BJL#@??:5+'T0EJE(7Q!7\
MKV-JZAW<>C'/V4(;..=<%2J%A1OK"(*LQ<2T[.WJ7TPI?3MY:8H+Q)]P?6-_
M?3-O?9YA+U8#VUTCA'U18X'4,Q_; F&"QL D/SFNSO,9D6%6$)-%#)2=Y6(S
MFG;%*UHS9]AX%U..)F2LH\N=U<2.N2&VDN33BZH6S L=@R(?2RO0 #_$H1,"
M7A@">:83+C<D#IF'0E1,P_JX!5@/3EB\!0_3I#@2,?N 1=1<%S>6!",WK9")
M?7:E1)=IEB[66O+F-+L)D_.D7I1HT,.1/L=NM? 3BO^,?TKKD6F"16<+ PT%
MA?.*C (7<)T)$=<&7L7.DIXZUFCSS-9+&85CA7)1:C"DWQ-PCV=!)]&1.E@G
MB33ZD19G_"!)R'-CFD+:=?!#&O 3B3CG0)Q(&O[BRMTG;/ADK;0Q8G\W>6/*
M&^_M;A+'7Q5_.\,!#[5)V5CF#=VS6_6;H='>>BO8P^>WFFPZG[39(,<UCAJ3
MF&NV!Q!15H+-3PDK F<9PK-1DDLDSA]8X )^&0'$-=SLC5 XE"(T1A7YXW\;
M_HM!!+LV/WEA"C\4=ZC9Q=RW9">+D@-S@4F;"7ZJ;02Q]J SK9<(7JF4J,7H
MJTS-*8*_*?("*RLO-2]#T;8%]X[")\EFH&>#3=2QI=XZ+^UA+M=\:=K)FF9G
M3Z<:CS,I$C/FH%*]:U<DPU-TG%=;:$YQ==)\N++E;F(5F)A65DP]@\)"I+4>
MV_;SB7D"GE@>04T+96"]/C],JX[Y@++"*0;QQBL=F\3"Z>3UM V<_Y9K[TR9
M"B93T2A>=WT$';?TBEAYFWXOO ^7 "Y-\K]MD[IPOICM1&2_/=4Q-SG#H+I
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MMOV>UK6HT'U3<!&[=%NWL2U;46DPX^3#*/5ON-.!+2S@:*H^+',A]S+7>HZ
MOEHC/2#[*9DG34B9;OIN+-7(UA(MB!L=\"K9OB3F_1%,+3XG*Z+T6MB!'Y;E
M4ARQXAG.G)9L-ER4E8WR%,ZZ)X[TM^%'J?&M!$H) E 0M?S548%8/]H6*=E
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M^[$_!/!Y-!W2%_]OIFNKG:7MP(;&!K#(>QS>/[@C*0GU<J6-@YO$D>9*3KQ
M&BX@Q?TF"\(:.]$G\IPS0RW(QUNF^US, SP;<H]QS3W>\6KB=.Y;@_+;':0W
M&E3O0/,=;4,#C-P7'QHCE(C2=HQ<"X$#^K804,(#/ J<-(HM !>S,2FG&=;5
M8<07<YD4@,VDUPA&WJ1(E+1O,-K.7TU6.3N$01Q+HPZBX3WP0B5=+7@ GY+-
MG*[6=IA:F*?/]W>C^<YL)]K2""6'+/%-!MIB8$Q(=$Z**JK7:9(7V5)%_!HW
M0OD2% A8"25:%P6HP :QU5HU1^7%WEO!$YPN$NM1ROE^+-E7VID*Q[&,O=NW
MCU&1T!Z33$[ACSOG.^M*\<@(<6I4<#U@/X/[O]#X4K<(A,,\-(JEF'E;E%51
M,!J1SL+:<Q#MF7JP"8CW,?K0X!+N//IP8UUE3LV2,6WH\+_.W)%-Z(99!\*,
M[)!V]]B?R&)L,+5$FW]M)G3ZUG3G/$D,JRL*SS2&<DN(L'8-9(<.E=&)HA,/
M$H-N5'8-G')I)T>HS\)<=4DEN%EE!@).]67]Z]T&3[0J5."9?5-_XFMY6_DB
M.EJ<L",6M@_-*DG - V#@@;FC. (9\ZH00/#V;#PP<]N;(D=J$9<B5@5-$JF
MO;<X:],ZX=1I5*V-1S@GX/J1*+ZUA%_\8PD2A6.3N;GPB/H_N6@TZP+>"B5V
M\RW ;RF/ N>G"@A$ZW_&(.]1"U%CF+Q*O'8P6'2'"1_KXMI6,$F$T=$1M;*Q
M98+=B0LWQ:CK*SAJ(B?5S2N2=I0\-X<7#)2%S&\ADH?88[7$3C&EK3 ESV_K
MO.GF !Q\<"K5L$RKJ@H<^HZ[<$@]AZO&1%<'!1Y$)N/F+CNRE3)$#F1+$XZ&
M%;01A03CV,"7+APD-&GSAF94O1CBE5DW9XXT'2=-DQL#@'19ZWQ/VB*P.%C%
MT"6#-?*Q,9=4_'MOL#3*(>PYN+J%JR0$&<'=Z,%K%88?[-[P]\'4J4!"X#(B
M9U9T;YX58TZ7H]2;\7:J&K>[+^EVP5R;E&;'F&&CP(5?L1/>52*S@!@)IXI&
MKR ]C]=L=O!@YDBH]#H<!OH3[@7&?^>@GS)JBT>:J#-@[<9(!%SE]):6E'ZB
M<3[K]>-Q),B::%R_%@9\&<1_9Y/5T7+[<+CD*AMF8B!0S'?%W0TF16[KO(-=
M85 4H+$3?9*$/>0Y!+S3P*1\EA@DMS=&R']VI>>!KR'80:=<W+#O06[9]_N4
MG'_7PKR2CQ"B/6XB[TNK1@Q4B2W ,L4.@O1++FD<4] 1V\'D')6,G8A68A)8
MO\.-6@D7:,,9/#KX/RW_/%"O'WWDRS/SPF<'7^2E805;YS2.!FTM@AF\HFA4
M-;B?-:U\_P=M^&1><1U4S.,-*D91,8__F*B8SW)"_6<%LN_L3?33V<6;T_/S
MZ*?O3]^?OGWEQS*QM2QU0AW[27W;]=B,>')JFAD*N<AU$I1;!>[/M)ED):*^
MJ:X*72L:6OYYVYVU%5A^36.TVR?1';_%I;_YVZ/'P%"OWKZY\&;-<?%C4<*!
M6,S!]\260W#=T8%)84:UGUY]<PR[<@3LB/<Z^,2!>D*'9[M_7FNR]]/U+ML/
MKOOX]<TQX)9?6J&!TG3U&CJ^<H3SX=NN#Z3VL"FU^6E?P7__][>/][][\4F$
M;R7M :F)UK\\P,,N,/#Y?)WGW-_<Q [Y?V2>>_30UM!+?,+1>O;*_N>R4M;1
MR7\ ,X"WYO/8JT<';]Y>G!V?1F]?1:?_/'U_?'9^^GG8[\%9W8QT6U<-7KQ]
M'AD]2"&RAB(4)?BPZ_T"K6G)%MK:&U 2AX)!,GE-@N0I @D93VG2G?\C_S2:
MB 8-4(-&^4XC@]3.#S4%@A18R"9.4S>94RCM#2G:C<D"4WNF34WDEB8KQGE/
M,[8Q&'R*+1-LN,N?,!I+2.W+VZ.?;^\?#T#P,R&ERRKV(:BYG<*,\NM;L%/8
MM<F2;5C\,GC^U1.)BZ)7S(3\+]?L^6]J2YG< %=1:G-I$MP_YA19I6+>BD=G
M?ZX5?FF*3)Q$%L4-G3Z>W-*+$#!=A?U)15@H+9N/NXJGD147T\2'F.%T8M,\
M>#2(.\$:TO'?S%MA>31+?LEFBUGWXD3@!4,(99956'?!V.PQ!KA6+?*^*_H_
M'VNL+U'V0:),N<L)]1FAL:(!1J9M6IJK?AB6[B!HZ4)F%SL$>9A.BYO?DQQZ
M=/ _J__Y/9@@W(@PG.!@H; *S#1CVP6XV.^=_'1X'!W*W)(WC-3^RBCR^]WK
MS9M]?6_VB8[3?YV?_?W-X<6/[T_[/? COW_[^N3T_7]_)F]IW44JR3[+HMZ(
M/COC>O/\,CJE@4+/HUL89^U_'IRL9P<V5P=O8COI1OQYP5!"\X;]'K\B)B\^
MXC4_UXZTO<>][,J#*TL:5?*0;_#@KX C,._O!'SNU0<R=U7$],DF8OHY(J9?
M*H[B1#$/SU'W_7 **NC5V_<_?(;0Z9?PYW8YJ84 CHM"D*KJD'.K3:?J6W+#
M['I3VT1NIS.?3Y>VNL>IM]F)3@I"7R\J]UMNK)$[@N\\)$[DUE=_N-S\6BL
M]HK^<?CZQ]/H_>GQZ=D_3D_BCBTP]9X"@;:0YUKA[V5JD/"5N-IU\45>ZRM.
MP(?9:KQWI^W1D0Z^];OKZKY/RGNOU'=MRV[]PI:$>]Z565X/'F))AU)Y?8=%
M/2C]]*?/8''\'I[S[@I1Z%[ YO?P6J=4_6MY\]U!@"9XV,>'Q^[W0M:[6/U_
MK/>]5_S+O0"G.MV]<</?@]_CR)&Z=U9&7UK-/=Q2@HY,)OXB6*AVK?6E%_W;
MI9]*Y >BWCW P3X"1/_I[M]'([S_F(]N"_C@*.YM#6QT17@ZM]5Q1AYYW\:W
MV:ZR7S&$Y$2"Z&XM82 E"@9>Y+]NX,5;Y!]IQX)'?W/T]N1?>$R_^?[BA]<'
M_Q]02P,$%     @ YH7E5@JVA6YI"P  :"(  !P   !E83$X,3(Y-F5X.3DM
M,5]I;G1E;G-I='DN:'1MW5IK;QI+$OV.Q']H9:\B6QH(?N!'XHV",;GQKA\1
MD!OE8\], VUFNB?=,V#NK[^GNF>&1YQH5TKRP9$BP-./>IRJ.E5P\6%\>_.V
MV;CX,.A=X971OXOQ]?AF\/;BE7_%TU?EXXO+^ZLO;#3^<C/X]XN)5OEK=M#)
M<C:6J;#L3BS94*=<!?X/ 1L)(R<OL!%;/U;[<O&8MW@BI^HU,W(ZR]^PE)NI
MQ,?.B[<7EV\'CS,9RIR=G[</+EY=0I"/.T?\KU=OG(RE_O27*K39FY]Z[ANV
MJ5,D5"Z,N^L:[Y25^8J-9\+P3!2YC'#(M8K:K*>4+E2$6SX:&4DU;3;TA'W*
MK/Q;Q%@B<\D3]K$($QFQ^\D$%ZMIP(9<6KQAO2PS^E&F/!?)BOUQ<-[NLEN9
M)%(K)A7[TVA+)^M(B-C^'G5_N6D?"IO+R>K%V\^#T?CC_7 <L+Y6JLW^4RC!
M#L\#=M@Y/ K82Q5S.WO#:OLW&T\X8.]E$G\M])MZU4OC/C-M6#X3K'S<UVG&
M5?5PG^W=<1OSKZ_9]=UXM!\PSJ)$*AGQI&5S/A4LE#H7T4SI1$]7+/+;V41'
MA14QG*S<Z;&TD5X(LV)<Q2P6"Y'H+(4Q&5  UV9&BIR;5< 4EB5,IBF4;(4<
MA\#!N>%YD6H#B$0<*'(B0T,)T\;"PEQ8EFLV!R286VG=15)%1N",9L,?R.S*
MYB)E1D1Z2IB#>!# GPE+Y3KF)*+':NQ$SSQ>:9W,+2M*R,H2LIF'K"XA2\N.
M@O-.)^AT.LS.N(&(=(5.4ZV:#9OK:,YX#D/N[J2+!*W]H]O&W@Q:NOUM.)#Q
M.';B!FLWLQFW;&HX/GM)"Q4+LS02"(7Z[+C;(FUTYM2$=;+"1-@CH&"S41T(
M%;IGW1UI25$O,:L%IAN^I[03/6")0!1N24(/G>\+E7N7T+'26MQLV[\Z<*H0
M_;6WP#L1XE)$SLY+F<^<#72=Q.A3'5>6XLHV&UOFE9:)QPPG>!B' I<R@#YV
MB%*44)D/1-8'ZG.XX):;N<CIH4L'1YTJ'3C;NSL1_7,"T2H-=5(%.,5Q%?JV
M"!]P:;.!.R>2H, ISR[P)ER5%[;=Y;6G=R2-$@T\.2&0E[N5#.7!M(($L3R7
M=L*C.MY@.E@;V8#VT[$PH(?C<P$%&4W!/UE9D\@4Z\B=&)UN@:39V$,,42K6
MC/*G>!0FDM:E@YW0KB#$*)_BWD3G/I&Z.*<4/<$JI,6XB%S\?3\@@\UHI.@$
M$I!/;.DI<K2RI#CRP@Y /5(V*O))^Y"EOB(_(Q=>"A7-L'A>!;#+8>\-7 H/
M;L<B@IKLQ+W5N<^$#QK5BX5:SUNF4(J>0!P43J3H25EZ*Q \([M9$16$-E^?
M(R-# (>'@*S#4BA\J83>1!*0;#9R)-4I6Z"LN6! K9Y*2P1 NG0)O'FX*_9>
MFY2-6@=L;[BYYDZWV='14>OPI-,]Z>[C:%2O)?R1&;&0NK# ZT0F$*C.U9_:
MHW:S,5H+35X>/*):*E"<O0U^-!KT:V[DJ4R40*.8"2@#SR]$G9(KAD895-JM
M%.KU3WE,JR$.#) *!!X6 424-"P%6^$PDKH*RTU>)8/U54_;I@U+.FI4KO>I
M?>-0(Q+N4X/^45E'D>**8EV'.9>@6 %;S@2XR(++A(>)H-)F=#'U1G2F*7/3
M4H1(=()XPW*Y; ,.[:E>$->DU/>:/1E; ;NYZ0>LER--DD:OB=&7,C<;5X)L
M0/H%[*#;88,VB,O%Z-/'M_GLXA6]>GB/<D0GK3DM'U:HIT^31&L3.'Q_T6:.
M=U^ ^X-NER0]/#AL'>'_R2G($$2%5T0*5>G9VGKOPDKNDNRV\0JO?3\O!.RX
MPSXC4[-*MNX9@/?^25DZ'531A>3KJP=?"]2,T0H5,H*'WTW\+1'/TGENZ7:'
M1-J#7"RRF58@O-BX=];I[+/3LY/6P?')^;/)+M)%LG4P)G)/O!6V53HG&H%E
M>4'(4Q['CMQ8@07P*&=6 ^%P3D5%JF6NJA6N_S#E@=1B"%?JD),L3ZIB;+?2
M&XB:>T[!1U<\X(&%I_*R-5W.9#0#(8IFU/'BIF!'!N//7NHBB>FV0B5\.2F2
M7^ZONH?]?9TLKNR%NLC9T[."WR'"[^H)?C +D?:;-AHU\,D^.@-$A"\;''QR
MN=T8.P[& 2_*XVAT<P>MV'? 55?;WC!V@L;;X#KK.KRK"7KTX>/+?YT=GSE%
MJNN;C0P%@DJ/X_ATLMCLTEELBJDK347B4&Q]D9UHL-&EIYB&^+]4#V5;1,UZ
MC$H'[HG&%B%45@X" R\%=O543DBJLK]W9D,NFPIJ'\&D=-7_1XCH3=7JR@,Q
MB?C2NEC&$-RB3UX(W\IK5UF0F7&05%CG\@2/>>;*:3DD0'+)H)/P2E%>H2)-
M*37GT=R6)?.A9,,D>H#< 3T2J[%<M;8?6M]"[72 \ 6/OY4VH$'+X5&G=1(0
M3I! -H<E,#GR&;5VY)-Z?@(?. ,Y/K,! 1NXQ$-<U'(#3'%GXY!F(GEER6IW
M>V>RL(8HT)B@WNN29_ I"A#=W6RX"V_1JLS9:,9-!IK$T^P-N]*S%+S)/=DG
M8POTE 6AJ-+.RYJ)-#20]^\BY>'.G&.3$?Y?\EPB ><Z:=VNB&2/4#W#<$L&
M.AG&"$&+W ';,CVUO78:6*EL]<<WO=:Q>Q_J&#5#9C*1::5#/85S4A,FT,U%
M!>&A%M6NN><]4+7D[ /XA2,-0Q08.&N&DZI:MG?_87CM^:;;H1"$4F\L  CZ
MWIOU[KW[Z_Z0;$\SIR)>K;6DBH5X5. 0;I*%HIG#"42(E= \?B@61+XS-RHZ
M9'XW53(-R;W<N")Q-8\&@%MH<ESY^NZOZ[O^]>7-P.^F,6)_W#D^/3LX/>SN
M@VKWZNE3LMIV]=I6^)-&KN N-&N]R A7&R'1JTS*]OK#WE5O?VW9.UX.N$K;
MU/9:3V$@%PS[%X\B\%NX'@MG;6HL&,*'HIR2'/> S#S;6$AXU[%:6;EZ(UFM
M^9A/AENZT20'TE%[_J[&"96$YU'T4-UAN24W<>L&#2_5@5'5DSRCVMX7AMJA
M=;_ETG3^+2]-^6J#D38;90LY*6V4E#9:GU/-Y0C!T@_.J2TLQ\JN446GAMAP
M9G5?I2PHH6TTKC=XF?JT-A2N@O<B5R0.SL_16' :4N"NV,]QJ.*XZD2<=E.=
M*"EB458UQ '50&0XZ<<_P>;:W5YR/28JQY<T8D+')'SG5@W\7&7V75/AQUS5
MI*S-/@M?LCW)\8S[^T:CJ-(%&$%A#*4!+T!)2^A\'%RR$$LC"*@T*?*")EH+
MX89@BE@1KJ'Q=0"9T.4A:<"514+'FW(A-"&*3@P% 4R#+R,I?ZVG>6!-"N>Y
MO+"^?TL@FKW1S)2^0 CH;)EFB<3'L,R#.XI2]JXU71*FYK7'4*CF_@KZML*!
MDC 0T(1I12;UO8<?N*PTUCD[^70?5%Y^[:ZELSS?^>% H/XFHQQ<$\1=XT4Z
M$;P@(UHGO&I*BJ6(ZQ%0B6I;LD(R4TZ%IPR-(4GQ'@X =ZF"H=RR;L#A(J_8
MSG2"E=\UC0;][\P?VH@)'KMO1V"3B!<D!)4][69-<%_D1J4%<<!$4M6H#OT^
M_FIQ(!Z?^WD.KV<OL6L+JS80?UFYN]WHASQGQ"0AINR'@G1@S35J0".!$-K@
MV TH!]\ '3T$A!:3;;[)8HVT0!H2.DG-(G-"N:Z5V.$/0JN$+V4US]VCA,O4
MNKUQ :*X/L[#IBZ7] 6'*OWR='84CY% EN7T%Y LXV* H?=]/M40/&@P&M\/
MV7!PTQM?W]^-6/_^;MSKCW]3L_W[.OOA(P$.[1/-J!PB_T1_E_W$7S/<(H"X
M2-A_V^Z;?V$N+H<X>^_\X'2?G1P=M4XZ9R>EPNY)FKIE[\RC-,3*?J(L.PAZ
M1;\4\3\=H5^8_ -02P,$%     @ YH7E5EIK-'DL"P  1R(  !P   !E83$X
M,3(Y-F5X.3DM,E]I;G1E;G-I='DN:'1MW5IK;]NX$OUNP/^!V+LH$D!6G:1.
MDR:WJ..XV^Q-D\+V[J(?*8FV64NDEJ3B>'_]GB$E/]*T6%QT\R$%"L<6'_,X
M,W-F[/,/DX_7;]NM\P_#_B5>&?T[GUQ-KH=OSU^&5SQ]63\^O[B]_,S&D\_7
MP__^--7*O6$'W=*QB2R$93=BR4:ZX"H*'T1L+(R<_H2-V/JIV>?$O>OP7,[4
M&V;D;.[.V#\]ZHP5W,PD-M+2[D]OSR_>#N_G,I&.G9[&A^<O+R#VIP<7_O^G
M_\"C+MZ^4(DMSWZHB&=LVYBI4$X8?]<5_E)6NA6;S(7AI:B<3''(E4ICUE=*
M5RK%+8-<6ZEF[9:>LM]**_\2&99()WG./E5)+E-V.YWB8C6+V(A+6LSZ96GT
MO2RX$_GJ:=3Y^> T[K&/,L^E5DPJ]HO1UK)/1J="9/9IA/C7_?>ELDY.5_ZR
M/X;CR:?;T21B ZU4S'ZM\A7K1>RP>WA$(D3LA<JXG9^QM:O;K4=\O?<BS_ZL
M]-EZU0OCWS-MF)L+5C\>Z*+DJGFXS_9NN,WXGV_8U<UDO!\QSM)<*IGRO&,=
MGPF62.U$.E<ZU[,52\-VQ'%:69$!3\J?GDF;ZCMA5HRKC&7B3N2Z+&!2!L !
M1:61PG&SBIC"LIS)HJB4Z"0<A\#-SG!7%=H C2D'8+W(T%#"P)FP,!J6.<T6
M  ;S*ZV_2*K4")S1;H4#F5U9)PIF1*IG!&^(!P'"F;"4TQDG$4-89%[T-(0&
MK9/.LJJ.#EE'1QFB0]?10<N.HM-N-^IVN\S.N8&(=(4N"JW:+>MTNF#<P9 /
M=\(&J:"U/_=B["VAI=\?PX&,9YD7-]JXF<VY93/#\3Y(6JE,F*61P"G49Z]Z
M'=)&EUY-6*>L3(H] @JV6\V!4*%WTGL@+2D:)&9K@>F&;RGM18]8+A"+.Y+0
M0^_[2KG@$CI66HN;;?QOAT\3J/_N+?!.BM 4J;?S4KJYMX%>YTMZMXXK2W%E
MVZT=\R9BQN$BPS,/(47)FH7(8P/ W,'F'[E9"$</?R4D'W5##HB"L?TE"/<%
MH695)#IO(IH"-Z[C^7D8G(RC8(JRSOJ$[4U43(TN=AS0;NT!GY3F-*/<).Z%
M2:7UH?8@;!KW,,I5N#?7+B0I'T.4_J98A9235:G']K?!'FTCG9#?;L&_RO(
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M,(;AZY%)YOO IN_#)RM_MY_8D.>,F.;$D\,<CPY<4XXUH)% "&UP[!:4HZ^
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MUK 0"1I6MC22.D J&D!(&$DCYZ/E(=L,4F)*ULN44G=6P0L2B83@&[M,U[$
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MV".Z8#WXIA:H.YF:7OX&4$L#!!0    ( .:%Y58M&F%+_@H  ("&   5
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MTE(& 5*O/?AW2*H(I$,<4W,K&1;U\[C<Q#PC&_!MA_X05P0--:\YZM,'0=-
MDR93>5CSY#H/1"K29S:C>G)[>(G7$#E>&5L,&@OCFB((1D!;T+*X_EL!?G+G
M;5<TB:XHQ_!5EH;&<<:\MCTC6=Y!$! !;5=0BKQ<B'*EE_[_C-F3V#YGT?Y.
M\(@0]9156HU6?=??!D:[9>9-36K2-"@T(,[>XA<@\% %JM7QH39C^;R8IQX:
M5]G<>/2T>,3R -YNLU3-H-(8?!6\,\CQ[84!#3!N,G1$!(3> )O0#8<\$N6A
M'U 1C&K1GL[/TD,60!)_WM^3!R+4>P=+LLL^RQT]=9QA#(AU??8VN#GFR5QO
M8! 0OM4M=*J7HGH%:*6>$2NK0+^I2E!>B^WWR^N;KN4GN5EODG^M<$KDEO\"
M4$L#!!0    ( .:%Y58-*K.V80<  .]7   5    :6YT<RTR,#(S,#8R.5]P
M<F4N>&ULS9Q-<]LV$(;OG>E_8-6S+$MN/NS8S=B*E='$B5W+2=I>,A )21B#
M@ 8 +>G?%R!%11\$N.Z!:Q]LF5H ^SX+@EP"X/G[9<JC)ZHTD^*BU3TZ;D54
MQ#)A8GK1^CIJ7X[ZPV$KTH:(A' IZ$5+R-;[/W_]);(_Y[^UV]& 49Z<11]D
MW!Z*B7P7?2$I/8L^4D$5,5*]B[X1GKDC<L X55%?IG-.#;5?% V?1:^.NF])
MU&X#ZOU&12+5U_OAIMZ9,7-]UNDL%HLC(9_(0JI'?13+%%;AR!"3Z4UMQ\OC
M]4]1_)PS\7CF?HV)II'E)?394K.+EFMWW>SBY$BJ::=W?-SM_/WY9A3/:$K:
M3#AN,6V5I5PM5>6ZIZ>GG?S;TO3 <CE6O&SCI%.ZLZG9?LL"]EN>:':F<_=N
M9$Q,'O;:9B*OA?NO79JUW:%VM]<^Z1XM==(JX><$E>3TGDXB]]=&;],J$X8*
MS<S*S&Q_F=/,L#B/7L=9=OK2]D[K=E['3-')1<N6T+:IWLGQZ]ZI:^CW'2.S
MFMM>JIGK9*VHL^/$7%%-A<EUW]@#.T7HTGJ2T*2LR+7_O]PTS+B2ZV[4C=JN
MSV6I;=A^+"S77I5^<1GON,)=;.2>[K*?YQ'0-#Z:RJ=.0EG'L7 ?<B@Y$/O/
MC[RAR[$VBL2FK(F3,>5Y_3^LS9Y)IP&O2A(/ML9JIW8M]GW:CN"EBB.I$JHL
MZ[(NHN*=N!UVV;5%9TZ4K:@=SQC?A'RB9.JCLR8A/8YN@[)--$/STK:?.!\&
MG$RK<>Z9 'EV,8!6JL$B^H'J6+&YXU(#=L<2R+>'RK="6\.8RW/GGDZ9\]>Y
MXB[$U!T,CPN>(D#P)Y@C15 M4@0NA<@(OZ=SJ6K [UH">?^!R;M*&Q+FOS*B
M#%5\!2%]8 R$_0H3MD<A$N\'1=SMFN4# 7YH#23^&O7&PZ,1"?EH1CEWR1T1
MH%Y>90_$_@83NU_G"P!__>2N[_;2 F>_502(_^U+P7^@%BD"=U0QF=A+N@*P
M/S &4C_%I.Y1B,K[6B10VAM3</Z##WM/'A+J =,QX85' WM,AW%7F$.1H^2<
MM3)1L?]#B0)#WS*&(D=)0VLD-@R\GRFUXTQP5/%;0Y&C)*!U(AMF?BT,,RLW
M&_ E2\<_'YSNLCZT@C)&23I]HE#8ED\:A'&3'"&^^Y90QBBY9D@<"N>^U:,(
M'XJ$+C_150CT@2F4-$J.&92'@OI.L92HU8C%]8/&H2T4-DIF&1:(0ON!+(>)
M5<4FK)@FK(?N+0)ECY)6@N2BA& H8JGF<NMQ<5]F]GQ<]642'-)K"D+#@9)O
M/D,Z2E ND\3BTNL_-TS0;B@4E>;@.2*\  1DOA#LO>=A[\&QH^2AM3)?"/:3
MYV$_@6-'R45K96)B[]N/M^I!+CPST%YC*'*47+1&(B;P_$ISJ^Z4?&+%:JDZ
MZ@<EH.@14]2P6-0.7USD(;V]M(3R1DQ7J\5A<KZ3VA#^+YO7W4E6VT.9(R:N
M(:%-/V LXNX>6OB6$NV90/FBY*J5<II&ZB*L*/%WWUT+*%"4!+1*3,,\;Z2;
M^YA)$7P>>V@%Y8J22?I$-3WP+O.%P[Y3?^MK\ HVE&%U7T;#&+\K9JP'?9FF
MF5@_H_',BGE,H7A1TK^@O(91CR1G,3-,3#_;.T3%"*_F7&4'A8R2[/F%-4SX
M3E$7:6ION_-U7&[;@;J=3'PC;\@>2APEUZL7BDM^J'5&U7/Y5Y2"1@$E[8.*
M;GJ<H7%FA[U5MS=^<#MF/*/,@164-4K*YQ/5,-LO\D$1MXMOM$K'DONWAU0:
M0@FC)'@!:0U#WO&C&N^>"10L2F97*0=I3+A>QC,BIM2_>J':$@H8)=,+B4,;
M>Z>@L7?ZS+$7)>/SB4)B6ZP-MV?4[9BS*?'O) L6 .^SP20>D-KT_KU\RX_;
MWZW2W(^!_5"-W6,*!8ZS13(DKVG46<(,30J7!DP0$=N4:K.OS9.=UY>"!@!G
M#R50-,KC_>^4\T]"+L2($BT%38I;_= 3?F\1:!00YQ!KY**$X)ODF:6D\H6@
MRG,.>$RAR!'G#CWR<-9>%HN:-]>>XD4>(>*^$E#PB).(8;%(Z],,=3ZS)_J!
M&++V,,3?5P+*'W%",2P6;?V\ZML+SU2&Y\SW#*&T$9?"5DI#@3Q*">=7F6:"
MZN#8LF<(A8RXYK52&@KDZY2JJ1W4/BJY,+/UWLX0;$\!*'3$E:U!J3CPES_W
MD1?[WX+D*ZS!;R= Q.X5B?7:C3AV"RF**[E(B/)0#]E#N:-NK/0+;9C\K7MS
MU_;]4^[,T.9MH44/]:6@44!)5Z&B<:ZM6SOY@Y?6'3LH;\3$M$H8SIZI;,Q9
M/."2!._+=\R@?!&ST I9*'BOB'A4V=S$JSLE8TK=](G>G&V A A8 30DB/GI
MLU#@/"Z0:>HV$\GX<32SHO5M9O+WFEK_@@\-@N6@H<'<Q D0CG07I']N]*+)
MU>J>3JARRQ0>Z-)<V88>PS=%@.+0^*"^40B,H2),YYT#73?V@'MS;?&-^^7>
MSFJ/_ =02P$"% ,4    " #FA>56=!8V1.$9   #D0  &0
M@ $     96$Q.#$R.38M.&M?:6YT96YS:71Y+FAT;5!+ 0(4 Q0    ( .:%
MY58&*><K";T  *&!!  <              "  1@:  !E83$X,3(Y-F5X,3 M
M,5]I;G1E;G-I='DN:'1M4$L! A0#%     @ YH7E5@,N>57J'@  -,0  !L
M             ( !6]<  &5A,3@Q,CDV97@S+3%?:6YT96YS:71Y+FAT;5!+
M 0(4 Q0    ( .:%Y59(+S"*4FH  !,  P ;              "  7[V  !E
M83$X,3(Y-F5X,RTR7VEN=&5N<VET>2YH=&U02P$"% ,4    " #FA>563H+,
M%!!-   QG0$ &P              @ $)80$ 96$Q.#$R.39E>#0M,5]I;G1E
M;G-I='DN:'1M4$L! A0#%     @ YH7E5@JVA6YI"P  :"(  !P
M     ( !4JX! &5A,3@Q,CDV97@Y.2TQ7VEN=&5N<VET>2YH=&U02P$"% ,4
M    " #FA>566FLT>2P+  !'(@  '               @ 'UN0$ 96$Q.#$R
M.39E>#DY+3)?:6YT96YS:71Y+FAT;5!+ 0(4 Q0    ( .:%Y59ZXHZG,P,
M -(+   1              "  5O% 0!I;G1S+3(P,C,P-C(Y+GAS9%!+ 0(4
M Q0    ( .:%Y58M&F%+_@H  ("&   5              "  ;W( 0!I;G1S
M+3(P,C,P-C(Y7VQA8BYX;6Q02P$"% ,4    " #FA>56#2JSMF$'  #O5P
M%0              @ 'NTP$ :6YT<RTR,#(S,#8R.5]P<F4N>&UL4$L%!@
0   *  H Q0(  (+; 0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
